Document:

Exhibit
10.2

 

CONFIDENTIAL

 

LICENSE
AGREEMENT

 

This
License Agreement (“Agreement”), dated as of [, 2018] (the “Effective Date”), is made
by and between, ONCOTELIC INC., a corporation organized and existing under the laws of the State of Delaware having its
principal place of business at 29397 Agoura Rd., Suite 107, Agoura Hills, CA 91301 (“ONCOTELIC”), and
AUTOTELIC BIO., a Korean corporation having its principal place of business at Room #302, 194-41, Osongsaengmyeong 1-ro,
Yeonje-ri, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea (“ATB”).

 

RECITALS

 

Whereas,
ONCOTELIC is engaged in the development and commercialization of novel oncology therapeutics for various types of cancer;

 

Whereas,
ATB is engaged in the research and development, and commercialization of novel therapeutics in various therapeutic areas of unmet
medical needs, including oncology;

 

Whereas,
ONCOTELIC owns or otherwise controls patents, patent applications, know-how and other information relating to Trabedersen (OT-101),
a TGF-beta2 antisense oligonucleotide program as listed in Exhibit A;

 

Whereas,
ATB and ONCOTELIC have mutual interest in developing and commercializing a combination therapy which includes Trabedersen and
another oncology therapeutic with a different mechanism of action such as Interleukin-2 (IL-2);

 

Whereas,
ATB and ONCOTELIC have signed a Term Sheet Agreement (Term Sheet) containing high level terms pertinent to this Agreement, with
an Effective Date of January 25, 2018, and the Termination Date of January 25, 2019;

 

Whereas,
ATB desires to obtain, and ONCOTELIC is willing to grant to ATB, an exclusive license under the ONCOTELIC Technology to develop,
make, have made, use, sell, offer for sale, import and export the Product in the Field, in the Territory, on the terms and subject
to the conditions set forth herein; and

 

Now,
Therefore, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency
of which are hereby acknowledged, the Parties hereby agree as follows:

 

Article
1

DEFINITIONS

 

Unless
specifically set forth to the contrary herein, the following terms shall have the respective meanings set forth below:

 

1.1
“Accounting Standards” shall mean (a) U.S. generally accepted accounting principles or (b) international
financial reporting standards; in either case, consistently applied throughout the organization of a Party.

 

    	 	 	1

    	Confidential	 	 

    

 

1.2
“Act” shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§301
et seq., and/or the Public Health Service Act, 42 U.S.C. §§262 et seq., as such may be amended from time to time.

 

1.3
“Administrator” shall have the meaning provided in Section 11.2(a).

 

1.4
“Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls,
is controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such Person
possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through
the ownership of fifty percent (50%) or more of the voting securities of such Person, by contract or otherwise. For clarity, once
a Person ceases to be an Affiliate of a Party then without any further action, such Person shall cease to have any rights under
this Agreement by reason of being an Affiliate of such Party.

 

1.5
“Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to any of the
Parties or their respective Affiliates in carrying out activities hereunder or to which any of the Parties or their respective
Affiliates in carrying out the activities hereunder is subject, and shall include all statutes, enactments, acts of legislature,
laws, ordinances, rules, regulations, notifications, guidelines, policies, directions, directives and orders of any statutory
authority, tribunal, board, or court or any central or state government or local authority or other governmental entity in such
jurisdictions.

 

1.6
“ATB Indemnitees” shall have the meaning provided in Section 10.2.

 

1.7
“ATB Know-How” shall mean all Know-How Controlled by ATB or its Affiliates as of the Execution Date or
any time during the Term, including all Know-How developed or generated by or on behalf of ATB or any of its Affiliates in the
course of conducting research, development, manufacturing, research, development, importation, exportation, sale, regulatory or
commercialization activities contemplated by this Agreement.

 

1.8
“ATB Patent Rights” shall mean all Patent Rights Controlled by ATB or its Affiliates as of the Execution
Date or any time during the Term that claim or cover the composition of matter, manufacture or use of the Molecule and/or Product.
The ATB Patent Rights shall include ATB’s (and its Affiliates’) rights in Joint Patent Rights.

 

1.9
“ATB Technology” shall mean ATB Patent Rights and ATB Know-How

 

1.10
“Bankruptcy Laws” shall have the meaning provided in Section 12.1.

 

1.11
“Calendar Year” shall mean the period from January 1 of a year through the end of December 31 of the same
year.

 

    	 	 	2

    	Confidential	 	 

    

 

1.12
“CGMP” shall mean the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration
(FDA) as described in 21 C.F.R. § 210 and § 211, as amended from time to time.

 

1.13
“Change of Control” means, with respect to a Party: (a) a merger, reorganization or consolidation involving
such Party, or any parent company of such Party and a Third Party in which the voting securities of such Party or its parent company,
as applicable, outstanding immediately prior thereto cease to represent more than fifty percent (50%) of the combined voting power
of the surviving entity immediately after such merger, reorganization or consolidation or (b) a Person, or group of Persons (acting
in concert), directly or indirectly, become the beneficial owner (as defined in Rule 13d-3 under the U.S. Securities Exchange
Act of 1934, as amended) of more than fifty percent (50%) of the voting equity securities or management control of such Party
or any parent company of such Party.

 

1.14
“Claim” shall have the meaning provided in Section 10.1.

 

1.15
 “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with
respect to any objective, the level of reasonable, diligent, good faith efforts that biopharmaceutical companies typically devote
to products owned by them that are at a similar stage in their development or product life and are of similar market potential
taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent
and other proprietary position of the product, the likelihood of regulatory approval, the profitability of the product, and other
relevant factors. As used in this Section 1.15, “biopharmaceutical companies” shall mean companies in the biopharmaceutical
industry of a size and stage of development similar to that of such Party, including having human pharmaceutical product candidates
or products in a similar stage of development to the Molecule. Commercially Reasonable Efforts shall be determined on a market-by-market
and Product-by-Product basis, and it is anticipated that the level of effort will be different for different markets, and will
change over time, reflecting changes in the status of the Product and the market(s) involved.

 

1.16
“Confidential Information” shall have the meaning provided in Section 6.2.

 

1.17
“Control”, “Controls” or “Controlled by” shall mean, with respect
to any Patent Rights, Information, Know How or other intellectual property rights, the possession by a Person of the ability (whether
by ownership, license or other right, other than pursuant to a license granted under this Agreement) to grant access to,
or a license or sublicense of, or a covenant not to sue, as applicable, to or under such Patent Rights, Know-How, Information
or other intellectual property rights without violating the terms of any agreement or other arrangement with any other Person,
or being obligated to pay any royalties or other consideration therefor in existence as of the time such Party or Affiliates would
first be required hereunder to grant the other Party such license or access.

 

1.18
“Cover” means (a) with respect to Know-How, such Know-How was used in the exploitation of the Product,
and (b) with respect to a Patent Right, a Valid Patent Claim would (absent a license thereunder or ownership thereof) be Infringed
by the exploitation of the Product; cognates of the word “Cover” shall have correlative meanings.

 

    	 	 	3

    	Confidential	 	 

    

 

1.19
“Data” means any and all scientific, technical or test data pertaining to the Molecule or Product that
is generated under this Agreement, including research data, clinical pharmacology data, CMC data (including analytical and quality
control data and stability data), preclinical data, clinical data or regulatory data including but not limited to, submissions
made in association with an IND, NDA or MAA with respect to the Molecule or Product.

 

1.20
“Develop” or “Development” means all activities that relate to the development of the Molecules
and Product or to (a) obtaining, maintaining or expanding regulatory approval of a Product, or (b) developing the ability to manufacture
clinical and commercial quantities of a Molecule or Product. This includes: (i) preclinical testing, toxicology, and clinical
trials; (ii) preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory
Authority to obtain, maintain or expand regulatory approval of a Product; and (iii) manufacturing process development and scale-up,
bulk production and fill/finish work associated with the supply of a Product for preclinical testing and clinical trials, and
related quality assurance and technical support activities.

 

1.21
“EMA” shall mean the European Medicines Agency or any successor entity thereto.

 

1.22
“Export Control Laws” shall mean all applicable U.S. laws and regulations relating to (a) sanctions and
embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of
commodities, technologies, or services, including, but not limited to, the Export Administration Act of 1979, 24 U.S.C. §§2401-2420,
the International Emergency Economic Powers Act, 50 U.S.C. §§1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§1
et. seq., the Arms Export Control Act, 22 U.S.C. §§2778 and 2779, and the International Boycott Provisions of Section
999 of the U.S. Internal Revenue Code of 1986 (as amended).

 

1.23
“FCPA” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. §§78dd-1, et. seq.) as amended.

 

1.24
“FDA” shall mean the U.S. Food and Drug Administration and any successor entity thereto.

 

1.25
“Field” shall mean all oncological uses of the Product for the treatment, palliation or prevention,
in humans.

 

1.26
“First Commercial Sale” shall mean, with respect to a given Product in a given country, the first commercial
transfer or disposition for value of such Product by ATB to a Third Party for end use or consumption of such Product in such country
after receipt of Regulatory Approval for such Product in such country, excluding, however, transfers or dispositions of Product,
without consideration: (i) in connection with patient assistance programs; (ii) for charitable or promotional purposes; (iii)
for preclinical, clinical, regulatory or governmental purposes or under so-called “named patient” or other limited
access programs; or (iv) for use in any tests or studies reasonably necessary to comply with Applicable Law, regulation or request
by a Regulatory Authority. For clarity, First Commercial Sale shall be determined on a Product-by-Product and country-by-country
basis.

 

    	 	 	4

    	Confidential	 	 

    

 

1.27
 “GCP” shall mean the then current “good clinical practices” as such term is defined from time
to time by the FDA, EMA or other Regulatory Authority of competent jurisdiction pursuant to its regulations, guidelines or otherwise,
as applicable.

 

1.28
“GLP” shall mean the then current “good laboratory practices” as such term is defined from
time to time by the FDA, EMA or other Regulatory Authority of competent jurisdiction pursuant to its regulations, guidelines or
otherwise, as applicable.

 

1.29
“GMP” shall mean the then current “good manufacturing practices” as such term is defined from
time to time by the FDA, EMA or other Regulatory Authority of competent jurisdiction pursuant to its regulations, guidelines or
otherwise, as applicable.

 

1.30
“Gross Profit from Sub-Licensing” shall have the meaning provided in Section 4.6.

 

1.31
“Gross Sales” shall mean the gross amounts invoiced for sales or other dispositions of Products by ATB
to Third Parties

 

1.32
“ICH” means the International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use.

 

1.33
“IND” shall mean an investigational new drug application, clinical study application, clinical trial exemption,
or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory
Authority in conformance with the requirements of such Regulatory Authority, including any such application filed with the FDA
pursuant to 21 CFR Part 312.

 

1.34
“Indemnified Party” shall have the meaning provided in Section 10.3.

 

1.35
“Indemnifying Party” shall have the meaning provided in Section 10.3.

 

1.36
“Indication” shall mean a separate and distinct disease or medical condition in humans or animals and potential
preventative, diagnostic, therapeutic and other uses: (a) which a Product is intended to treat or prevent, as evidenced by the
protocol for a clinical trial of such Product or by the proposed Product labeling in an NDA filed with a Regulatory Authority
for such Product; or (b) which is contained in a Product’s labeling approved by a Regulatory Authority as part of the Marketing
Approval for such Product.

 

1.37
“Information” shall mean any and all proprietary data, information, materials and know-how (whether patentable
or not) that are not in the public domain, including, but not limited to, (a) ideas, discoveries, inventions, improvements, technology
or trade secrets, (b) pharmaceutical, chemical and biological materials, products, components or compositions, (c) methods, procedures,
formulas, processes, tests, assays, techniques, regulatory requirements and strategies, (d) biological, chemical, pharmacological,
toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control data and information
related thereto, (e) technical and non-technical data and other information related to the foregoing, and (f) drawings, plans,
designs, diagrams, sketches, specifications or other documents containing or relating to such information or materials.

 

    	 	 	5

    	Confidential	 	 

    

 

1.38
“Infringe” or “Infringement” means any infringement as determined by Applicable Law,
including, but not limited to, direct infringement, contributory infringement or any inducement to infringe.

 

1.39
“Invention” shall mean any invention, whether or not patentable, made in the course and as a result of
the conduct of the activities contemplated by this Agreement.

 

1.40
“Joint Inventions” shall have the meaning provided in Section 8.1.

 

1.41
“Joint Patent Rights” shall have the meaning provided in Section 8.1.

 

1.42
“Know-How” shall mean any and all Information related to a Product or any active ingredient contained in
a Product, or any general knowledge and understanding of chemistry, formulation, blending, scaling manufacturing, etc., including
all technical information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications,
instructions, processes, formulae, materials, expertise and other technology applicable to compounds, molecules, formulations,
compositions, products or to their manufacture, development, registration, use or commercialization or methods of assaying or
testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and
including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety,
quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory
filings and copies thereof, relevant to the development, manufacture, use or commercialization of and/or which may be useful in
studying, testing, development, production or formulation of Products, or intermediates for the synthesis of a Product.

 

1.43
“License Grant” shall have the meaning provided in Section 2.1.

 

1.44
“Losses” has the meaning provided in Section 10.1.

 

1.45
“Molecule” shall mean Trabedersen.

 

1.46
“ONCOTELIC Indemnitee” shall have the meaning provided in Section 10.1.

 

1.47
“ONCOTELIC Know-How” shall mean all Know-How Controlled by ONCOTELIC or any of its Affiliates as of the Execution
Date or at any time during the Term.

 

1.48
“ONCOTELIC Patent Rights” shall mean any and all Patent Rights Controlled by ONCOTELIC or any of its Affiliates
as of the Execution Date or at any time during the Term that claim or Cover the Molecule and/or the composition of matter, manufacture,
research, development, importation, exportation, sale or use of the Product. The ONCOTELIC Patent Rights shall include ONCOTELIC’s
(and its Affiliates’) rights in Joint Patent Rights. The ONCOTELIC Patent Rights shall include those listed in Exhibit
A.

 

1.49
“ONCOTELIC Technology” shall mean ONCOTELIC Patent Rights and ONCOTELIC Know-How.

 

    	 	 	6

    	Confidential	 	 

    

 

1.50
“Marketing Approval” shall mean all required approvals from the relevant Regulatory Authority in a given
country necessary to market and sell a pharmaceutical product in such country, including, but not limited to, pricing and reimbursement
approvals if required for marketing or sale of such product in such country.

 

1.51
“NDA” shall mean: (a) in the United States, a New Drug Application (as more fully defined in 21 CFR 314.5,
et seq.) filed with the FDA, or any successor application thereto; or (b) in any other country or group of countries, the equivalent
application or submission for approval to market a pharmaceutical product filed with the governing Regulatory Authority in such
country or group of countries.

 

1.52
“Net Profit” shall mean the “Net Sales” less the following deductions actually incurred,
allowed, paid, accrued or otherwise specifically allocated to Products by ATB, all in compliance with applicable Accounting Standards,
consistently applied by the ATB:

 

(a)
all manufacturing costs including direct and indirect costs related to manufacturing of the intermediates, active pharmaceutical
ingredients, excipients, other raw materials, drug products, packaging and labeling;

 

(b)
sales and marketing costs such as promotion events, educational symposiums, marketing events, etc., to increase awareness
of the Products and promote sales of the Products;

 

1.53
“Net Sales” shall mean the “Gross Sales” less the following deductions actually incurred,
allowed, paid, accrued or otherwise specifically allocated to Products by ATB, all in compliance with applicable Accounting Standards,
consistently applied by the ATB:

 

(a)
normal and customary trade discounts, including, but not limited to, trade, cash and quantity discounts or rebates credits
or refunds, actually allowed or taken;

 

(b)
credits or allowances actually granted or made for rejection of or return of previously sold Products, including, but not
limited to, recalls, or for retroactive price reductions and billing errors or for stocking allowances;

 

(c)
governmental and other rebates (or credits or other equivalents thereof) actually granted to managed health care organizations,
commercial insurance companies, pharmacy benefit managers (or equivalents thereof), distributors, national, state/provincial,
local, and other governments, their agencies and purchasers, and reimbursers, or to trade customers;

 

(d)
reasonable fees paid to wholesalers, distributors, selling agents (excluding sales representatives of the ATB), group purchasing
organizations, Third Party payors, other contractees and managed care entities, in each case with respect to the Product;

 

(e)
charges separately invoiced for freight, insurance, transportation, postage and handling;

 

(f)
taxes, custom duties or other governmental charges (including any tax such as a value added or similar tax or government charge
but excluding what is commonly known as income tax) levied on or measured by the billing amount for Products, as adjusted for
rebates and refunds; and to the extent these taxes and charges are included in the gross sales.

 

    	 	 	7

    	Confidential	 	 

    

 

For
clarification, transfers or dispositions of Product, without consideration: (A) in connection with patient assistance programs;
(B) for charitable or promotional purposes; (C) for preclinical, clinical, regulatory or governmental purposes or under so-called
“named patient” or other limited access programs; or (D) for use in any tests or studies reasonably necessary to comply
with Applicable Law, regulation or request by a Regulatory Authority, shall not, in each case of (A) through (D), be deemed sales
of such Product for purposes of this definition of “Net Sales.”

 

1.54
“Party” shall mean ATB and ONCOTELIC, individually, and “Parties” shall mean ATB and ONCOTELIC,
collectively.

 

1.55
“Patent Certification” shall have the meaning provided in Section 8.3(a).

 

1.56
“Patent Rights” shall mean (i) patents and patent applications (which for the purposes of this Agreement
shall be deemed to include certificates of invention and applications for certificates of invention), (ii) any and all divisionals,
continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions,
supplementary protection certificates and the like of any such patents and patent applications, and (iii) any and all foreign
equivalents of the foregoing.

 

1.57
“Person” means any individual, partnership, joint venture, limited liability company, corporation, firm,
trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed
herein.

 

1.58
“Phase I Clinical Trial” means a human clinical trial of a Product, the principal purpose of which is to
evaluate safety in healthy individuals or patients, to determine pharmacokinetic parameters and other key pharmaceutical properties
of the Product (including absorption, metabolism, and elimination), or to determine the appropriate range of doses to evaluate
in further clinical trials, in each case as described in 21 C.F.R. § 312.21(a), as amended from time to time, or the corresponding
foreign regulation. However, Phase I Clinical Trial with oncology Products differ from other Phase I Clinical Trials in that they
are evaluated in patients rather than healthy volunteers the goal of an oncology Phase I Clinical Trial is to find out if a Product
is safe, find the best route to administer the new treatment, and determine if there are signs that cancer responds to the new
Product. An oncology Phase I Clinial Trial usually includes 15 to 30 patients who are divided into small cohorts and the dose
is increased with each new cohort until the best dose for future testing is established.

 

1.59
“Phase Ib Clinical Trial” means an oncology clinical trial of a Product (whether or not denominated a “Phase
IIa” clinical trial under applicable regulations) with the principal purpose of determining if the Product works in
one type of cancer and usually involves dose escalation to test safety of the Product at various dose levels. Upon mutual consensus,
the Parties may negotiate to revise the definition of the Phase Ib (Phase IIa) Clinical Trial during the Term of the Agreement.

 

    	 	 	8

    	Confidential	 	 

    

 

1.60
“Phase II Clinical Trial” means a human clinical trial of a Product, the principal purpose of which is to evaluate
the effectiveness and/or safety of such Product in the target patient population, as described in 21 C.F.R. § 312.21(b),
as amended from time to time, or the corresponding foreign regulations. In the field of oncology, Phase II Clinical Trials are
often larger than Phase I Clinical Trial as there may be up to 100 or so patients participating. Sometimes in a Phase II Clinical
Trial, a new Product is compared with another treatment already in use, or with a placebo. Some Phase II Clinial Trials are randomized.

 

1.61
“Pivotal Clinical Trial” means a pivotal human clinical trial of a Product (whether or not denominated a “Phase
III” clinical trial under applicable regulations) with a defined dose or a set of defined doses of such Product designed
to ascertain efficacy and safety of such Product for the purpose of enabling, without the performance of additional human clinical
trials, the preparation and submission of an MAA to the applicable Regulatory Authorities in a country of the Licensed Territory,
as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.
In the field of oncology, Pivotal (Phase III) Clinical Trials test if a new Product is better than standard treatment and may
include hundreds to thousands of patients around the country or world. The control group receives the standard treatment and the
study group receives the new Product being investigated.

 

1.62
“Product” shall mean the combination of Molecule and Interleukin-2 (IL-2).

 

1.63
“Regulatory Approval” means, with respect to the Molecule and/or Products, any and all approvals, licenses, registrations
or authorizations of any Regulatory Authority that is necessary to Develop, store or handle the Molecule and/or to Develop, store,
handle, Manufacture or Commercialize the Product, including, where applicable, (a) pricing or reimbursement approval, (b) pre-
and post-approval marketing authorizations (including any prerequisite manufacturing approval or authorization related thereto),
(c) labeling approval and (d) technical, medical and scientific licenses.

 

1.64
“Regulatory Authority” shall mean any country, federal, supranational, state or local regulatory agency,
department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development
or marketing of pharmaceutical products in any country or other jurisdiction.

 

1.65
“Regulatory Documentation” shall mean all regulatory applications, registrations, licenses, authorizations
and approvals (including, but not limited to, all INDs, NDAs and Marketing Approvals), all correspondence submitted to or received
from Regulatory Authorities (including, but not limited to, minutes and official contact reports relating to any communications
with any Regulatory Authority), and all reports and documentation in connection with clinical studies and tests (including, but
not limited to, study reports and study protocols, and copies of all interim study analysis), and all data contained in any of
the foregoing, including, but not limited to, all INDs, NDAs, advertising and promotion documents, manufacturing data, drug master
files, clinical data, adverse event files and complaint files, in each case related to the Molecule and/or Product.

 

1.66
“Royalty Term” shall have the meaning provided in Section 4.3.

 

    	 	 	9

    	Confidential	 	 

    

 

1.67
“Rules” shall have the meaning provided in Section 11.2(a).

 

1.68
“Sublicensee” shall mean a Third Party sublicensee under the license granted by ONCOTELIC to ATB pursuant
to Section 2.1, whether such Third Party’s sublicense was granted to it directly by ATB or its Affiliate or indirectly through
one or more tiers of sublicense.

 

1.69
“Technical Assistance” shall have the meaning provided in Section 2.3(c).

 

1.70
“Term” shall have the meaning provided in Section 9.1.

 

1.71
“Territory” shall mean the whole world, excluding “Territory-M”

 

1.72
“Territory-M” shall mean the USA and Canada

 

1.73
“Territory New Data” shall mean all technical, chemical, biological, pharmaceutical, pre-clinical, clinical,
bibliographic and marketing data, literature, dossiers, copies of authorizations, samples, documentation and intellectual property
newly generated by ATB and/or Sublicensees in the Territory, on the terms and conditions hereof which relate to the Product.

 

1.74
“Territory-M New Data” shall mean all technical, chemical, biological, pharmaceutical, pre-clinical, clinical,
bibliographic and marketing data, literature, dossiers, copies of authorizations, samples, documentation and intellectual property
newly generated by ONCOTELIC and/or Sublicensees in the Territory-M, on the terms and conditions hereof which relate to the Product.

 

1.75
“Third Party” shall mean a Person other than ATB and its Affiliates, and ONCOTELIC and its Affiliates.

 

1.76
“Third Party Patent Licenses” shall have the meaning provided in Section 4.4.

 

1.77
“Trademark” shall mean any word, name, logo, tagline, slogan, symbol, device, design, color, shape, designation
or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product
configuration rights, program name, delivery form name, certification mark or collective mark, that functions as an identifier
of source, origin or quality, in each case, whether or not registered, and all statutory and common law rights therein and all
registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.

 

1.78
“Valid Patent Claim” shall mean a claim of an issued and unexpired patent included within the ONCOTELIC
Patent Rights, in a country within the Territory that, unless licensed would be infringed by the manufacture, use, importation,
exportation or sale of such Product in such country in the Territory, which claim (i) has not been held invalid or unenforceable
by a decision of a court or other governmental agency of competent jurisdiction, which decision is an unappealable or unappealed
decision within the time allowed for appeal, and which is not lost in an interference proceeding or through disclaimer or otherwise
not admitted to be invalid.

 

    	 	 	10

    	Confidential	 	 

    

 

Article
2

LICENSE
GRANT

 

2.1
License Grant. Subject to the terms and conditions of this Agreement, as of the Execution Date, ONCOTELIC hereby grants ATB,
a perpetual exclusive, license (or sublicense, including the right to freely sublicense through multiple tiers of sublicense as
set forth in Section 2.2 and elsewhere in this Agreement, under the ONCOTELIC Patent Rights and the ONCOTELIC Know-How to the
extent specific to the Molecule and the Product, under the ONCOTELIC Know-How that is not specific to the Molecule and the Product;
in each case, to develop, make, have made, use, sell, have sold, offer for sale, market, export, import, and otherwise commercialize
the Product in the Field in the Territory (collectively, the “License Grant”).

 

2.2
Sublicensing.

 

(a)
Right to Sublicense. Subject to Section 2.2(b), ATB shall have the right to grant sublicenses, through multiple tiers of sublicensees,
under the licenses and rights granted in Section 2.1 to any Third Parties.

 

(b)
Sublicense Terms. Any sublicense granted by ATB under this Agreement (directly or indirectly through its Affiliate) to a Third
Party shall be (i) in writing and (ii) subject and subordinate in all respects to, and consistent with, the terms and conditions
of this Agreement. ATB shall be responsible for its Sublicensees and their respective compliance with the relevant obligations
under this Agreement and shall, at its own cost, enforce compliance by Sublicensees with the terms of this Agreement.

 

2.3
Know-How Transfer, Supply Rights, ONCOTELIC Assistance, and Manufacturing Technology Transfer.

 

(a)
Know-How Transfer. Within thirty (30) days after the Execution Date, ONCOTELIC shall transfer to ATB all scientific, mechanism
of action, preclinical, clinical safety, toxicology and other Data within the ONCOTELIC Technology related to the Molecule and
the Product in ONCOTELIC’s possession and that is available in written, graphic, electronic or other tangible form (or true
and complete copies thereof), and to the extent such data exists in electronic form, ONCOTELIC may provide the same to ATB in
electronic form. During the Term, ONCOTELIC shall promptly notify ATB of the development or acquisition of additional ONCOTELIC
Know-How which may be required by ATB to fulfill its development, regulatory and commercial obligations of this Agreement in the
Territory, and shall promptly convey such ONCOTELIC Know-How to ATB.

 

(b)
Supply Rights. ATB shall have the exclusive rights to supply ONCOTELIC with the Molecule or the Product at cost plus 30% markup,
provided however: (i) ATB’s Product has to meet the CGMP standards as described in Section 1.12 required for the marketing
approval in the US and Canada, and (ii) ATB has to abide by ONCOTELIC’s development and commercial timelines.

 

(c)
ONCOTELIC Assistance. At ATB’s request, ONCOTELIC shall provide reasonable technical assistance and regulatory consultation
to ATB, its Sublicensee or CMO, in the preparation of CGMP audit or certification by the FDA, with a mutual goal to obtain marketing
approval of the Product in Territory-M with the drug product supplied by ATB.

 

    	 	 	11

    	Confidential	 	 

    

 

(d)
Manufacturing Technology Transfer. If ATB is unable to supply the Molecule or the Product manufactured under the CGMP standard
within ninety (90) days after ONCOTELIC notifies ATB that it wishes to purchase such Product from ATB, then ONCOTELIC shall have
the right to manufacture the Molecule or the Product at any CGMP manufacturing site of its choice, and ATB’s Supply Rights
provided in Section 2.3(b) shall convert to a non-exclusive rights. Upon conversion of Supply Rights from exclusive to non-exclusive,
ATB shall be required to initiate the manufacturing technology transfer (including from its Third Party contract manufacturers)
to ONCOTELIC or a Third Party manufacturer designated by ONCOTELIC. ATB shall be required to initiate the manufacturing technology
transfer process within thirty (30) days of termination of Section 2.3(b). Copies of all ATB Know-How that is available in written,
graphic, electronic or other tangible form (and to the extent such Know-How exists in electronic form, ATB may provide the same
to ONCOTELIC in electronic form) and related to the manufacture of the Molecule or the Product in ATB’s possession and Control,
in order to enable ONCOTELIC (or its designee) to manufacture the Molecule or the Product for use in the Territory-M using the
process employed by or on behalf of ATB to manufacture the Molecule or the Product. In addition, ATB shall provide ONCOTELIC with
an introduction to ATB’s Third Party contract manufacturer(s) for the Molecule or the Product.

 

Article
3

RESEARCH,
DEVELOPMENT, REGULATORY ACTITIVES AND COMMERCIALIZATION

 

3.1
Research.

 

(a)
by ATB.

 

ATB
shall be solely resopnsbile, at its own expense, to perform in vivo combination efficacy studies with Trabedersen and various
immuno therapies including IL-2 and others, using a global CRO or a local CRO with equivalent quality. ATB shall be allowed to
perform the efficacy studies until January 25, 2019 (“Research Deadline”).

 

(b)
by ATB and ONCOTELIC.

 

ATB
shall use commercially reasonable efforts to complete the research activities described in Section 3.1(a) prior to the Research
Deadline. Should the outcome of the in vivo combination efficacy studies determined to be positive, both Parties may mutually
identify additional combination partner(s) for Trabedersen and negotiate in good faith to expand the scope of this Agreement in
a separate agreement.

 

    	 	 	12

    	Confidential	 	 

    

 

3.2
Development, Regulatory Activities and Commercialization.

 

(a)
by ATB. 

 

 

ATB
shall be solely responsible, at its own expense, for, and shall control all aspects of Development (including, but not limited
to, pre-clinical and clinical development), manufacture, registration and commercialization (including, but not limited to, marketing,
promoting, selling, distributing and determining pricing for), and generation of the Territory New Data for the Product in the
Field in the Territory. Without limiting the generality of the foregoing, ATB shall be solely responsible for preparing and submitting
all required regulatory filings in connection with obtaining and maintaining Marketing Approvals with respect to Product in the
Field in the Territory, including all INDs, NDAs, MAs, at ATB’s sole expense. All of such submissions and other regulatory
filings relating to Product in the Field shall be submitted in the name of, and owned by, ATB.

 

ATB
shall use Commercially Reasonable Efforts to make appropriate investment in the manufacturing process optimization and manufacturing
clinical sample of Molecule, in the Territory.

 

ATB
shall use Commercially Reasonable Efforts to conduct the Phase I and Phase Ib (IIa) Clinical Trials at its own cost and complete
further Development, seek Marketing Approval for, and commercialize the Product in the Territory, either independently or through
Sublicensee(s).

 

ATB
shall use Commercially Reasonable Efforts to Develop the Product in the Territory, alone or with or through one (1) or more Affiliates
or Sublicensees; provided, however, if ATB fails to conduct any meaningful development activities for the Molecule or the Product
over a period of six (6) continuous months, then such failure shall be deemed to be a failure to meet the diligence obligations
set forth in this Section and a material breach of a material provision of this Agreement, and ONCOTELIC shall have the right
to terminate this Agreement in accordance with Section 9.2 (Termination by Either Party for Material Breach) below. Meaningful
development activities include, without limitation, (a) planning, preparing for the conduct of (including drafting protocols and
negotiating with clinical research organization and clinical trial sites) and writing study reports for clinical trials and (b)
conducting regulatory affairs, including planning for and attending regulatory meetings, preparing Regulatory Filings and addressing
issues raised by Regulatory Authorities; provided, however, if ATB has failed to submit to or discuss with a Regulatory Authority
a Regulatory Filing that includes ATB’s proposed protocol for the then subsequent clinical trial within twelve (12) months
after the last patient out (LPO) of each Phase I Clinical Trial and Phase Ib Clinical Trial (excluding a Phase II Clinical Trial
that is a Pivotal Clinical Trial or that is otherwise the final clinical trial before submission of an MAA for a Product) conducted
by ATB, then ATB shall be deemed to be in material breach of its diligence obligations hereunder, and ONCOTELIC shall have the
right to terminate this Agreement in accordance with Section 9.2 (Termination by Either Party for Material Breach) below; provided
that such twelve (12)-month period will be extended automatically by the amount of any delay resulting from (i) clinical or regulatory
delays that are outside of ATB’s reasonable control, including requests or requirements of a Regulatory Authority beyond
what would be reasonably anticipated, (ii) development or regulatory delays that are outside of ATB’s reasonable control
attributable to insufficient data package related to CMC, received from ONCOTELIC, and any delays related to Section 2.3a (Know-How
Transfer) and 2.3c (ONCOTELIC Assistance), or (iii) delays in manufacturing needed quantities of the Molecule or Product that
are outside of ATB’s reasonable control.

 

    	 	 	13

    	Confidential	 	 

    

 

ATB
shall use Commercially Reasonable Efforts to achieve the Sales Forecast in the Territory, as set forth in Exhibit B.

 

(b)
by ONCOTELIC.

 

ONCOTELIC
shall be solely responsible, at its own expense, for, and shall control all aspects of Development (including, but not limited
to, pre-clinical and clinical development), manufacture, registration and commercialization (including, but not limited to, marketing,
promoting, selling, distributing and determining pricing for), and generation of the Territory-M New Data for the Product in the
Field in the Territory-M.

 

3.3
Access to Data.

 

(a)
by ATB.

 

On
an annual basis after the Effective Date, ATB shall provide ONCOTELIC with copies of or access to all Territory New Data not previously
provided to ONCOTELIC and ONCOTELIC shall have the right to but not obligation, to use the Territory New Data as necessary to
incorporate it into ONCOTELIC’s Development plan and to seek to obtain and maintain Regulatory Approval for Products in
Territory-M, including the right to but not obligation, to incorporate Territory New Data in Regulatory Filings with Regulatory
Authorities in Territory-M and to cross-reference Regulatory Filings Controlled by ATB in the Territory, in each case for the
purpose of obtaining and maintaining Regulatory Approval for Products in Territory-M, and otherwise to exercise its rights or
fulfill its obligations under this Agreement. If ONCOTELIC uses any portion of the Territory New Data for Development and/or Regulatory
Filings/Approval in the Territory-M, then ONCOTELIC shall be obligated to pay Royalties to ATB, pursuant to Section 4.2(c).

 

(b)
by ONCOTELIC.

 

On
an annual basis after the Effective Date, ONCOTELIC shall provide ATB with copies of or access to all Territory-M New Data not
previously provided to ATB and ATB shall have the right to but not obligation, to use the Territory-M New Data as necessary to
incorporate it into ATB’s Development plan and to seek to obtain and maintain Regulatory Approval for Products in Territory,
including the right to but not obligation, to incorporate Territory-M New Data in Regulatory Filings with Regulatory Authorities
in Territory and to cross-reference Regulatory Filings Controlled by ONCOTELIC in the Territory-M, in each case for the purpose
of obtaining and maintaining Regulatory Approval for Products in Territory, and otherwise to exercise its rights or fulfill its
obligations under this Agreement. Without limiting foregoing, if ATB uses the Phase III portion of the Territory-M New Data for
Development and/or Regulatory Filings/Approval in the Territory, then ATB shall be obligated to pay a higher percentage Royalties
to ONCOTELIC, pursuant to Section 4.2(b).

 

    	 	 	14

    	Confidential	 	 

    

 

3.4
Access to Sublicensee Data.

 

(a)
by ATB.

 

In
the event that ATB enters into an agreement with a Sublicensee in accordance with Section 2.2 above, if such Sublicensee is involved
in generation of Territory New Data, ATB shall ensure such Sublicensee allow ATB to provide ONCOTELIC access to, and the right
to use, all such Data generated by such Sublicensee, to the extent that such Data is reasonably necessary or useful for Development
or Commercialization of the Product in the Field in the Territory-M, including preparation and filing of MAAs for a Product with
the applicable Regulatory Authorities in the Territory-M, in accordance with this Agreement; provided that ATB shall require each
Sublicensee to allow ATB to provide to ONCOTELIC access and the right to use all Data related to the Molecule and the Product
that is (i) Safety Data or (ii) otherwise necessary to be provided to any Regulatory Authority in the Territory-M in connection
with the Development and Commercialization of the Product in the Field in the Territory-M. ONCOTELIC shall ensure that each of
its Affiliates and licensees allows ONCOTELIC to provide ATB access to and the right to use all Data generated by such Affiliate
or licensee, and ATB shall have the right to but not obligation, to use such Data to the extent permitted under this Agreement,
including the right to incorporate all Data into any Regulatory Filings for a Product in the Territory. For avoidance of doubt,
both ATB and ONCOTELIC shall have the right to access but not obligation to use, the Territory-M New Data and Territory New Data,
for Development and/or Regulatory Filings/Approval in the Territory and Territory-M, respectfully.

 

(b)
by ONCOTELIC.

 

In
the event that ONCOTELIC enters into an agreement with a Sublicensee, if such Sublicensee is involved in generation of Territory-M
New Data, ONCOTELIC shall ensure that such Sublicensee allow ONCOTELIC to provide ATB access to, and the right to use, all such
Data generated by such Sublicensee, to the extent that such Data is reasonably necessary or useful for Development or Commercialization
of the Product in the Field in the Territory, including preparation and filing of MAAs for a Product with the applicable Regulatory
Authorities in the Territory, in accordance with this Agreement; provided that ONCOTELIC shall require each Sublicensee to allow
ONCOTELIC to provide to ATB access and the right to use all Data related to the Molecule and the Product that is (i) Safety Data
or (ii) otherwise necessary to be provided to any Regulatory Authority in the Territory in connection with the Development and
Commercialization of the Product in the Field in the Territory. ATB shall ensure that each of its Affiliates and licensees allows
ATB to provide ONCOTELIC access to and the right to, use all Data generated by such Affiliate or licensee, and ONCOTELIC shall
have the right to but not obligation to use such Data to the extent permitted under this Agreement, including the right to incorporate
all Data into any Regulatory Filings for a Product in the Territory-M. For avoidance of doubt, both ONCOTELIC and ATB shall have
the right to access but not obligation to use, the Territory New Data and Territory-M New Data, for Development and/or Regulatory
Filings/Approval in the Territory-M and Territory, respectfully.

 

3.5
Diligence. ATB shall use Commercially Reasonable Efforts to Develop, seek Marketing Approval for, and commercialize the Products
in the Territory. Without limiting the foregoing, ATB shall first use Commercially Reasonable Efforts to develop, seek Marketing
Approval, and commercialize at least one Product for at least one Indication in the Field in the Territory.

 

    	 	 	15

    	Confidential	 	 

    

 

3.6
Records.
ATB shall maintain, or cause to be maintained, complete and accurate records of all Development work conducted by or on behalf
of ATB with respect to Product, including all results, data, inventions and developments made in the performance of such Development
work. All such records maintained shall be in sufficient detail and in good scientific manner appropriate for patent and regulatory
purposes, and all such records shall be ATB’s Information and ATB shall retain all intellectual property and ownership rights
of every kind and nature in such records. ATB shall provide ONCOTELIC access to such records upon
ONCOTELIC’s reasonable request.

 

3.7
Meetings. Prior
to initiation of the first Pivotal Clinical Trial of a Product, the Parties shall, at ONCOTELIC’s written request but no
more than annually, hold periodic meetings (by telephone or videoconference unless otherwise agreed) at which qualified representatives
of ATB responsible for Product development will notify ONCOTELIC, and respond to ONCOTELIC’s reasonable questions regarding,
the progress and results of ATB’s Product development and registration efforts.

 

3.8
Compliance with Applicable Laws.
ATB shall conduct, all Development, regulatory, manufacturing and commercialization activities with respect to the Molecule and
the Product in the Territory in compliance with all Applicable Laws and, as applicable, GLP, GCP and/or GMP/CGMP. ONCOTELIC shall
comply with all Applicable Laws having jurisdiction over the performance of this Agreement with respect to any activities it performs
hereunder.

 

Article
4

PAYMENTS

 

4.1
Milestone Payments.

 

	 	(a)	In
    consideration for the rights and licenses granted to ATB hereunder, ATB within sixty (60) days from the sucessful completion
    of the in vivo efficacy studies pursuant to Section 3.1(a), shall pay ONCOTELIC, five hundred thousand dollars (USD
    500,000) in cash. 
	 	 	 
	 	(b)	ATB
    shall pay ONCOTELIC, five hundred thousand dollars (USD 500,000) in cash within sixty (60) days from ONCOTELIC’s completion
    of both events set forth in Section 2.3(a) (Know-How Transfer) and 2.3(c) (ONCOTELIC Assistance).
	 	 	 
	 	(c)	ATB
    shall pay ONCOTELIC, one million dollars (USD 1,000,000) in cash within sixty (60) days from receiving Marketing Approval
    of the Product in any of the following countries: Japan, China, Brazil, Mexico, Russia and Korea. 
	 	 	 
	 	(d)	ATB
    shall pay ONCOTELIC, two million dollars (USD 2,000,000) in cash within sixty (60) days from receiving Marketing Approval
    of the Product in any of the following countries: Germany, France, Spain, Italy and UK.

 

    	 	 	16

    	Confidential	 	 

    

 

4.2
Royalties.

 

(a)
by ATB, for sales in the Territory, without
using Phase III data from Territory-M for Development and regulatory purposes in the Territory.

 

(i)
ATB shall pay royalties to ONCOTELIC on its
Net Sales at the applicable rate set forth below:

 

	Royalty Rate	3% of Net Sales

 

(ii)
In case ATB does not sub-license the Product
to sub-licensee(s) during the Term of the Agreement and sells the Product on its own, then ATB shall pay
royalties to ONCOTELIC on its Net Profit at the applicable rate set forth below:

 

	Royalty Rate	5% of Net Profit

 

(b)
by ATB, for sales in the Territory, using
Phase III data from Territory-M for Development and regulatory purposes in the Territory.

 

(i)
ATB shall pay royalties to ONCOTELIC on its
Net Sales at the applicable rate set forth below:

 

	Royalty Rate	6% of Net Sales

 

(ii)
In case ATB does not sub-license the Product
to sub-licensee(s) during the Term of the Agreement and sells the Product on its own, then ATB shall pay
royalties to ONCOTELIC on its Net Profit at the applicable rate set forth below:

 

	Royalty Rate	8% of Net Profit

 

(c)
by ONCOTELIC, for sales in the Territory-M,
using Territory New Data for Development and regulatory purposes in the Territory-M.

 

In
case ATB is able to satisfy the conditions described in Section 2.3(b) (Supply Rights) and ONCOTELIC uses Territory New Data for
development and regulatory purposes in the Territory-M, then ONCOTELIC shall pay royalties to
ATB on its Net Sales at the applicable rate set forth below:

 

	Royalty Rate	3% of Net Sales

 

4.3
Royalty Term.
Royalties under Section 4.2 shall be payable on a annual
basis due within sixty (60) days after the
end of each Calendar Year for aggregate Net Sales or Net Profit in all countries for all
markets for all indications, for ten (10) years from the First Commercial Sale on a Product-by-Product and country-by-country
basis (the “Royalty Term”). Upon expiration of the Royalty Term for a Product in a country, ATB’s license
under Section 2.1 with respect to such Product in such country shall become fully-paid and irrevocable and ATB’s obligation
to pay royalties to ONCOTELIC shall cease. Upon expiration of the Royalty Term for a Product in a country, ONCOTELIC’s obligation
to pay royalties to ATB shall cease, should ONCOTELIC become obligated to pay royalties to ATB pursuant to Sections 3.3(a) and
4.2(c).

 

    	 	 	17

    	Confidential	 	 

    

 

4.4
Profit Sharing.
On a Product-by-Product and country-by-country basis, during the Royalty Term, for a Product in a country, should ATB engage in
any sub-licensing transaction(s), then ATB and ONCOTELIC shall equally share ATB’s Gross Profit from Sub-Licensing.
Gross Profit from Sublicensing shall mean all revenues ATB receives from its Sublicensee(s) which includes any upfront payments,
development and regulatory milestone payments, sales milestone payments and royalty payments, minus Development costs incurred
by ATB. Development costs shall include but not limited to non-clinical and clinical development costs, CMC (chemistry, manufacturing
and control) costs and costs related to regulatory affairs. For avoidance of doubt, all financial investments obtained by ATB
shall be excluded from the calculation of the Gross Profit from Sub-Licensing and these may include but not limited to issuance
of ATB stocks, convertible bonds and any other financial instruments that are typically utilized by private and/or public companies
from Korean biotech and pharmaceutical sector such as ATB. Additionally, all milestone payments due to ONCOTELIC pursuant to Section
4.1, shall be excluded from the calculation of the Gross Profit from Sublicensing.

 

Article
5

PAYMENT;
RECORDS; AUDITS

 

5.1
Payment; Reports.

 

(a)
Royalties under Section 4.2 shall be calculated
and reported to ONCOTELIC each Calendar Year by ATB during the Royalty Term and shall be
paid sixty (60) days after the end of each Calendar Year. Each payment of royalties shall
be accompanied by a report of Net Sales or Net Profit of Products in U.S. dollars by ATB
in sufficient detail to permit confirmation of the accuracy of the payment made, including Gross Sales and Net Profit of Products
on a Product-by-Product and country-by-country basis, the deductions from Gross Sales, details of any royalty credits taken pursuant
to Section 4.4 on a Third Party Patent License-by-Third Party Patent License basis, any
applicable reductions or adjustments made pursuant to Section 4.5, the applicable royalty rate,
the royalty payable, the methods used to calculate the royalty rate and the exchange rates
used.

 

(b)
Royalties under Section 4.2 shall be calculated
and reported to ATB each Calendar Year by ONCOTELIC during the Royalty Term and shall be
paid sixty (60) days after the end of each Calendar Year. Each payment of royalties shall
be accompanied by a report of Net Sales of Products in U.S. dollars by ONCOTELIC in sufficient
detail to permit confirmation of the accuracy of the payment made, including Net Sales of Products on a Product-by-Product and
country-by-country basis, the applicable royalty rate, the royalty payable, the
methods used to calculate the royalty rate and the exchange rates used.

 

5.2
Exchange Rate; Manner and Place of Payment.
All payment amounts in this Agreement are expressed in U.S. dollars, and all payments hereunder shall be payable in U.S. dollars.
When conversion of payments from any foreign currency is required, such conversion shall be calculated using an exchange rate
equal to the average of the interbank rates of exchange for such currency as reported at www.OANDA.com during the year, up to
that point, for which payment is due. All payments owed under this Agreement shall be made by wire transfer in immediately available
funds to the bank and account designated by the receiving Party.

 

    	 	 	18

    	Confidential	 	 

    

 

5.3
Income Tax Withholding.

 

(a)
ONCOTELIC represents, warrants, and covenants
that ONCOTELIC will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are
required to be withheld by ATB from any payment made to ONCOTELIC under this Agreement, ATB shall (i) deduct such taxes from the
payment made to ONCOTELIC, (ii) timely pay the taxes to the proper taxing authority, (iii) send proof of payment to ONCOTELIC
and certify its receipt by the taxing authority within thirty (30) days following such payment, and (iv) cooperate with ONCOTELIC
in any way reasonably requested by ONCOTELIC, to obtain available reductions, credits or refunds of such taxes. Also, ONCOTELIC
shall cooperate with ATB in any way reasonably requested by ATB, to obtain available reductions, credits or refunds of such taxes.
Without limiting the generality of the foregoing, upon request each Party shall provide the other Party such information in the
Party’s possession as may be reasonably necessary for the Party to obtain the benefit of any present or future treaty against
double taxation which may apply to payments made to ONCOTELIC under this Agreement or any other terms of this Agreement.

 

(b)
ATB represents, warrants, and covenants that
ATB will pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are required to
be withheld by ONCOTELIC from any payment made to ATB under this Agreement, ONCOTELIC shall (i) deduct such taxes from the payment
made to ATB, (ii) timely pay the taxes to the proper taxing authority, (iii) send proof of payment to ATB and certify its receipt
by the taxing authority within thirty (30) days following such payment, and (iv) cooperate with ATB in any way reasonably requested
by ATB, to obtain available reductions, credits or refunds of such taxes. Also, ATB shall cooperate with ONCOTELIC in any way
reasonably requested by ONCOTELIC, to obtain available reductions, credits or refunds of such taxes. Without limiting the generality
of the foregoing, upon request each Party shall provide the other Party such information in the Party’s possession as may
be reasonably necessary for the Party to obtain the benefit of any present or future treaty against double taxation which may
apply to payments made to ATB under this Agreement or any other terms of this Agreement.

 

5.4
Audits.

 

	 	(a)	Records
    Maintenance. The Parties shall keep (and shall cause its Affiliates and Sublicensees to keep) complete and accurate records
    (owned exclusively by Parties) pertaining to the sale or other disposition of Products in sufficient detail to permit each
    other to confirm the accuracy of all royalty payments due hereunder for at least three (3) full Calendar Years following the
    end of the Calendar Year to which they pertain.

 

    	 	 	19

    	Confidential	 	 

    

 

	 	(b)	Audit
    Rights. Both Parties shall have the right, once annually, to cause an independent, certified public accountant reasonably
    acceptable to each other to audit such records solely to confirm Net Sales or Net Profit and royalties for a period covering
    not more than the preceding three (3) full Calendar Years. No Calendar Year shall be subject to audit under this section more
    than once. Such audits may be exercised during normal business hours upon reasonable prior written notice of not less than
    thirty (30) days, to the Party being audited (“Audited Party”), in the location where the records are maintained.
    The auditor will execute a reasonable written confidentiality agreement with the Audited Party and will disclose to the Party
    requesting the audit (“Auditing Party”) only such information as is reasonably necessary to provide the
    Auditing Party with information regarding any actual or potential discrepancies between royalty amounts reported and actually
    paid and amounts payable under this Agreement. The auditor will send a copy of the report to Audited Party at the same time
    it is sent to Auditing Party. The report shall be confidential and will be sent to both Parties will include the methodology
    and calculations used to determine the results. Prompt adjustments shall be made by the Parties to reflect the results of
    such audit. The Auditing Party shall bear the full cost of such audit unless such audit discloses an underpayment by Audited
    Party by 10% or more, for any Calendar Year under this Agreement, in which case, the Audited Party shall bear the full cost
    of such audit and shall promptly remit to the Auditing Party the amount of any underpayment. If such audit discloses an overpayment
    by Audited Party, then the Audited Party will deduct the amount of such overpayment from amounts otherwise owed to the Auditing
    Party under this Agreement, or if no payments are owed by the Audited Party to Auditing Party then the Auditing Party shall
    promptly issue a refund to the Audited Party for such overpayment. 

 

5.5
Late Payments.
Any late payment shall accrue interest at a rate of five percent (5%) per annum beginning on the date that the payment is past
due until the date of actual payment; provided, however, that in no event shall such rate exceed the maximum legal annual interest
rate.

 

Article
6

CONFIDENTIALITY
AND PUBLICATION

 

6.1
Confidential Obligations.
Except to the extent expressly authorized by this Agreement, each Party (in such capacity, the “Receiving Party”)
agrees that, during the Term and for five (5) years thereafter, it shall keep confidential and shall not publish or otherwise
disclose to any Third Party, and shall not use for any purpose other than as expressly provided for in this Agreement or any other
written agreement between the Parties, any Confidential Information furnished or made available to it by or on behalf of the other
Party (in such capacity, the “Disclosing Party”). The Parties shall also protect the trade secrets received
from the other Party for so long as they remain trade secrets pursuant to the laws of State of New York. The Receiving Party shall
use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event
less than reasonable care) to ensure that its, and its Affiliates’, employees, agents, consultants and other representatives
do not disclose or make any unauthorized use of the Confidential Information The Receiving Party shall promptly notify the Disclosing
Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information.

 

    	 	 	20

    	Confidential	 	 

    

 

6.2
Confidential Information.
“Confidential Information” means any technical, business or other Information provided by or on behalf of one
Party to the other Party in connection with this Agreement, whether prior to, on or after the Execution Date, including Information
relating to the terms of this Agreement (subject to Section 6.5), information relating to the Molecule or the Product (including
Regulatory Documentation), any exploitation of the Molecule or the Product, any Know-How with respect thereto developed by or
on behalf of the Disclosing Party or its Affiliates (including the ONCOTELIC Know-How and ATB Know-How, as applicable) or the
scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, the terms of this
Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the receiving
Party and the disclosing Party with respect thereto. Notwithstanding the foregoing, the confidentiality and non-use obligations
under this Article 6 with respect to any Confidential Information shall not include any information that: (i) is now, or hereafter
becomes, through no act or failure to act on the part of the Receiving Party, generally known or available; (ii) is known by the
Receiving Party and/or any of its Affiliates at the time of receiving such information, as evidenced by its records; (iii) is
hereafter furnished to the Receiving Party and/or any of its Affiliates by a Third Party, as a matter of right and without restriction
on disclosure; or (iv) is independently discovered or developed by the Receiving Party and/or any of its Affiliates, without the
use of Confidential Information of the Disclosing Party. Any combination of features or disclosures shall not be deemed to fall
within such exclusions set forth in preceding Section 6.2(i) and (ii) merely because individual features are published or available
to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation
are published or available to the general public or in the rightful possession of the Receiving Party.

 

6.3
Authorized Disclosure.
Notwithstanding the provisions of Section 6.1, the Receiving Party may disclose Confidential Information of the Disclosing Party
as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:

 

(a)
filing or prosecuting Patents as permitted
by this Agreement;

 

(b)
enforcing such Party’s rights under
this Agreement and in connection with, Marketing Approvals and other regulatory filings and communications;.

 

(c)
prosecuting or defending litigation as permitted
by this Agreement;

 

(d)
complying with applicable court orders, applicable
laws, rules or regulations, or the listing rules of any exchange on which the Receiving Party’s securities are traded;

 

(e)
disclosure to Affiliates, actual and potential
licensees and sublicensees, employees, consultants or agents of the Receiving Party who have a need to know such information in
order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in each case,
that any such Affiliate, actual or potential licensee or sublicensee, employee, consultant or agent agrees to be bound by terms
of confidentiality and non-use comparable in scope to those set forth in this Article 6;

 

(f)
disclosure to Third Parties in connection
with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential
financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality
and non-use that are no less restrictive than the confidentiality obligations herein.

 

    	 	 	21

    	Confidential	 	 

    

 

Notwithstanding
the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential
Information pursuant to Section 6.3(c) or 6.3(d), it will, except where prohibited by applicable law, give reasonable advance
notice to the Disclosing Party of such disclosure and use efforts to secure confidential treatment of such information at least
as diligent as the Receiving Party would use to protect its own confidential information, but in no event less than reasonable
efforts. The Disclosing Party shall then have the right to disapprove of the disclosure, except where prohibited by applicable
law, in the Disclosing Party’s reasonable judgment. In any event, the Receiving Party agrees to take all reasonable action
to avoid disclosure of Confidential Information hereunder.

 

6.4
Publications.
ATB shall not publish any information relating to the Molecule or Product in the Territory without the prior written consent of
ONCOTELIC (such consent not to be unreasonably withheld, delayed, or conditioned). ATB shall have the right to publish peer reviewed
manuscripts, or provide other forms of public disclosure, including abstracts and presentations, of results of studies or activities
with respect to the Molecule or Products, in the Territory. ONCOTELIC shall have the right to review and comment on any material
proposed for disclosure or publication by ATB or its Affiliate, such as by oral presentation, manuscript or abstract, that relates
to the development, manufacture or commercialization of Molecule or Product and/or that includes Confidential Information of ONCOTELIC.
Before any such material is submitted for publication or disclosure (other than oral presentation materials and abstracts, which
are addressed below), ATB shall deliver a complete copy to ONCOTELIC at least sixty (60) days prior to submitting the material
to a publisher or initiating such other disclosure, and ONCOTELIC shall review any such material and give its final comments to
ATB within thirty (30) days of the delivery of such material to ONCOTELIC. With respect to oral presentation materials and abstracts,
ATB shall deliver a complete copy to ONCOTELIC at least ten (10) days prior to the anticipated date of the presentation, and ONCOTELIC
shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable
to ATB with appropriate comments, if any, but in no event later than five (5) days from the date of delivery to ONCOTELIC which
comments shall be considered by ATB. ATB shall reasonably comply, or cause its Affiliate to comply (as applicable), with ONCOTELIC’s
reasonable requests to delete references to ONCOTELIC’s Confidential Information in any such material and agrees to delay
any submission for publication or other public disclosure for a period of up to an additional sixty (60) days for the purpose
of preparing and filing appropriate patent applications.

 

6.5
Publicity.

 

(a)
Press Releases.
No later than one (1) business day following the
Execution Date, the Parties shall issue a joint press release announcing the execution of this Agreement. Except as required
by applicable securities laws or the listing rules of any stock exchange on which securities issued by a Party or its Affiliates
are traded, both Parties shall not make any other public announcement concerning this Agreement or the subject matter hereof without
the prior written consent of the other, which shall not be unreasonably withheld, conditioned, or delayed; provided that each
Party may make any public statement in response to questions by the press, analysts, investors or those attending industry conferences
or financial analyst calls, respond to queries by any exchange on which such Party’s securities are traded, or issue press
releases, so long as any such public statement, response, or press release is not inconsistent with prior public disclosures or
public statements made in accordance with this Section 6.5 and which do not reveal non-public information about the other Party.

 

    	 	 	22

    	Confidential	 	 

    

 

(b)
Filing of this Agreement.
To the extent applicable, the Parties shall coordinate in advance with each other in connection with the filing of this Agreement
(including redaction of certain provisions of this Agreement) with any securities authority or with any stock exchange on which
securities issued by a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment
for the terms proposed to be redacted; provided that each Party will ultimately retain control over what information to disclose
to any securities authority or stock exchange, as the case may be, and provided further that the Parties will use their reasonable
efforts to file redacted versions with any governing bodies which are consistent with redacted versions previously filed with
any other governing bodies. Other than such obligation, neither Party (nor any of its Affiliates) will be obligated to consult
with or obtain approval from the other Party with respect to any filings to any securities authority or stock exchange.

 

Article
7

REPRESENTATIONS
AND WARRANTIES; CERTAIN COVENANTS

 

7.1
Mutual Representations and Warranties.
Each Party represents andwarrants to the other that: (i) it is duly organized and validly existing under the laws of its jurisdiction
of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out
the provisions hereof; (ii) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder,
and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate
or partnership action; and (iii) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does
not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound,
nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it.

 

7.2
ONCOTELIC Representations and Warranties.
ONCOTELIC represents and warrants to ATB that:

 

(a)
Exhibit A
attached hereto contains a true and complete list of the ONCOTELIC Patent Rights existing on the Execution Date. The ONCOTELIC
Patent Rights listed in Exhibit A include all of the Patent Rights Controlled by ONCOTELIC as of the Execution Date that
cover the Molecule and Product or the manufacture, use, sale, offer for sale, import or export of any of the foregoing;

 

(b)
ONCOTELIC or its Affiliates (i) have the right
to grant the License Grant that it purports to grant in Section 2.1; and (ii) has not granted to any Third Party any license or
other right with respect to the Molecule, Product or ONCOTELIC Technology that conflicts with or in any way jeopardizes the License
Grant and rights granted to ATB herein;

 

    	 	 	23

    	Confidential	 	 

    

 

(c)
ONCOTELIC has neither assigned nor otherwise
entered into an agreement by which ONCOTELIC purports to assign or transfer to a Third Party any right, title or interest in or
to any technology or intellectual property right that would conflict with ONCOTELIC’s obligations under this Agreement;

 

(d)
there are no agreements between ONCOTELIC
and a Third Party under which rights with respect to the ONCOTELIC Technology are being licensed to ATB;

 

(e)
ONCOTELIC or
its Affiliates are the sole and exclusive owner of all right, title and interest in and to the ONCOTELIC Patent Rights
in existence on the Execution Date;

 

(f)
to ONCOTELIC’s knowledge, the issued
and unexpired claims included in the ONCOTELIC Patent Rights existing as of the Execution Date are valid and enforceable;

 

(g)
no reexamination, interference, invalidity,
opposition, nullity or similar claim or proceeding is pending or threatened with respect to any ONCOTELIC Patent Right;

 

(h)
To ONCOTELIC’s knowledge, the development, manufacture, use, sale, offer for sale, import or export of any Product does
not infringe or constitute a misappropriation or violation of the rights of any Third Party;

 

(i)
there are no claims, judgments, liens or
settlements against or owed by ONCOTELIC (or any of its Affiliates) with respect to the ONCOTELIC Technology, and ONCOTELIC is
not a party to any legal action, suit or proceeding relating to the ONCOTELIC Technology or the Molecule or the Product, nor has
ONCOTELIC received any written communication from any Third Party, including, but not limited to, any Regulatory Authority or
other government agency, threatening such action, suit or proceeding;

 

(j)
neither ONCOTELIC nor any of its Affiliates
has obtained, or filed for, any INDs, NDAs or Marketing Approvals for the Molecule or the Product in the Field within the Territory;

 

(k)
all research and development (including non-clinical
studies and clinical trials) conducted by or, to ONCOTELIC’s knowledge, on behalf of ONCOTELIC or any of its Affiliates,
related to the Molecule or the Product prior to the Execution Date was conducted in compliance in all material respects with all
Applicable Laws and, as applicable, GLP, GCP and/or GMP/CGMP;

 

(l)
neither ONCOTELIC nor any of its Affiliates
is debarred or disqualified under the Act or comparable Applicable Laws outside of the United States;

 

(m)
neither ONCOTELIC nor any of its Affiliates
has employed or otherwise used in any capacity, in connection with the development or manufacture of the Molecule or the Product,
the services of any Person debarred or disqualified under United States law, including 21 U.S.C. §335a, or any foreign equivalent
thereof;

 

(n)
ONCOTELIC and, its directors, officers, employees,
and any agent, representative, subcontractor or other third party acting for or on such its behalf, has not, directly or indirectly,
offered, paid, promised to pay, or authorized such offer, promise or payment, of anything of value, to any Person for the purposes
of obtaining or retaining business through any improper advantage in connection with the development of a Product, or that would
otherwise violate any applicable Laws, rules and regulations concerning or relating to public or commercial bribery or corruption,
and ONCOTELIC’s books, accounts, records and invoices related to the Product are complete and accurate in all material respects;
and

 

    	 	 	24

    	Confidential	 	 

    

 

(o)
ONCOTELIC has not violated the FCPA or Export
Control Laws in connection with the development of the Molecule or the Product prior to the Execution Date of this Agreement.

 

7.3
ATB Representations and Warranties. ATB
represents and warrants to ONCOTELIC that neither ATB nor any of its Affiliates is debarred or disqualified under the Act or comparable
Applicable Laws outside of the United States;

 

7.4
ATB Covenants.
In addition to any covenants made by ATB elsewhere in this Agreement, ATB hereby covenants to ONCOTELIC as follows:

 

(a)
neither ATB nor any of its Affiliates will
employ or use the services of any Person who is debarred or disqualified under United States law, including, but not limited to,
21 U.S.C. §335a, or any foreign equivalent thereof, in connection with activities relating to the Molecule or the Product;
and in the event that ATB becomes aware of the debarment or disqualification or threatened debarment or disqualification of any
Person providing services to ATB or any of its Affiliates with respect to any activities relating to the Molecule or the Product,
ATB will promptly notify ONCOTELIC in writing and ATB will cease, or cause its Affiliate to cease (as applicable), employing,
contracting with, or retaining any such Person to perform any services relating to the Molecule or the Product;

 

(b)
neither ATB nor any of its Affiliates will,
in connection with the exercise of its rights or performance of its obligations under this Agreement, directly or indirectly through
Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize
the giving of anything of value to a public official or entity or other Person for purpose of obtaining or retaining business
for or with, or directing business to, any Person, including ATB and its Affiliates, nor will ATB or any of its Affiliates directly
or indirectly promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality
or other illegal or unethical benefit to a public official or entity or any other Person in connection with the exercise of ATB’s
rights or performance of ATB’s obligations under this Agreement;

 

(c)
neither ATB nor any of its Affiliates (or
any of their respective employees and contractors), in connection with the exercise of ATB’s rights or performance of ATB’s
obligations under this Agreement, shall cause ONCOTELIC to be in violation of the FCPA or Export Control Laws;

 

(d)
ATB shall promptly notify ONCOTELIC if it
has any information or suspicion that there may be a violation of the FCPA or Export Control Laws in connection with the exercise
of ATB’s rights or performance of ATB’s obligations under this Agreement;

 

    	 	 	25

    	Confidential	 	 

    

 

7.5
Performance by Affiliates, Sublicensees
and Subcontractors. The Parties recognize that each Party may
perform some or all of its obligations or exercise some or all of its rights under this Agreement through one or more Affiliates,
subcontractors, or, in the case of ATB and subject to Section 2.2, Sublicensees; provided, in each case, that (i) none of the
other Party’s rights hereunder are diminished or otherwise adversely affected as a result of such delegation or subcontracting,
and (ii) each such Affiliate, subcontractor or Sublicensee undertakes in writing obligations of confidentiality and non-use regarding
Confidential Information and ownership of Inventions which are substantially the same as those undertaken by the Parties pursuant
to Article 6 and Section 8.1; and provided, further, that such Party shall at all times be fully responsible for the performance
and payment of such Affiliate, subcontractor or Sublicensee and the acts or omissions of each Affiliate, subcontractor or Sublicensee.

 

7.6
Disclaimer.
Except as expressly set forth in this Agreement, THE TECHNOLOGY, AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY ONCOTELIC HEREUNDER
ARE PROVIDED “AS IS”. Except as expressly set forth in this Agreement, ONCOTELIC EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES
OF ANY KIND, EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF QUALITY, DESIGN, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES,
OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.

 

Article
8

INTELLECTUAL
PROPERTY

 

8.1
Ownership.
As between the Parties, ONCOTELIC (or its Affiliates) is/are the sole and exclusive owner of all right, title and interest in
and to the ONCOTELIC Technology, other than Joint Inventions and Joint Patent Rights, and ATB is the sole and exclusive owner
of all right, title and interest in and to the ATB Technology, other than Joint Inventions and Joint Patent Rights. A Party shall
have and retain all right, title and interest in any Invention made solely by one or more employees or agents of such Party and
or its Affiliates or other persons acting under its authority. The Parties shall jointly own rights in any Invention made jointly
by one or more employees or agents of each Party and/or its Affiliates or other persons acting under its authority (“Joint
Inventions”) and Patent Rights therein (“Joint Patent Rights”). Subject to the rights and licenses
granted under the Agreement, each Party shall have the right to practice and use, and grant licenses to practice and use, any
Joint Inventions and Joint Patent Rights without the other Party’s consent and has no duty to account to the other Party
for such practice, use and license, and each Party hereby waives any right it may have under the laws of any country to require
any such consent or accounting, provided however, each Party shall resonably inform to the other Party if and when Joint Patent
Rights are practiced, used, and licenses to practice are granted.

 

    	 	 	26

    	Confidential	 	 

    

 

8.2
Patent Prosecution and Maintenance. 

 

(a)
ONCOTELIC Patent Rights

 

(i)
 ONCOTELIC shall have the sole right, but
not the obligation, to control the preparation, filing, prosecution and maintenance of ONCOTELIC Patent Rights that are not included
in the license grant in Section 2.1 by counsel of its choice. ONCOTELIC shall be solely responsible for such expenses relating
thereto.

 

(ii)
ATB shall have the first right to control the preparation, filing, prosecution and maintenance of ONCOTELIC Patent Rights
that are included in the license grant in Section 2.1 at ATB’s expense and by counsel of its choice. ATB shall consult with
ONCOTELIC as to the preparation, filing, prosecution and maintenance of such Patent Rights reasonably prior to any deadline or
action with any patent office, and shall furnish to ONCOTELIC copies of all relevant drafts and documents reasonably in advance
of such consultation.

 

(b)
ATB Patent Rights. ATB shall have the sole right, to control the preparation, filing, prosecution and maintenance of ATB Patent
Rights, at ATB’s sole expense and by counsel of its choice.

 

(c)
Joint Patent Rights. ATB shall have the first right to control the preparation, filing, prosecution and maintenance of Joint
Patent Rights at ATB’s expense and by counsel
of its choice. ATB shall consult with ONCOTELIC as to the preparation, filing, prosecution and maintenance of such
Patent Rights reasonably prior to any deadline or action with any patent office, and shall furnish to ONCOTELIC copies
of all relevant drafts and documents reasonably in advance of such consultation. ATB shall keep ONCOTELIC reasonably informed
of progress with regard to the preparation, filing, prosecution and maintenance of such
Patent Rights and shall provide to ONCOTELIC copies of all material patent office submissions within a reasonable amount of time
following submission thereof by ATB. In the event that ATB desires to abandon or cease prosecution or maintenance of any of
such Patent Rights, ATB shall provide written notice to ONCOTELIC of such intention
to abandon promptly after ATB makes such determination (which notice shall be given no later than sixty
(60) days prior to the next deadline for any action that must be taken with respect
to such Patent Rights in the relevant patent office). In such case, ONCOTELIC shall have
the right, in its discretion, exercisable upon written notice to ATB delivered no later than thirty
(30) days after receipt of notice from ATB, to assume responsibility for prosecution
and maintenance of such Patent Rights, at its sole cost and expense and by counsel of its
own choice and if ONCOTELIC exercises such right, then such Patent Rights are expressly excluded
from the definition of Joint Patent Rights and ATB will assign its right, title and interest in such Patent
Rights to ONCOTELIC.

 

(d)
Cooperation of the Parties.
Each Party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of Joint Patent Rights under this
Agreement and in the obtaining and maintenance of any patent extensions, supplementary protection certificates and the like with
respect to any Patent Right. Such cooperation includes, but is not limited to: (i) promptly executing all papers and instruments,
or requiring its employees or contractors to execute such papers and instruments, so as to effectuate the joint ownership of Joint
Inventions and Joint Patent Rights set forth in Section 8.1, and to enable the other Party to apply for and to prosecute patent
applications in any country in accordance with the foregoing provisions of this Section 8.2; and (ii) promptly informing the other
Party of any matters coming to such Party’s attention that may affect the preparation, filing, prosecution or maintenance
of any such patent applications.

 

    	 	 	27

    	Confidential	 	 

    

 

8.3
Enforcement and Defense of Patent Rights.

 

(a)
Notice. Each Party shall notify the other Party
in writing within ten (10) days (except as expressly set forth below) of becoming aware
of any alleged or threatened Infringement by a Third Party of any of the ONCOTELIC
Patent Rights, Joint Patent Rights or ATB Patent Rights, including, but not limited to, (i) any such alleged or threatened Infringement
on account of a Third Party’s manufacture, use or sale of the Molecule or the Product in the Field, (ii) any certification
filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions
in connection with an ANDA (an Abbreviated New Drug Application in the United States or a comparable application for Marketing
Approval under Applicable Law in any country other than the United States) or other NDA for a Product in the Field (a “Patent
Certification”), and (iii) any declaratory judgment action filed by a Third Party that is developing, manufacturing
or commercializing the Molecule or the Product in the Field alleging the invalidity, unenforceability or non-infringement of any
of the ONCOTELIC Patent Rights, Joint Patent Rights or ATB Patent Rights ((i)-(iii), (collectively, “ATB Competitive
Infringement”); provided, however, that each Party shall notify the other Party of any Patent Certification regarding
any ONCOTELIC Patent Right or Joint Patent Right that it receives, and such Party shall provide the other Party with a copy of
such Patent Certification, within five (5) days of receipt.

 

(b)
ONCOTELIC Patent Rights.

 

(i)
ATB Competitive Infringement.
ATB shall have the first right, but not the obligation, to bring (or defend) and control any action or proceeding with respect
to ATB Competitive Infringement of a ONCOTELIC Patent Right, at ATB’s own expense and by counsel of its own choice, and
ONCOTELIC shall have the right to be represented in any such action or proceeding, at ONCOTELIC’s own expense and by counsel
of its own choice. If ATB fails to bring any such action or proceeding with respect to ATB Competitive Infringement of any ONCOTELIC
Patent Right within sixty (60) days following the
notice of alleged ATB Competitive Infringement, ONCOTELIC shall have the right to bring (or defend) and control any such action
at its own expense and by counsel of its own choice, and ATB shall have the right, at its own expense, to be represented in any
such action by counsel of its own choice; provided, however, that if the applicable ATB Competitive Infringement is the result
of ATB’s receipt of a Patent Certification with respect to a ONCOTELIC Patent Right, ATB shall notify ONCOTELIC of ATB’s
decision to bring (or defend) and control any action or proceeding within ten (10) days of ATB’s receipt of such Patent
Certification with respect to a ONCOTELIC Patent Right, after which time, in each case, ONCOTELIC
shall have the right to bring (or defend) and prosecute such action, and ATB shall have the right, at its own expense, to be represented
in any such action by counsel of its own choice.

 

(ii)
Other Infringement.
ONCOTELIC shall have the sole right, but not the obligation, to bring (or defend) and control any action or proceeding with respect
to any Infringement of any ONCOTELIC Patent Right that is not ATB Competitive Infringement, at its own expense and by counsel
of its own choice.

 

    	 	 	28

    	Confidential	 	 

    

 

(c)
Joint Patent Rights.

 

(i)
 ATB Competitive Infringement.
ATB shall have the first right, but not the obligation, to bring (or defend) and control any action or proceeding with respect
to ATB Competitive Infringement of any Joint Patent Right, at its own expense and by counsel of its own choice, and ONCOTELIC
shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If ATB fails to bring
any such action or proceeding with respect to ATB Competitive Infringement of any Joint Patent Right within sixty (60) days following
the notice of alleged infringement, ONCOTELIC shall have the right to bring (or defend) and control any such action at its own
expense and by counsel of its own choice, and ATB shall have the right, at its own expense, to be represented in any such action
by counsel of its own choice; provided, however, that if the applicable ATB Competitive Infringement is the result of ATB’s
receipt of a Patent Certification with respect to a Joint Patent Right, ATB shall notify ONCOTELIC of ATB’s decision to
bring (or defend) and control any action or proceeding within ten (10) days of ATB’s
receipt of such Patent Certification with respect to a Joint Patent Right, after which time ONCOTELIC shall have the right to
bring (or defend) and prosecute such action, and ATB shall have the right, at its own expense, to be represented in any such action
by counsel of its own choice.

 

(ii)
ONCOTELIC Competitive Infringement.
ONCOTELIC shall have the first right, but not the obligation, to bring (or defend) and control any action or proceeding with respect
to Infringement of any Joint Patent Right to the extent the Infringement is not a ATB Competitive
Infringement (“ONCOTELIC Competitive Infringement”), at its own expense and by counsel of its own choice, and
ATB shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. If ONCOTELIC
fails to bring any such action or proceeding with respect to ONCOTELIC Competitive Infringement of any Joint Patent Right within
sixty (60) days following the notice of alleged infringement, ATB shall have the right to bring (or defend) and control any such
action at its own expense and by counsel of its own choice, and ONCOTELIC shall have the right, at its own expense, to be represented
in any such action by counsel of its own choice; provided, however, that if the applicable ONCOTELIC Competitive Infringement
is the result of ONCOTELIC’s receipt of a Patent Certification with respect to a Joint Patent Right, ONCOTELIC shall notify
ATB of ONCOTELIC’s decision to bring (or defend) and control any action or proceeding within ten (10) days of ONCOTELIC’s
receipt of such Patent Certification with respect to a ONCOTELIC Patent Right, after which time ONCOTELIC shall have the right
to bring (or defend) and prosecute such action, and ATB shall have the right, at its own expense, to be represented in any such
action by counsel of its own choice.

 

(d)
ATB Patent Rights.
ATB shall have the sole right, but not the obligation, to bring (or defend) and control any action or proceeding with respect
to infringement of any ATB Patent Right at its own expense and by counsel of its own choice.

 

(e)
Cooperation.
In the event a Party brings (or defends) an infringement action in accordance with this Section 8.3,
or in the event a Party is entitled to bring (or defend) an infringement action in accordance with this Section 8.3
but lacks standing to do so, the other Party shall cooperate fully, including, but not limited to, if required to bring
(or defend) such action, the furnishing of a power of attorney or being named as a party. Neither Party shall enter into any settlement
or compromise of any action under this Section 8.3 which would in any manner alter, diminish,
or be in derogation of the other Party’s rights under this Agreement without the prior written consent of such other Party,
which shall not be unreasonably withheld, conditioned, or delayed.

 

    	 	 	29

    	Confidential	 	 

    

 

(f)
Duty to Protect Patent Rights.
As of the Execution Date, during the Royalty Term on a country-by-country basis, the Parties
shall use Commercially Reasonable Efforts to preserve, protect and maintain the ONCOTELIC Patent
Rights and the Joint Patent Rights and keep them in good standing in every country where rights exist and, if necessary,
shall initiate legal remedies to keep the ONCOTELIC Patent Rights and Joint Patent Rights
valid, enforceable, and pertinent to the requirements hereunder.

 

8.4
Infringement of Third Party Rights.
Each Party shall promptly notify the other in writing of any allegation by a Third Party that the activity of either Party pursuant
to this Agreement infringes or may infringe the intellectual property rights of such Third Party, or of any other deficiency with
respect to those intellectual property rights. Neither Party shall have the right to settle any patent infringement litigation
under this Section 8.4 in a manner that diminishes the rights or interests of the other Party without the written consent of such
other Party (which shall not be unreasonably withheld, conditioned, or delayed).

 

Article
9

TERM
AND TERMINATION

 

9.1
Term.
The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless earlier terminated in accordance
with this Article 9, shall continue in full force and effect, on a Product-by-Product and country-by-country basis, until the
expiration of the Royalty Term with respect to such Product in such country.

 

9.2
Termination by Either Party for Material Breach.
Each Party shall have the right to terminate this Agreement in its entirety upon written notice to the other Party if such other
Party is in material breach of this Agreement and has not cured such breach within sixty (60) days after written notice from the
terminating Party requesting cure of the breach. Any such termination shall become effective at the end of such sixty (60)-day
period unless the breaching Party has cured such breach prior to the end of such period (or if such breach is not capable of being
cured during such sixty (60)-day period, the breaching Party fails to present a mutually agreeable remediation plan for such breach
or ceases to exert Commercially Reasonable efforts to pursue the cure as provided in the remediation plan). Any right to terminate
under this Section 9.2 shall be stayed and the cure period tolled in the event that, during any cure period, the Party alleged
to have been in material breach shall have initiated dispute resolution in accordance with Article 11 with respect to the alleged
breach, which stay and tolling shall continue until such dispute has been resolved in accordance with Article 11.

 

9.3
Termination by ONCOTELIC for Patent Challenge.
ONCOTELIC shall have the right to terminate this Agreement immediately upon written notice to ATB if ATB or its Affiliate directly,
or through assistance granted to a Third Party, commences any interference or opposition proceeding with respect to, challenges
the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect
to, any ONCOTELIC Patent Right.

 

    	 	 	30

    	Confidential	 	 

    

 

9.4
Termination by ATB.
ATB may terminate this Agreement in its entirety or on a country-by-country or product-by-product basis at any time upon sixty
(60) days’ prior written notice to ONCOTELIC, in the event (i) ATB reasonably determines that it is unsafe to continue the
clinical studies or commercialization of the Product, (ii) circumstances beyond ATB’s reasonable control preventing completion
of such clinical studies, and commercialization of the Product, including without limitation, failure to demonstrate clinical
effectiveness by failing to meet the primary endpoint in any such clinical study as set forth in the protocol, or (iii) ATB reasonably
determines that it would be commercially unwise to either Develop or commercialize the Product due to highly unfavorable market
conditions, unenforceable patent rights or other reasons making further Development or commercialization of the Product in such
countries, commercially unattractive. In case of a partial termination by ATB either on a country-by-country or product-by-product
basis, the rest of the Agreement shall continue in full force and effect.

 

9.5
Termination by Either Party for Insolvency.
In the event that either Party (a) files for protection under bankruptcy or insolvency laws, (b) makes an assignment for the benefit
of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not
discharged within sixty (60) days of such filing, (d) proposes a written agreement of composition or extension of its debts, (e)
proposes or is a voluntary party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency act
or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other
Party shall have the right to terminate this Agreement in its entirety, immediately upon written notice to such Party.

 

9.6
Additional Termination Rights.

 

(a)
ATB shall have the right to terminate this
Agreement in the event of the occurrence of any of the following with written notification to ONCOTELIC and sixty (60) days to
cure each breach from the date of provision of such notice, provided, however, that the total cumulative cure periods ONCOTELIC
is entitled to use hereunder shall not exceed one hundred and eighty (180) days:

 

(i)
ONCOTELIC fails to pay royalty payment to ATB pursuant to Sections 3.3(a) and 4.2(c);

 

(b)
ONCOTELIC shall have the right to terminate
this Agreement in the event of the occurrence of any of the following with written notification to ATB and sixty (60) days to
cure each breach from the date of provision of such notice, provided, however, that the total cumulative cure periods ATB is entitled
to use hereunder shall not exceed one hundred and eighty (180) days

 

(i)
ATB fails to pay a milestone payment or royalty
payment to ONCOTELIC under Section 4.1, Section 4.2(a) or Section 4.2(b); or

 

(ii)
ATB fails to accomplish one (1) of the following
events prior to January 25, 2019, the Termination Date of the Term Sheet;

 

    	 	 	31

    	Confidential	 	 

    

 

1.
To secure funding of KRW 500,000,000 for performing the efficacy evaluation and necessary non-clinical studies for obtaining the
IND approval from the MFDS of Korea,

 

2.
To execute a partnering deal (either co-development or licensing agreement) involving the Product, with a third party biotechnology
or pharmaceutical company, or

 

3.
To secure a government sponsored R&D grant in Korea. Should ATB be successful in obtaining such grant, ATB and ONCOTELIC shall
equally share the R&D grant provided by the government for the co-development of the Product in Korea and the US. For avoidance
of doubt, ATB may pay the licensing fee, USD 500,000 milestone payment pursuant to Section 4.1(b) through the R&D grant. ATB
shall bear the matching cost for the half amount, supplied to ONCOTELIC.

 

9.7
Termination for Force Majeure.
The non-affected Party may terminate this Agreement due to force majeure pursuant to Section
12.8 upon sixty (60) days written notice to the other Party.

 

9.8
Effect of Expiration or Termination.

 

(a)
Expiration of Royalty Term.
On a Product-by-Product and country-by-country basis, upon expiration (but not on earlier termination) of the Royalty Term, all
licenses granted by ONCOTELIC to ATB pursuant to this Agreement that were in effect immediately prior to such expiration shall
survive on a perpetual, irrevocable, fully-paid, worldwide, royalty-free basis. 

 

(b)
Termination by ONCOTELIC. In the event of termination of this Agreement Sections 9.2, 9.3, or 9.6(b), the following provisions
shall also apply:

 

(i)
Effective as of such termination, all licenses granted by ONCOTELIC to ATB under this Agreement will terminate.

 

(ii)
As promptly as practicable (and in any event within sixty (60) days) after such termination, ATB shall: (A) to the extent not
previously provided to ONCOTELIC, deliver to ONCOTELIC true, correct and complete copies of all Regulatory Documents, and disclose
to ONCOTELIC all previously undisclosed ATB Know How; (B) transfer or assign, or cause to be transferred or assigned, to ONCOTELIC
or its designee (or to the extent not so assignable, take all reasonable actions to make available to ONCOTELIC or its designee
the benefits of) all INDs, NDAs and Marketing Approvals for Products, whether held in the name of ATB or any of its Related Parties;
and (C) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence
and record the transfer, assignment or other conveyance of rights under this Section 9.8 to ONCOTELIC.

 

(iii)
ATB shall, as directed by ONCOTELIC, either promptly wind-down any ongoing development activities with respect to Products in
an orderly fashion or promptly transition such development activities to ONCOTELIC or its designee, with due regard for patient
safety and in compliance with all Applicable Laws and GCP.

 

    	 	 	32

    	Confidential	 	 

    

 

(iv)
ONCOTELIC shall have the right to but not obligation to purchase from ATB any or all usable inventory of the Molecule or the Product
in ATB’s or it’s Affiliates’ possession as of the date of termination. Such inventory shall be provided at a
transfer price equal to ATB’s cost of such inventory plus 30% markup.

 

9.9
Accrued Obligations; Survival.
Neither expiration nor any termination of this Agreement shall relieve either Party of any obligation or liability accruing prior
to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either Party from pursuing
all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In addition,
the Parties’ rights and obligations under Sections 6.1 through 6.3, 12.1 through 12.15 and 12.17 and Articles 9 and 11 of
this Agreement shall survive expiration or any termination of this Agreement.

 

9.10
Return of Confidential Information.
Within sixty (60) days following the expiration or termination of this Agreement, except to the extent that a Party retains a
license from the other Party as provided in this Article 9, each Party shall promptly return to the other Party, or delete or
destroy, all relevant records and materials in such Party’s possession or control containing Confidential Information of
the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to a continuing
confidentiality obligations.

 

9.11
Damages; Relief.
Termination of this Agreement shall not preclude either Party from claiming any other damages, compensation or relief that it
may be entitled to hereunder.

 

Article
10

INDEMNIFICATION

 

10.1
Indemnification by ATB.
ATB hereby agrees to save, defend, indemnify and hold harmless ONCOTELIC, its Affiliates, its and their respective officers, directors,
agents, employees, successors and assigns (the “ONCOTELIC Indemnitees”) from and against any and all losses,
damages, liabilities, expenses and costs, including, but not limited to, reasonable legal expense and attorneys’ fees (“Losses”),
to which any ONCOTELIC Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third
Party (each, a “Claim”) to the extent such Losses arise out of or relate to (a) the gross negligence or willful
misconduct of any ATB Indemnitee (defined below); (b) the breach by ATB of this Agreement, including or any warranty, representation,
covenant or agreement made by ATB in this Agreement; or (c) the development, commercialization or use of the Molecule or the Product
by or on behalf of ATB, its Sublicensees or any of its or their respective Affiliates, including any Third Party claims alleging
death, personal injury or other product liability to the extent arising out of or related to the use of the Molecule or the Product
sold by or on behalf of ATB in the Territory; except, in each case, to the extent such Losses result from the gross negligence
or willful misconduct of any ONCOTELIC Indemnitee or the breach by ONCOTELIC of any warranty, representation, covenant or agreement
made by ONCOTELIC in this Agreement.

 

    	 	 	33

    	Confidential	 	 

    

 

10.2
Indemnification by ONCOTELIC.
ONCOTELIC hereby agrees to save, defend, indemnify and hold harmless ATB, its Affiliates and their respective officers, directors,
agents, employees, consultants, attorneys, successors, and agents (the “ATB Indemnitees”) from and against
any and all Losses to which any ATB Indemnitee may become subject as a result of any Claim
by any Third Party to the extent such Losses arise out of or relate to (a) the gross negligence or willful misconduct of any ONCOTELIC
Indemnitee; or (b) the breach by ONCOTELIC of this Agreement, including breach by ONCOTELIC of any warranty, representation, covenant
or agreement made by ONCOTELIC in this Agreement; in each case except to the extent such Losses result from the gross negligence
or willful misconduct of any ATB Indemnitee or the breach by ATB of any warranty, representation, covenant or agreement made by
ATB in this Agreement.

 

10.3
Control of Defense.
In the event a Party (the “Indemnified Party”) seeks indemnification under Section 10.1 or 10.2, it shall inform
the other Party (the “Indemnifying Party”) of a Claim as soon as reasonably
practicable after it receives notice of the Claim (it being understood and agreed, however, that the failure by an Indemnified
Party to give notice of a Claim as provided in this Section 10.3 shall not relieve the Indemnifying Party of its indemnification
obligation under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of
such failure to give notice), shall permit the Indemnifying Party to assume direction and control of the defense of the Claim
(including, but not limited to, the right to settle the Claim solely for monetary consideration) using counsel reasonably satisfactory
to the Indemnified Party, and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the Claim.
If the Indemnifying Party does not assume control of such defense within fifteen (15) days after receiving notice of the Claim
from the Indemnified Party, the Indemnified Party shall control such defense and, without limiting the Indemnifying Party’s
indemnification obligations, the Indemnifying Party shall reimburse the Indemnified Party for all costs, including, but not limited
to, reasonable attorney fees, incurred by the Indemnified Party in defending itself within thirty (30) days after receipt of any
invoice therefor from the Indemnified Party. The Party not controlling such defense may participate therein at its own expense.
The Party controlling such defense shall keep the other Party advised of the status of such Claim and the defense thereof and
shall consider recommendations made by the other Party with respect thereto. The Indemnified Party shall not agree to any settlement
of such Claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, conditioned,
or delayed. The Indemnifying Party shall not agree to any settlement of such Claim or consent to any judgment in respect thereof
that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that
imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party without the prior
written consent of the Indemnified Party. If the Parties cannot agree as to the application of Section 10.1 or 10.2 to any Claim,
pending resolution of the dispute pursuant to Article 11, the Parties may conduct separate defenses of such Claims, with each
Party retaining the right to Claim indemnification from the other Party in accordance with Section 10.1 or 10.2, as applicable,
upon resolution of the underlying Claim.

 

    	 	 	34

    	Confidential	 	 

    

 

10.4
Limitation of Liability.
EXCEPT FOR LIABILITY FOR BREACH OF ARTICLE 6 OR IN THE CASE OF FRAUD OR INTENTIONAL MISCONDUCT OR TO THE EXTENT ANY SUCH DAMAGES
ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 10,
NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN
CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.

 

Article
11

DISPUTE
RESOLUTION

 

11.1
Disputes.
Subject to Section 11.3, the Parties will refer any claim, dispute, or controversy as to the breach, enforcement, interpretation
or validity of this Agreement (each, a “Dispute”) to the President of the Division or Chief Executive Officer
of ONCOTELIC and the Chief Executive Officer or Executive Chairman of ATB (as determined solely by ATB) for attempted resolution.
In the event such executives are unable to resolve such Dispute within thirty (30) days of such Dispute being referred to them,
then, upon the written request of either Party to the other Party, the Dispute shall be subject to arbitration in accordance with
Section 11.2, except as expressly set forth in Section 11.3.

 

11.2
Arbitration.

 

(a)
Claims.
Subject to Section 11.3 below, any Dispute that is not resolved under Section 11.1 within the applicable thirty (30)-day period
shall be resolved by final and binding arbitration administered by the Judicial Arbitration and Mediation Services (the “Administrator”)
in accordance with its then-effective Comprehensive Arbitration Rules and Procedures (the “Rules”), except
to the extent any such Rule conflicts with the express provisions of this Section 11.2. (Capitalized terms used but not otherwise
defined in this Agreement shall have the meanings provided in the Rules.) The Arbitration shall be conducted by three neutral
arbitrators (one each selected by each Party, and the third mutually selected by the Parties), provided that such individuals
shall not be a current or former employee or director, or a current stockholder, of either Party or any of their respective Affiliates
(or any licensee or sublicensee of the rights granted to such Party under this Agreement). The arbitrators shall have extensive
backgrounds and experience in the subject matter of this Agreement. The arbitration and all associated discovery proceedings and
communications shall be conducted in English, and the arbitration shall be held at NY International Arbitration Center, NY, USA.

 

(b)
Discovery.
Within thirty (30) days after selection of the Arbitrator, the Arbitrator shall conduct the Preliminary Conference. In addressing
any of the subjects within the scope of the Preliminary Conference, the Arbitrator shall take into account both the desirability
of making discovery efficient and cost-effective and the needs of the Parties for an understanding of any legitimate issue raised
in the Arbitration. In that regard, the Parties agree to the application of the E-Discovery procedures set forth in Rule 16.2(c)
of the JAMS Expedited Procedures. In addition, each Party shall have the right to take up to forty (40) hours of deposition testimony,
including, but not limited to, expert deposition testimony.

 

    	 	 	35

    	Confidential	 	 

    

 

(c)
Hearing; Decision.
The Hearing shall commence within sixty (60) days after the discovery cutoff. The Arbitrator shall require that each Party submit
concise written statements of position and shall permit the submission of rebuttal statements, subject to reasonable limitations
on the length of such statements to be established by the Arbitrator. The Hearing shall be no longer than five (5) business days
in duration. The Arbitrator shall also permit the submission of expert reports. The Arbitrator shall render the Award within thirty
(30) days after the Arbitrator declares the Hearing closed, and the Award shall include a written statement describing the essential
findings and conclusions on which the Award is based, including, but not limited to, the calculation of any damages awarded. The
Arbitrator will, in rendering his or her decision, apply the substantive law of the State of New York, excluding its conflicts
of laws principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. The Arbitrator’s
authority to award special, incidental, consequential or punitive damages shall be subject to the limitation set forth in Section
10.5. The Award rendered by the Arbitrator shall be final, binding and non-appealable, and judgment may be entered upon it in
any court of competent jurisdiction.

 

(d)
Costs.
Each Party shall bear its own attorney’s fees, costs, and disbursements arising out of the arbitration, and shall pay an
equal share of the fees and costs of the arbitrator; provided, however, the Arbitrator shall be authorized to determine whether
a Party is the prevailing party, and if so, to award to that prevailing party reimbursement for any or all of its reasonable attorneys’
fees, costs and disbursements (including, but not limited to, expert witness fees and expenses, photocopy charges, travel expenses,
etc.), and/or the fees and costs of the Administrator and the Arbitrator.

 

11.3
Court Actions.
Nothing contained in this Agreement shall deny either Party the right to seek injunctive or other equitable relief from a court
of competent jurisdiction in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed
and maintained notwithstanding any ongoing discussions between the Parties or any ongoing arbitration proceeding. In addition,
either Party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the validity, construction,
scope, enforceability, infringement or other violations of Patent Rights or other intellectual property rights, and no such claim
shall be subject to arbitration pursuant to Section 11.2.

 

Article
12

MISCELLANEOUS

 

12.1
Rights Upon Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of Title 11 of the United States Code and other similar laws in any jurisdiction outside the U.S. (collectively,
the “Bankruptcy Laws”), licenses of rights to be “intellectual property” as defined under the Bankruptcy
Laws. If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement
is rejected as provided in such Bankruptcy Laws, such Party (in any capacity, including, but not limited to, debtor in possession)
and its successors and assigns (including a trustee) shall perform all of the obligations provided in this Agreement to be performed
by such Party. If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, the Agreement is rejected
as provided in the Bankruptcy Laws and the other Party elects to retain its rights hereunder as provided in the Bankruptcy Laws,
then the Party subject to such case under the Bankruptcy Laws (in any capacity, including, but not limited to, debtor in possession)
and its successors and assigns (including, but not limited to, a Title 11 trustee), shall provide to the other Party copies of
all Information necessary for such other Party to prosecute, maintain and enjoy its rights under the terms of this Agreement promptly
upon such other Party’s written request therefor. All rights, powers and remedies of the non-bankrupt Party as provided
herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing
at law or in equity (including, but not limited to, the Bankruptcy Laws) in the event of the commencement of a case by or against
a Party under the Bankruptcy Laws.

 

    	 	 	36

    	Confidential	 	 

    

 

12.2
Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of New York.

 

12.3
Jurisdiction and Venue.
Excluding arbitration pursuant to Section 11.2, (i) the Parties hereby consent to the exclusive jurisdiction of the Federal and
State courts in New York, NY with respect to any disputes, claims, controversies or other actions or proceedings arising under
this Agreement and agree that exclusive venue for any such action shall lie in New York, NY, and (ii) the Parties hereby waive
any and all rights to commence any action or proceeding before any other court or judicial body or in any other venue. Each Party
hereby waives any objection on the grounds of lack of jurisdiction, and/or forum non conveniens or otherwise to the exercise of
such jurisdiction over it by any such courts.

 

12.4
Waiver of Jury Trial.
THE PARTIES HEREBY UNCONDITIONALLY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING DIRECTLY
OR INDIRECTLY OUT OF, RELATED TO, OR IN ANY WAY CONNECTED WITH, THE PERFORMANCE OR BREACH OF THIS AGREEMENT, OR THE RELATIONSHIP
THAT IS BEING ESTABLISHED BETWEEN THEM. The scope of this waiver is intended to be all encompassing of any and all disputes that
may be filed in any court or other tribunal (including, without limitation, contract claims, tort claims, breach of duty claims,
and all other common law and statutory claims).

 

12.5
Entire Agreement; Amendments.
This Agreement (including the Exhibits hereto) is both a final expression of the Parties’ agreement and a complete and exclusive
statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications,
whether oral, written or otherwise, concerning any and all matters contained herein. The Exhibits to this Agreement are incorporated
herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified,
only by a written instrument duly executed by authorized representatives of both Parties hereto. In the event of a conflict between
the terms of this Agreement and any terms set forth in this Exhibits the terms of this Agreement shall take precedence.

 

12.6
Non-Waiver.
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out
of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or
in part, in that instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing,
shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.

 

    	 	 	37

    	Confidential	 	 

    

 

12.7
Assignment.
Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise
transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld,
conditioned, or delayed) and neither may undergo a Change of Control without the prior written consent of the other Party (which
consent shall not be unreasonably withheld, conditioned, or delayed).

 

12.8
Force Majeure.
Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement (except
for ATB’s obligation to submit payment) by reason of any event beyond such Party’s reasonable control, including,
but not limited to, Acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, acts of terrorism,
accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw
materials, any strike or labor disturbance, or any other event similar to those enumerated above. Such excuse from liability shall
be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the
Party has not caused such event(s) to occur. The affected Party shall notify the other Party of such force majeure circumstances
as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances.
If the period of the delay shall exceed one hundred eighty (180) days, then the non-delayed Party may cancel further performance
of the delayed obligation or terminate this Agreement without any penalty whatsoever.

 

12.9
Severability.
If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired
thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties
shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal
and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

 

12.10
Notices.
All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by nationally-recognized
overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

 

	If
    to ONCOTELIC, to:	Oncotelic
    Inc.
	 	29397
    Agoura Rd., Suite 107
	 	Agoura
    Hills, CA 91301
	 	U.S.A
	 	Attn:Vuong
    Trieu, Chairman
	 	 
	If
    to ATB, to:	Autotelic
    Bio
	 	Room
    #302, 194-41, Osongsaengmyeong 1-ro, 
	 	Yeonje-ri,
                                         Osong-eup, Heungdeok-gu, Cheongju-si,

        Chungcheongbuk-do,
        Republic of Korea

	 	Attn:Tae
    Hun Kim, CEO

 

    	 	 	38

    	Confidential	 	 

    

 

or
to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance
herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered on a business day (or
if delivered or sent on a non-business day, then on the next business day); or (b) on the business day after dispatch, if sent
by nationally-recognized overnight courier.

 

12.11
Interpretation.
The headings of Sections contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are
inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect
on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable.
Unless otherwise specified, references to “$” or “dollars” means U.S. dollars. The term “including”
or “includes” as used in this Agreement means including, without limiting the generality of any description preceding
such term, and the word “or” has the inclusive meaning represented by the phrase “and/or.” Unless otherwise
specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references
in this Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement
shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted
against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement
has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices
required or permitted to be given hereunder, and all written, electronic, oral or other communications between the Parties regarding
this Agreement shall be in the English language.

 

12.12
Relationship between the Parties.
The Parties’ relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does
not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is a legal representative
of the other Party and neither Party may assume or create any obligation, representation, warranty or guarantee, express or implied,
on behalf of the other Party for any purpose whatsoever.

 

12.13
Cumulative Remedies.
No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other
remedy referred to in this Agreement or otherwise available under law.

 

12.14
No Third Party Rights.
The provisions of this Agreement are for the exclusive benefit of the Parties, and no other person or entity shall have any right
or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party.

 

12.15
Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together
with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures
shall have the same force and effect as original signatures.

 

12.16
Attorneys’ Fees.
In the event of litigation between the Parties to enforce the provisions of or with respect to this Agreement, the prevailing
Party shall be entitled to reimbursement for reasonable attorneys’ fees and costs at trial and on appeal.

 

[Remainder
of this page intentionally left blank.]

 

    	 	 	39

    	Confidential	 	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their
respective authorized representatives. The parties hereby affirm that this Agreement accurately and completely reflects their
understanding and agreements.

 

	ONCOTELIC
    INC.,	 	AUTOTELIC
    BIO
	 	 	 
	By:	/s/Vuong
    Trieu	 	By:	/s/Tae
    Hun Kim
	 	 	 	 	 
	Name:	Vuong Trieu	 	Name:	Tae Hun Kim
	 	 	 	 	 
	Title:	Chairman	 	Title:	Chief Executive
    Officer
	 	 	 	 	 
	Date:	7/7/2018	 	Date:	7/7/2018

 

    	 	 	40EX-4.1

 Exhibit 4.1 
  

 
 COUPA SOFTWARE INCORPORATED 

AND 
 WILMINGTON TRUST, NATIONAL
ASSOCIATION, 
 as Trustee 

INDENTURE 
 Dated as of
June 15, 2020 
 0.375% Convertible Senior Notes due 2026 
  

 

 TABLE OF CONTENTS 

 
  

 
  

					
	 	  	PAGE	 
	ARTICLE 1	  			
	DEFINITIONS	  			
		
	 Section 1.01. Definitions
	  	 	1	 
	 Section 1.02. References to Interest
	  	 	13	 
		
	ARTICLE 2	  			
	ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES	  			
		
	 Section 2.01. Designation and Amount
	  	 	13	 
	 Section 2.02. Form of Notes
	  	 	13	 
	 Section 2.03. Date and Denomination of Notes; Payments of Interest and Defaulted
Amounts
	  	 	14	 
	 Section 2.04. Execution, Authentication and Delivery of Notes
	  	 	15	 
	 Section 2.05. Exchange and Registration of Transfer of Notes; Restrictions on Transfer;
Depositary
	  	 	16	 
	 Section 2.06. Mutilated, Destroyed, Lost or Stolen Notes
	  	 	22	 
	 Section 2.07. Temporary Notes
	  	 	23	 
	 Section 2.08. Cancellation of Notes Paid, Converted, Etc
	  	 	24	 
	 Section 2.09. CUSIP Numbers
	  	 	24	 
	 Section 2.10. Additional Notes; Repurchases
	  	 	24	 
		
	ARTICLE 3	  			
	SATISFACTION AND DISCHARGE	  			
		
	 Section 3.01. Satisfaction and Discharge
	  	 	25	 
		
	ARTICLE 4	  			
	PARTICULAR COVENANTS OF THE COMPANY	  			
		
	 Section 4.01. Payment of Principal and Interest
	  	 	25	 
	 Section 4.02. Maintenance of Office or Agency
	  	 	25	 
	 Section 4.03. Appointments to Fill Vacancies in Trustee’s Office
	  	 	26	 
	 Section 4.04. Provisions as to Paying Agent
	  	 	26	 
	 Section 4.05. Existence
	  	 	27	 
	 Section 4.06. Rule 144A Information Requirement and Annual Reports
	  	 	27	 
	 Section 4.07. Stay, Extension and Usury Laws
	  	 	29	 
	 Section 4.08. Compliance Certificate; Statements as to Defaults
	  	 	29	 
	 Section 4.09. Further Instruments and Acts
	  	 	30	 

  
 i 

					
	ARTICLE 5	  	 	 
	LISTS OF HOLDERS AND REPORTS BY THE COMPANY AND THE
TRUSTEE	  	 	 
		
	 Section 5.01. Lists of Holders
	  	 	30	 
	 Section 5.02. Preservation and Disclosure of Lists
	  	 	30	 
		
	ARTICLE 6	  	 	 
	DEFAULTS AND REMEDIES	  	 	 
		
	 Section 6.01. Events of Default
	  	 	30	 
	 Section 6.02. Acceleration; Rescission and Annulment
	  	 	31	 
	 Section 6.03. Additional Interest
	  	 	32	 
	 Section 6.04. Payments of Notes on Default; Suit Therefor
	  	 	33	 
	 Section 6.05. Application of Monies Collected by Trustee
	  	 	35	 
	 Section 6.06. Proceedings by Holders
	  	 	35	 
	 Section 6.07. Proceedings by Trustee
	  	 	36	 
	 Section 6.08. Remedies Cumulative and Continuing
	  	 	36	 
	 Section 6.09. Direction of Proceedings and Waiver of Defaults by Majority of
Holders
	  	 	37	 
	 Section 6.10. Notice of Defaults
	  	 	37	 
	 Section 6.11. Undertaking to Pay Costs
	  	 	38	 
		
	ARTICLE 7	  	 	 
	CONCERNING THE TRUSTEE	  	 	 
		
	 Section 7.01. Duties and Responsibilities of Trustee
	  	 	38	 
	 Section 7.02. Reliance on Documents, Opinions, Etc
	  	 	40	 
	 Section 7.03. No Responsibility for Recitals, Etc
	  	 	41	 
	 Section 7.04. Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note
Registrar May Own Notes
	  	 	41	 
	 Section 7.05. Monies and Shares of Common Stock to Be Held in Trust
	  	 	41	 
	 Section 7.06. Compensation and Expenses of Trustee
	  	 	41	 
	 Section 7.07. Officer’s Certificate as Evidence
	  	 	42	 
	 Section 7.08. Eligibility of Trustee
	  	 	42	 
	 Section 7.09. Resignation or Removal of Trustee
	  	 	43	 
	 Section 7.10. Acceptance by Successor Trustee
	  	 	44	 
	 Section 7.11. Succession by Merger, Etc
	  	 	44	 
	 Section 7.12. Trustee’s Application for Instructions from the Company
	  	 	45	 
		
	ARTICLE 8	  	 	 
	CONCERNING THE HOLDERS	  	 	 
		
	 Section 8.01. Action by Holders
	  	 	45	 
	 Section 8.02. Proof of Execution by Holders
	  	 	45	 
	 Section 8.03. Who Are Deemed Absolute Owners
	  	 	45	 
	 Section 8.04. Company-Owned Notes Disregarded
	  	 	46	 
	 Section 8.05. Revocation of Consents; Future Holders Bound
	  	 	46	 

  
 ii 

					
	ARTICLE 9	  	 	 
	HOLDERS’ MEETINGS	  	 	 
		
	 Section 9.01. Purpose of Meetings
	  	 	47	 
	 Section 9.02. Call of Meetings by Trustee
	  	 	47	 
	 Section 9.03. Call of Meetings by Company or Holders
	  	 	47	 
	 Section 9.04. Qualifications for Voting
	  	 	48	 
	 Section 9.05. Regulations
	  	 	48	 
	 Section 9.06. Voting
	  	 	48	 
	 Section 9.07. No Delay of Rights by Meeting
	  	 	49	 
		
	ARTICLE 10	  	 	 
	SUPPLEMENTAL INDENTURES	  	 	 
		
	 Section 10.01. Supplemental Indentures Without Consent of Holders
	  	 	49	 
	 Section 10.02. Supplemental Indentures with Consent of Holders
	  	 	50	 
	 Section 10.03. Effect of Supplemental Indentures
	  	 	51	 
	 Section 10.04. Notation on Notes
	  	 	51	 
	 Section 10.05. Evidence of Compliance of Supplemental Indenture to Be Furnished
Trustee
	  	 	52	 
		
	ARTICLE 11	  	 	 
	CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE	  	 	 
	  
 Section 11.01.
Company May Consolidate, Etc. on Certain Terms
	  	 	52	 
	 Section 11.02. Successor Corporation to Be Substituted
	  	 	52	 
	 Section 11.03. Opinion of Counsel to Be Given to Trustee
	  	 	53	 
		
	ARTICLE 12	  	 	 
	IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS	  	 	 
	  
  

Section 12.01. Indenture and Notes Solely Corporate Obligations
	  	 	53	 
		
	ARTICLE 13	  	 	 
	INTENTIONALLY OMITTED	  	 	 
		
	ARTICLE 14	  	 	 
	CONVERSION OF NOTES	  	 	 
		
	 Section 14.01. Conversion Privilege
	  	 	54	 
	 Section 14.02. Conversion Procedure; Settlement Upon Conversion.
	  	 	57	 
	 Section 14.03. Increased Conversion Rate Applicable to Certain Notes Surrendered in
Connection with Make-Whole Fundamental Changes or Called Notes During a Redemption Period
	  	 	62	 
	 Section 14.04. Adjustment of Conversion Rate
	  	 	65	 
	 Section 14.05. Adjustments of Prices
	  	 	74	 
	 Section 14.06. Shares to Be Fully Paid
	  	 	74	 

  
 iii 

					
	 Section 14.07. Effect of Recapitalizations, Reclassifications and Changes of the Common
Stock
	  	 	74	 
	 Section 14.08. Certain Covenants
	  	 	76	 
	 Section 14.09. Responsibility of Trustee
	  	 	76	 
	 Section 14.10. Notice to Holders Prior to Certain Actions
	  	 	77	 
	 Section 14.11. Stockholder Rights Plans
	  	 	78	 
	 Section 14.12. Exchange In Lieu Of Conversion
	  	 	78	 
		
	ARTICLE 15	  	 	 
	REPURCHASE OF NOTES AT OPTION OF HOLDERS	  	 	 
		
	 Section 15.01. Intentionally Omitted
	  	 	79	 
	 Section 15.02. Repurchase at Option of Holders Upon a Fundamental
Change
	  	 	79	 
	 Section 15.03. Withdrawal of Fundamental Change Repurchase Notice
	  	 	81	 
	 Section 15.04. Deposit of Fundamental Change Repurchase Price
	  	 	82	 
	 Section 15.05. Covenant to Comply with Applicable Laws Upon Repurchase of
Notes
	  	 	83	 
		
	ARTICLE 16	  	 	 
	OPTIONAL REDEMPTION	  	 	 
		
	 Section 16.01. Optional Redemption
	  	 	83	 
	 Section 16.02. Notice of Optional Redemption; Selection of Notes
	  	 	83	 
	 Section 16.03. Payment of Notes Called for Redemption
	  	 	84	 
	 Section 16.04. Restrictions on Redemption
	  	 	85	 
		
	ARTICLE 17	  	 	 
	MISCELLANEOUS PROVISIONS	  	 	 
		
	 Section 17.01. Provisions Binding on Company’s Successors
	  	 	85	 
	 Section 17.02. Official Acts by Successor Corporation
	  	 	85	 
	 Section 17.03. Addresses for Notices, Etc
	  	 	85	 
	 Section 17.04. Governing Law; Jurisdiction
	  	 	86	 
	 Section 17.05. Evidence of Compliance with Conditions Precedent; Certificates and Opinions
of Counsel to Trustee
	  	 	86	 
	 Section 17.06. Legal Holidays
	  	 	87	 
	 Section 17.07. No Security Interest Created
	  	 	87	 
	 Section 17.08. Benefits of Indenture
	  	 	87	 
	 Section 17.09. Table of Contents, Headings, Etc
	  	 	88	 
	 Section 17.10. Authenticating Agent
	  	 	88	 
	 Section 17.11. Execution in Counterparts
	  	 	89	 
	 Section 17.12. Severability
	  	 	89	 
	 Section 17.13. Waiver of Jury Trial
	  	 	89	 
	 Section 17.14. Force Majeure
	  	 	89	 
	 Section 17.15. Calculations
	  	 	90	 
	 Section 17.16. U.S.A. PATRIOT Act
	  	 	90	 
	 Section 17.17. No Personal Liability of Directors, Officers, Employees or
Stockholders
	  	 	90	 

 EXHIBIT 
  

					
			
	Exhibit A	  	Form of Note	  	A-1

  
 iv 

 Exhibit 4.1 

INDENTURE, dated as of June 15, 2020, between COUPA SOFTWARE INCORPORATED, a Delaware corporation, as issuer (the
“Company”, as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee”, as more fully set forth in Section 1.01). 

W I T N E S S E T H: 
 WHEREAS,
for its lawful corporate purposes, the Company has duly authorized the issuance of its 0.375% Convertible Senior Notes due 2026 (the “Notes”), initially in an aggregate principal amount not to exceed $1,380,000,000, and in order to
provide the terms and conditions upon which the Notes are to be authenticated, issued and delivered, the Company has duly authorized the execution and delivery of this Indenture; and 

WHEREAS, the Form of Note, the certificate of authentication to be borne by each Note, the Form of Notice of Conversion, the Form of
Fundamental Change Repurchase Notice and the Form of Assignment and Transfer to be borne by the Notes are to be substantially in the forms hereinafter provided; and 

WHEREAS, all acts and things necessary to make the Notes, when executed by the Company and authenticated and delivered by the Trustee or a
duly authorized authenticating agent, as in this Indenture provided, the valid, binding and legal obligations of the Company, and this Indenture a valid agreement according to its terms, have been done and performed, and the execution of this
Indenture and the issuance hereunder of the Notes have in all respects been duly authorized. 
 NOW, THEREFORE, THIS INDENTURE WITNESSETH:

 That in order to declare the terms and conditions upon which the Notes are, and are to be, authenticated, issued and delivered, and in
consideration of the premises and of the purchase and acceptance of the Notes by the Holders thereof, the Company covenants and agrees with the Trustee for the equal and proportionate benefit of the respective Holders from time to time of the Notes
(except as otherwise provided below), as follows: 
 ARTICLE 1 

DEFINITIONS 

Section 1.01. Definitions. The terms defined in this Section 1.01 (except as herein otherwise expressly provided or unless
the context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section 1.01. The words “herein,” “hereof,”
“hereunder,” and words of similar import refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. The terms defined in this Article include the plural as well as the singular. 

 “Additional Interest” means all amounts, if any, payable pursuant to
Section 4.06(d), Section 4.06(e) and Section 6.03, as applicable. 
 “Additional Shares” shall have the
meaning specified in Section 14.03(a). 
 “Affiliate” of any specified Person means any other Person directly or
indirectly controlling or controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control,” when used with respect to any specified Person means the power to direct or
cause the direction of the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings
correlative to the foregoing. Notwithstanding anything to the contrary herein, the determination of whether one Person is an “Affiliate” of another Person for purposes of this Indenture shall be made based on the facts at the time such
determination is made or required to be made, as the case may be, hereunder. 
 “Bid Solicitation Agent” means the Company
or the Person appointed by the Company to solicit bids for the Trading Price of the Notes in accordance with Section 14.01(b)(i). The Trustee shall initially act as the Bid Solicitation Agent. 

“Board of Directors” means the board of directors of the Company or a committee of such board duly authorized to act for it
hereunder. 
 “Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the
Company to have been duly adopted by the Board of Directors, and to be in full force and effect on the date of such certification, and delivered to the Trustee. 

“Business Day” means, with respect to any Note, any day other than a Saturday, a Sunday or a day on which the Federal Reserve
Bank of New York is authorized or required by law or executive order to close or be closed. 
 “Called Notes” means Notes
called for redemption pursuant to Article 16 or subject to a Deemed Redemption. 
 “Capital Stock” means, for any entity,
any and all shares, interests, rights to purchase, warrants, options, participations or other equivalents of or interests in (however designated) stock issued by that entity. 

“Cash Settlement” shall have the meaning specified in Section 14.02(a). 

“Clause A Distribution” shall have the meaning specified in Section 14.04(c). 

“Clause B Distribution” shall have the meaning specified in Section 14.04(c). 

“Clause C Distribution” shall have the meaning specified in Section 14.04(c). 

“close of business” means 5:00 p.m. (New York City time). 

  
 2 

 “Combination Settlement” shall have the meaning specified in
Section 14.02(a). 
 “Commission” means the U.S. Securities and Exchange Commission. 

“Common Equity” of any Person means Capital Stock of such Person that is generally entitled (a) to vote in the election
of directors of such Person or (b) if such Person is not a corporation, to vote or otherwise participate in the selection of the governing body, partners, managers or others that will control the management or policies of such Person. 

“Common Stock” means the common stock of the Company, par value $0.0001 per share, at the date of this Indenture, subject to
Section 14.07. 
 “Company” shall have the meaning specified in the first paragraph of this Indenture, and subject to
the provisions of Article 11, shall include its successors and assigns. 
 “Company Order” means a written order of the
Company, signed by the Company’s Chief Executive Officer, Chief Financial Officer, any President or Vice President (whether or not designated by a number or numbers or word or words added before or after the title “President” or
“Vice President”) or the Company’s Treasurer, and delivered to the Trustee. 
 “Conversion Agent” shall have
the meaning specified in Section 4.02. 
 “Conversion Consideration” shall have the meaning specified in
Section 14.12(a). 
 “Conversion Date” shall have the meaning specified in Section 14.02(c). 

“Conversion Obligation” shall have the meaning specified in Section 14.01(a). 

“Conversion Price” means as of any time, $1,000, divided by the Conversion Rate as of such time. 

“Conversion Rate” shall have the meaning specified in Section 14.01(a). 

“Corporate Trust Office” means the designated office of the Trustee at which at any time this Indenture shall be
administered, which office at the date hereof is located at 246 Goose Lane, Suite 105, Guilford, CT 06437, Attention: Coupa Software Incorporated Administrator or such other address as the Trustee may designate from time to time by notice to the
Holders and the Company, or the designated corporate trust office of any successor trustee (or such other address as such successor trustee may designate from time to time by notice to the Holders and the Company). 

“Custodian” means the Trustee, as custodian for The Depository Trust Company, with respect to the Global Notes, or any
successor entity thereto. 
 “Daily Conversion Value” means, for each of the 20 consecutive Trading Days during the
relevant Observation Period, 5% of the product of (a) the Conversion Rate on such Trading Day and (b) the Daily VWAP on such Trading Day. 

  
 3 

 “Daily Measurement Value” means the Specified Dollar Amount (if any),
divided by 20. 
 “Daily Settlement Amount,” for each of the 20 consecutive Trading Days during the relevant
Observation Period, shall consist of: 
 (a) cash in an amount equal to the lesser of (i) the Daily Measurement Value
and (ii) the Daily Conversion Value on such Trading Day; and 
 (b) if the Daily Conversion Value on such Trading Day
exceeds the Daily Measurement Value, a number of shares of Common Stock equal to (i) the difference between the Daily Conversion Value and the Daily Measurement Value, divided by (ii) the Daily VWAP for such Trading Day. 

“Daily VWAP” means the per share volume-weighted average price as displayed under the heading “Bloomberg VWAP” on
Bloomberg page “COUP <equity> AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such
Trading Day (or if such volume-weighted average price is unavailable, the market value of one share of the Common Stock on such Trading Day determined, using a volume-weighted average method, by a nationally recognized independent investment banking
firm retained for this purpose by the Company). The “Daily VWAP” shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours. 

“Deemed Redemption” shall have the meaning specified in Section 14.01(b)(v). 

“Default” means any event that is, or after notice or passage of time, or both, would be, an Event of Default. 

“Defaulted Amounts” means any amounts on any Note (including, without limitation, the Redemption Price, the Fundamental
Change Repurchase Price, principal and interest) that are payable but are not punctually paid or duly provided for. 

“delivered” with respect to any notice to be delivered, given or mailed to a Holder pursuant to this Indenture, shall mean
notice (x) given to the Depositary (or its designee) pursuant to the standing instructions from the Depositary or its designee, including by electronic mail in accordance with accepted practices or procedures at the Depositary (in the case of a
Global Note) or (y) mailed to such Holder by first class mail, postage prepaid, at its address as it appears on the Note Register, in each case in accordance with Section 17.03. Notice so “delivered” shall be deemed to include
any notice to be “mailed” or “given,” as applicable, under this Indenture. 
 “Depositary” means, with
respect to each Global Note, the Person specified in Section 2.05(c) as the Depositary with respect to such Notes, until a successor shall have been appointed and become such pursuant to the applicable provisions of this Indenture, and
thereafter, “Depositary” shall mean or include such successor. 
 “Designated Institution” shall have the
meaning specified in Section 14.12(a). 

  
 4 

 “Distributed Property” shall have the meaning specified in
Section 14.04(c). 
 “Effective Date” shall have the meaning specified in Section 14.03(c), except that, as used
in Section 14.04 and Section 14.05, “Effective Date” means the first date on which shares of the Common Stock trade on the applicable exchange or in the applicable market, regular way, reflecting the relevant share split
or share combination, as applicable. 
 “Event of Default” shall have the meaning specified in Section 6.01. 

“Ex-Dividend Date” means the first date on which shares of the Common Stock trade on
the applicable exchange or in the applicable market, regular way, without the right to receive the issuance, dividend or distribution in question, from the Company or, if applicable, from the seller of the Common Stock on such exchange or market (in
the form of due bills or otherwise) as determined by such exchange or market. 
 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 “Exchange Election” shall have
the meaning specified in Section 14.12(a). 
 “Form of Assignment and Transfer” shall mean the “Form of
Assignment and Transfer” attached as Attachment 3 to the Form of Note attached hereto as Exhibit A. 
 “Form of Fundamental
Change Repurchase Notice” shall mean the “Form of Fundamental Change Repurchase Notice” attached as Attachment 2 to the Form of Note attached hereto as Exhibit A. 

“Form of Note” shall mean the “Form of Note” attached hereto as Exhibit A. 

“Form of Notice of Conversion” shall mean the “Form of Notice of Conversion” attached as Attachment 1 to the Form
of Note attached hereto as Exhibit A. 
 “Fundamental Change” shall be deemed to have occurred at the time after the Notes
are originally issued if any of the following occurs prior to the Maturity Date: 
 (a) a “person” or
“group” within the meaning of Section 13(d) of the Exchange Act, other than the Company, its Wholly Owned Subsidiaries and the employee benefit plans of the Company and its Wholly Owned Subsidiaries, files a Schedule TO or any
schedule, form or report under the Exchange Act disclosing that such person or group has become the direct or indirect “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act, of the
Common Stock representing more than 50% of the voting power of the Common Stock; 
 (b) the consummation of (A) any
recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or combination) as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other
property or assets; (B) any share exchange, consolidation or merger of the Company pursuant to which the Common Stock will be converted into cash, 

  
 5 

 
securities or other property or assets; or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of the consolidated assets of the
Company and its Subsidiaries, taken as a whole, to any Person other than one of the Company’s Wholly Owned Subsidiaries; provided, however, that a transaction described in clause (B) in which the holders of all classes of the
Company’s Common Equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of Common Equity of the continuing or surviving corporation or transferee or the parent thereof immediately after such
transaction in substantially the same proportions (relative to each other) as such ownership immediately prior to such transaction shall not be a Fundamental Change pursuant to this clause (b); 

(c) the stockholders of the Company approve any plan or proposal for the liquidation or dissolution of the Company; or 

(d) the Common Stock ceases to be listed or quoted on any of The New York Stock Exchange, The Nasdaq Global Select Market or
The Nasdaq Global Market (or any of their respective successors); 
 provided, however, that a transaction or transactions described in clause
(a) or (b) above shall not constitute a Fundamental Change if at least 90% of the consideration received or to be received by the common stockholders of the Company, excluding cash payments for fractional shares and cash payments made in
respect of dissenters’ statutory appraisal rights, in connection with such transaction or transactions consists of shares of common stock that are listed or quoted on any of The New York Stock Exchange, The Nasdaq Global Select Market or The
Nasdaq Global Market (or any of their respective successors) or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions and as a result of such transaction or transactions the Notes become convertible
into such consideration, excluding cash payments for fractional shares and cash payments made in respect of dissenters’ statutory appraisal rights (subject to the provisions of Section 14.07). If any transaction in which the Common Stock
is replaced by the securities of another entity occurs, following completion of any related Make-Whole Fundamental Change Period (or, in the case of a transaction that would have been a Fundamental Change or a Make-Whole Fundamental Change but for
the proviso in the immediately preceding paragraph, following the effective date of such transaction) references to the Company in this definition shall instead be references to such other entity. 

For purposes of this definition of “Fundamental Change,” any transaction that constitutes a Fundamental Change pursuant to both clause (a) and
clause (b) (excluding the proviso to such clause (b)) of such definition shall be deemed a Fundamental Change solely under clause (b) of such definition (subject to such proviso). 

“Fundamental Change Company Notice” shall have the meaning specified in Section 15.02(c). 

“Fundamental Change Repurchase Date” shall have the meaning specified in Section 15.02(a). 

  
 6 

 “Fundamental Change Repurchase Notice” shall have the meaning specified in
Section 15.02(b)(i). 
 “Fundamental Change Repurchase Price” shall have the meaning specified in
Section 15.02(a). 
 “Global Note” shall have the meaning specified in Section 2.05(b). 

“Holder,” as applied to any Note, or other similar terms, shall mean any Person in whose name at the time a particular Note
is registered on the Note Register. 
 “Indenture” means this instrument as originally executed or, if amended or
supplemented as herein provided, as so amended or supplemented. 
 “Interest Payment Date” means each June 15 and
December 15 of each year, beginning on December 15, 2020. 
 “Last Reported Sale Price” of the Common Stock on
any date means the closing sale price per share (or if no closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported
in composite transactions for the principal U.S. national or regional securities exchange on which the Common Stock is traded. If the Common Stock is not listed for trading on a U.S. national or regional securities exchange on the relevant date, the
“Last Reported Sale Price” shall be the last quoted bid price for the Common Stock in the over-the-counter market on the relevant date as reported by
OTC Markets Group Inc. or a similar organization. If the Common Stock is not so quoted, the “Last Reported Sale Price” shall be the average of the mid-point of the last bid and ask prices for
the Common Stock on the relevant date from each of at least three nationally recognized independent investment banking firms selected by the Company for this purpose. The “Last Reported Sale Price” shall be determined without regard to
after-hours trading or any other trading outside of regular trading session hours. 
 “Make-Whole Fundamental Change” means
any transaction or event that constitutes a Fundamental Change (as defined above and determined after giving effect to any exceptions to or exclusions from such definition, but without regard to the proviso in clause (b) of the
definition thereof). 
 “Make-Whole Fundamental Change Period” shall have the meaning specified in Section 14.03(a).

 “Market Disruption Event” means, for the purposes of determining amounts due upon conversion (a) a failure by the
primary U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading to open for trading during its regular trading session or (b) the occurrence or existence prior to 1:00 p.m., New York
City time, on any Scheduled Trading Day for the Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on trading (by reason of movements in price exceeding limits
permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts traded on any U.S. exchange relating to the Common Stock. 

  
 7 

 “Maturity Date” means June 15, 2026. 

“Measurement Period” shall have the meaning specified in Section 14.01(b)(i). 

“Merger Event” shall have the meaning specified in Section 14.07(a). 

“Minimum Specified Amount” shall have the meaning specified in Section 14.02(a)(iii). 

“Note” or “Notes” shall have the meaning specified in the first paragraph of the recitals of this Indenture.

 “Note Register” shall have the meaning specified in Section 2.05(a). 

“Note Registrar” shall have the meaning specified in Section 2.05(a). 

“Notice of Conversion” shall have the meaning specified in Section 14.02(b). 

“Observation Period” with respect to any Note surrendered for conversion means: (i) subject to clause (ii), if the
relevant Conversion Date occurs prior to March 15, 2026, the 20 consecutive Trading Day period beginning on, and including, the second Trading Day immediately succeeding such Conversion Date; (ii) if the relevant Conversion Date occurs
during a Redemption Period pursuant to Section 16.02, the 20 consecutive Trading Days beginning on, and including, the 21st Scheduled Trading Day immediately preceding the relevant Redemption Date; and (iii) subject to clause (ii), if the
relevant Conversion Date occurs on or after March 15, 2026, the 20 consecutive Trading Days beginning on, and including, the 21st Scheduled Trading Day immediately preceding the Maturity Date. 

“Offering Memorandum” means the preliminary offering memorandum dated June 9, 2020, as supplemented by the related
pricing term sheet dated June 10, 2020, relating to the offering and sale of the Notes. 
 “Officer” means, with
respect to the Company, the Chief Executive Officer, the Chief Financial Officer, the Chief Accounting Officer, the Treasurer, the Secretary, or any President or Vice President (whether or not designated by a number or numbers or word or words added
before or after the title “President” or “Vice President”). 
 “Officer’s Certificate,” when used
with respect to the Company, means a certificate that is delivered to the Trustee and that is signed by an Officer of the Company. Each such certificate shall include the statements provided for in Section 17.05 if and to the extent required by
the provisions of such Section. The Officer giving an Officer’s Certificate pursuant to Section 4.08 shall be the principal executive, financial or accounting officer of the Company. 

“open of business” means 9:00 a.m. (New York City time). 

“Opinion of Counsel” means an opinion in writing signed by legal counsel, who may be an employee of or counsel to the
Company, or other counsel who is reasonably acceptable to the Trustee, that is delivered to the Trustee, which opinion may contain customary exceptions and qualifications as to the matters set forth therein. Each such opinion shall include the
statements provided for in Section 17.05 if and to the extent required by the provisions of such Section 17.05. 

  
 8 

 “Optional Redemption” shall have the meaning specified in
Section 16.01. 
 “outstanding,” when used with reference to Notes, shall, subject to the provisions of
Section 8.04, mean, as of any particular time, all Notes authenticated and delivered by the Trustee under this Indenture, except: 

(a) Notes theretofore canceled by the Trustee or accepted by the Trustee for cancellation; 

(b) Notes, or portions thereof, that have become due and payable and in respect of which monies in the necessary amount shall
have been deposited in trust with the Trustee or with any Paying Agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own Paying Agent); 

(c) Notes that have been paid pursuant to Section 2.06 or Notes in lieu of which, or in substitution for which, other
Notes shall have been authenticated and delivered pursuant to the terms of Section 2.06 unless proof satisfactory to the Trustee is presented that any such Notes are held by protected purchasers in due course; 

(d) Notes converted pursuant to Article 14 and required to be cancelled pursuant to Section 2.08; 

(e) Notes redeemed pursuant to Article 16; and 

(f) Notes repurchased by the Company pursuant to the penultimate sentence of Section 2.10. 

“Paying Agent” shall have the meaning specified in Section 4.02. 

“Person” means an individual, a corporation, a limited liability company, an association, a partnership, a joint venture, a
joint stock company, a trust, an unincorporated organization or a government or an agency or a political subdivision thereof. 

“Physical Notes” means permanent certificated Notes in registered form issued in denominations of $1,000 principal amount and
multiples thereof. 
 “Physical Settlement” shall have the meaning specified in Section 14.02(a). 

“Predecessor Note” of any particular Note means every previous Note evidencing all or a portion of the same debt as that
evidenced by such particular Note; and, for the purposes of this definition, any Note authenticated and delivered under Section 2.06 in lieu of or in exchange for a mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same
debt as the mutilated, lost, destroyed or stolen Note that it replaces. 

  
 9 

 “Record Date” means, with respect to any dividend, distribution or other
transaction or event in which the holders of Common Stock (or other applicable security) have the right to receive any cash, securities or other property or in which the Common Stock (or such other security) is exchanged for or converted into any
combination of cash, securities or other property, the date fixed for determination of holders of the Common Stock (or such other security) entitled to receive such cash, securities or other property (whether such date is fixed by the Company, by
statute, by contract or otherwise). 
 “Redemption Date” shall have the meaning specified in Section 16.02(a). 

“Redemption Notice” shall have the meaning specified in Section 16.02(a). 

“Redemption Notice Date” means the date on which a Redemption Notice is delivered pursuant to Section 16.02. 

“Redemption Period” means the period from, and including, the relevant Redemption Notice Date until the close of business on
the second Scheduled Trading Day immediately preceding the related Redemption Date. 
 “Redemption Price” means, for any
Notes to be redeemed pursuant to Section 16.01, 100% of the principal amount of such Notes, plus accrued and unpaid interest, if any, to, but excluding, the Redemption Date (unless the Redemption Date falls after a Regular Record Date
but on or prior to the immediately succeeding Interest Payment Date, in which case interest accrued to the Interest Payment Date will be paid to Holders of record of such Notes on such Regular Record Date, and the Redemption Price will be equal to
100% of the principal amount of such Notes). 
 “Reference Property” shall have the meaning specified in
Section 14.07(a)(iv). 
 “Regular Record Date,” with respect to any Interest Payment Date, shall mean the June 1
or December 1 (whether or not such day is a Business Day) immediately preceding the applicable June 15 or December 15 Interest Payment Date, respectively. 

“Resale Restriction Termination Date” shall have the meaning specified in Section 2.05(c). 

“Responsible Officer” means, when used with respect to the Trustee, any officer within the corporate trust department of the
Trustee, including any vice president, assistant vice president, assistant secretary, assistant treasurer, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the time
shall be such officers, respectively, or to whom any corporate trust matter relating to this Indenture is referred because of such person’s knowledge of and familiarity with the particular subject and who, in each case, shall have direct
responsibility for the administration of this Indenture. 
 “Restricted Securities” shall have the meaning specified in
Section 2.05(c). 
 “Rule 144” means Rule 144 as promulgated under the Securities Act. 

  
 10 

 “Rule 144A” means Rule 144A as promulgated under the Securities Act. 

“Scheduled Trading Day” means a day that is scheduled to be a Trading Day on the principal U.S. national or regional
securities exchange or market on which the Common Stock is listed or admitted for trading. If the Common Stock is not so listed or admitted for trading, “Scheduled Trading Day” means a Business Day. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

“Settlement Amount” has the meaning specified in Section 14.02(a)(iv). 

“Settlement Method” means, with respect to any conversion of Notes, Physical Settlement, Cash Settlement or Combination
Settlement, as elected (or deemed to have been elected) by the Company. 
 “Settlement Notice” has the meaning specified in
Section 14.02(a)(ii). 
 “Significant Subsidiary” for purposes of Section 6.01(g)-(i), means a Subsidiary of the
Company that meets the definition of “significant subsidiary” in Article 1, Rule 1-02 of Regulation S-X promulgated by the Commission (or any successor rule).

 “Specified Dollar Amount” means the maximum cash amount per $1,000 principal amount of Notes to be received upon
conversion as specified in the Settlement Notice related to any converted Notes (or deemed specified pursuant to Section 14.02(a)). 

“Spin-Off” shall have the meaning specified in Section 14.04(c). 

“Stock Price” shall have the meaning specified in Section 14.03(c). 

“Subsidiary” means, with respect to any Person, any corporation, association, partnership or other business entity of which
more than 50% of the total voting power of shares of Capital Stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers, general partners
or trustees thereof is at the time owned or controlled, directly or indirectly, by (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person. 

“Successor Company” shall have the meaning specified in Section 11.01(a). 

“Trading Day” means, except for determining amounts due upon conversion as set forth below, a day on which (i) trading
in the Common Stock (or other security for which a closing sale price must be determined) generally occurs on The Nasdaq Global Select Market or, if the Common Stock (or such other security) is not then listed on The Nasdaq Global Select Market, on
the principal other U.S. national or regional securities exchange on which the Common Stock (or such other security) is then listed or, if the Common Stock (or such other security) is not then listed on a U.S. national or regional securities
exchange, on the principal other market on which the Common Stock (or such other security) is then traded and (ii) a Last Reported Sale Price for 

  
 11 

 
the Common Stock (or closing sale price for such other security) is available on such securities exchange or market; provided that if the Common Stock (or such other security) is not so
listed or traded, “Trading Day” means a Business Day; and provided, further, that for purposes of determining amounts due upon conversion only, “Trading Day” means a day on which (x) there is no
Market Disruption Event and (y) trading in the Common Stock generally occurs on The Nasdaq Global Select Market or, if the Common Stock is not then listed on The Nasdaq Global Select Market, on the principal other U.S. national or regional
securities exchange on which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then listed or admitted for
trading, except that if the Common Stock is not so listed or admitted for trading, “Trading Day” means a Business Day. 

“Trading Price” of the Notes on any date of determination means the average of the secondary market bid quotations obtained
by the Bid Solicitation Agent for $1,000,000 principal amount of Notes at approximately 3:30 p.m., New York City time, on such determination date from three independent nationally recognized securities dealers the Company selects for this purpose;
provided that if three such bids cannot reasonably be obtained by the Bid Solicitation Agent but two such bids are obtained, then the average of the two bids shall be used, and if only one such bid can reasonably be obtained by the Bid
Solicitation Agent, that one bid shall be used. If the Bid Solicitation Agent cannot reasonably obtain at least one bid for $1,000,000 principal amount of Notes from a nationally recognized securities dealer on any determination date, then the
Trading Price per $1,000 principal amount of Notes on such determination date shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate. 

“transfer” shall have the meaning specified in Section 2.05(c). 

“Trigger Event” shall have the meaning specified in Section 14.04(c). 

“Trust Indenture Act” means the Trust Indenture Act of 1939, as amended, as it was in force at the date of execution of this
Indenture; provided, however, that in the event the Trust Indenture Act of 1939 is amended after the date hereof, the term “Trust Indenture Act” shall mean, to the extent required by such amendment, the Trust Indenture Act of
1939, as so amended. 
 “Trustee” means the Person named as the “Trustee” in the first paragraph of this
Indenture until a successor trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean or include each Person who is then a Trustee hereunder. 

“unit of Reference Property” shall have the meaning specified in Section 14.07(a). 

“Valuation Period” shall have the meaning specified in Section 14.04(c). 

“Wholly Owned Subsidiary” means, with respect to any Person, any Subsidiary of such Person, except that, solely for purposes
of this definition, the reference to “more than 50%” in the definition of “Subsidiary” shall be deemed replaced by a reference to “100%”. 

  
 12 

 Section 1.02. References to Interest. Unless the context otherwise requires, any
reference to interest on, or in respect of, any Note in this Indenture shall be deemed to include Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to any of Section 4.06(d), Section 4.06(e)
and Section 6.03. Unless the context otherwise requires, any express mention of Additional Interest in any provision hereof shall not be construed as excluding Additional Interest in those provisions hereof where such express mention is not
made. 
 ARTICLE 2 

ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND
EXCHANGE OF NOTES 
 Section 2.01. Designation and Amount. The Notes shall be
designated as the “0.375% Convertible Senior Notes due 2026.” The aggregate principal amount of Notes that may be authenticated and delivered under this Indenture is initially limited to $1,380,000,000, subject to Section 2.10 and
except for Notes authenticated and delivered upon registration or transfer of, or in exchange for, or in lieu of other Notes to the extent permitted hereunder. 

Section 2.02. Form of Notes. The Notes and the Trustee’s certificate of authentication to be borne by such Notes shall be
substantially in the respective forms set forth in Exhibit A, the terms and provisions of which shall constitute, and are hereby expressly incorporated in and made a part of this Indenture. To the extent applicable, the Company and the Trustee, by
their execution and delivery of this Indenture, expressly agree to such terms and provisions and to be bound thereby. In the case of any conflict between this Indenture and a Note, the provisions of this Indenture shall control and govern to the
extent of such conflict. 
 Any Global Note may be endorsed with or have incorporated in the text thereof such legends or recitals or
changes not inconsistent with the provisions of this Indenture as may be required by the Custodian or the Depositary, or as may be required to comply with any applicable law or any regulation thereunder or with the rules and regulations of any
securities exchange or automated quotation system upon which the Notes may be listed or traded or designated for issuance or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any
particular Notes are subject. 
 Any of the Notes may have such letters, numbers or other marks of identification and such notations,
legends or endorsements as the Officer executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or
with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, or to conform to usage or to indicate any special
limitations or restrictions to which any particular Notes are subject. 
 Each Global Note shall represent such principal amount of the
outstanding Notes as shall be specified therein and shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of outstanding Notes represented
thereby may from time to time be increased or reduced to reflect 

  
 13 

 
redemptions, repurchases, cancellations, conversions, transfers or exchanges permitted hereby. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the amount of
outstanding Notes represented thereby shall be made by the Trustee or the Custodian, at the direction of the Trustee, in such manner and upon instructions given by the Holder of such Notes in accordance with this Indenture. Payment of principal
(including the Redemption Price and the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, a Global Note shall be made to the Holder of such Note on the date of payment, unless a record date or other means of
determining Holders eligible to receive payment is provided for herein. 
 Section 2.03. Date and Denomination of Notes; Payments of
Interest and Defaulted Amounts. (a) The Notes shall be issuable in registered form without coupons in denominations of $1,000 principal amount and multiples thereof. Each Note shall be dated the date of its authentication and shall bear
interest from the date specified on the face of such Note. Accrued interest on the Notes shall be computed on the basis of a 360-day year composed of twelve 30-day
months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month. 

(b) The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register at the close of business on any Regular
Record Date with respect to any Interest Payment Date shall be entitled to receive the interest payable on such Interest Payment Date. The principal amount of any Note (x) in the case of any Physical Note, shall be payable at the office or
agency of the Company designated by the Company for such purposes in the contiguous United States of America, which shall initially be the Corporate Trust Office and (y) in the case of any Global Note, shall be payable by wire transfer of
immediately available funds to the account of the Depositary or its nominee. The Company shall pay (or cause the Paying Agent to pay to the extent funded by the Company) interest (i) on any Physical Notes (A) to Holders holding Physical
Notes having an aggregate principal amount of $5,000,000 or less, by check mailed to the Holders of these Notes at their address as it appears in the Note Register and (B) to Holders holding Physical Notes having an aggregate principal amount
of more than $5,000,000, either by check mailed to each such Holder or, upon application by such a Holder to the Note Registrar (containing the requisite information for the Trustee or Paying Agent to make such wire transfer) not later than the
relevant Regular Record Date, by wire transfer in immediately available funds to that Holder’s account within the United States of America, which application shall remain in effect until the Holder notifies, in writing, the Note Registrar to
the contrary or (ii) on any Global Note by wire transfer of immediately available funds to the account of the Depositary or its nominee. 

  
 14 

 (c) Any Defaulted Amounts shall forthwith cease to be payable to the Holder on the relevant
payment date but shall accrue interest per annum at the rate borne by the Notes from, and including, such relevant payment date, and such Defaulted Amounts together with such interest thereon shall be paid by the Company, at its election in each
case, as provided in clause (i) or (ii) below: 
 (i) The Company may elect to make payment of any Defaulted Amounts to
the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the close of business on a special record date for the payment of such Defaulted Amounts, which shall be fixed in the following manner. The Company shall
notify the Trustee in writing of the amount of the Defaulted Amounts proposed to be paid on each Note and the date of the proposed payment (which shall be not less than 25 days after the receipt by the Trustee of such notice, unless the Trustee
shall consent to an earlier date), and at the same time the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to be paid in respect of such Defaulted Amounts or shall make arrangements satisfactory to the
Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited to be held in trust for the benefit of the Persons entitled to such Defaulted Amounts as in this clause provided. Thereupon the Company shall fix a
special record date for the payment of such Defaulted Amounts which shall be not more than 15 days and not less than 10 days prior to the date of the proposed payment, and not less than 10 days after the receipt by the Trustee of the notice of the
proposed payment. The Company shall promptly notify the Trustee in writing of such special record date and the Trustee, in the name and at the expense of the Company, shall cause notice of the proposed payment of such Defaulted Amounts and the
special record date therefor to be delivered to each Holder at its address as it appears in the Note Register, or by electronic means to the Depositary in the case of Global Notes, not less than 10 days prior to such special record date. Notice of
the proposed payment of such Defaulted Amounts and the special record date therefor having been so delivered, such Defaulted Amounts shall be paid to the Persons in whose names the Notes (or their respective Predecessor Notes) are registered at the
close of business on such special record date and shall no longer be payable pursuant to the following clause (ii) of this Section 2.03(c). The Trustee shall have no responsibility whatsoever for the calculation of the Defaulted Amounts.

 (ii) The Company may make payment of any Defaulted Amounts in any other lawful manner not inconsistent with the
requirements of any securities exchange or automated quotation system on which the Notes may be listed or designated for issuance, and upon such notice as may be required by such exchange or automated quotation system, if, after written notice given
by the Company to the Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. 

Section 2.04. Execution, Authentication and Delivery of Notes. The Notes shall be signed in the name and on behalf of the
Company by the manual or facsimile signature of any of its Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary or any of its Executive or Senior Vice Presidents. 

At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Notes executed by the Company to
the Trustee for authentication, together with a Company Order for the authentication and delivery of such Notes, and the Trustee in accordance with such Company Order shall authenticate and deliver such Notes, without any further action by the
Company hereunder; provided that the Trustee shall be entitled to receive an Officer’s Certificate and an Opinion of Counsel of the Company with respect to the issuance, authentication and delivery of such Notes. 

  
 15 

 Only such Notes as shall bear thereon a certificate of authentication substantially in the
form set forth on the Form of Note attached as Exhibit A hereto, executed manually by an authorized signatory of the Trustee (or an authenticating agent appointed by the Trustee as provided by Section 17.10), shall be entitled to the benefits
of this Indenture or be valid or obligatory for any purpose. Such certificate by the Trustee (or such an authenticating agent) upon any Note executed by the Company shall be conclusive evidence that the Note so authenticated has been duly
authenticated and delivered hereunder and that the Holder is entitled to the benefits of this Indenture. 
 In case any Officer of the
Company who shall have signed any of the Notes shall cease to be such Officer before the Notes so signed shall have been authenticated and delivered by the Trustee, or disposed of by the Company, such Notes nevertheless may be authenticated and
delivered or disposed of as though the Person who signed such Notes had not ceased to be such Officer of the Company; and any Note may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Note, shall be
the Officers of the Company, although at the date of the execution of this Indenture any such Person was not such an Officer. 

Section 2.05. Exchange and Registration of Transfer of Notes; Restrictions on Transfer; Depositary. (a) The Company shall
cause to be kept at the Corporate Trust Office a register (the register maintained in such office or in any other office or agency of the Company designated pursuant to Section 4.02, the “Note Register”) in which, subject to
such reasonable regulations as it may prescribe, the Company shall provide for the registration of Notes and of transfers of Notes. Such register shall be in written form or in any form capable of being converted into written form within a
reasonable period of time. The Trustee is hereby initially appointed the “Note Registrar” for the purpose of registering Notes and transfers of Notes as herein provided. The Company may appoint one or more co-Note Registrars in accordance with Section 4.02. 
 Upon surrender for registration of transfer of
any Physical Note to the Note Registrar or any co-Note Registrar, and satisfaction of the requirements for such transfer set forth in this Section 2.05, the Company shall execute, and the Trustee shall
authenticate and deliver, in the name of the designated transferee or transferees, one or more new Physical Notes of any authorized denominations and of a like aggregate principal amount and bearing such restrictive legends as may be required by
this Indenture. 
 Physical Notes may be exchanged for other Physical Notes of any authorized denominations and of a like aggregate
principal amount, upon surrender of the Notes to be exchanged at any such office or agency maintained by the Company pursuant to Section 4.02. Whenever any Physical Notes are so surrendered for exchange, the Company shall execute, and the
Trustee shall authenticate and deliver, the Physical Notes that the Holder making the exchange is entitled to receive, bearing registration numbers not contemporaneously outstanding. A holder of a beneficial interest in a note in a Global Note may
transfer or exchange such beneficial interest in accordance with this Indenture and the applicable procedures of the Depositary. 
 All
Notes presented or surrendered for registration of transfer or for exchange, repurchase or conversion shall (if so required by the Company, the Trustee, the Note Registrar or any co-Note Registrar) be duly
endorsed, or be accompanied by a written instrument or instruments of transfer in form satisfactory to the Company and duly executed, by the Holder thereof or its
attorney-in-fact duly authorized in writing. 

  
 16 

 No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent for any exchange or registration of transfer of Notes, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer
tax or other similar governmental charge required in connection therewith as a result of the name of the Holder of new Notes issued upon such exchange or registration of transfer being different from the name of the Holder of the old Notes
surrendered for exchange or registration of transfer or otherwise required by law. 
 None of the Company, the Trustee, the Note Registrar
or any co-Note Registrar shall be required to exchange or register a transfer of (i) any Notes surrendered for conversion or, if a portion of any Note is surrendered for conversion, such portion thereof
surrendered for conversion, (ii) any Notes, or a portion of any Note, surrendered for repurchase (and not withdrawn) in accordance with Article 15 or (iii) any Notes selected for redemption in accordance with Article 16, except the
unredeemed portion of any Note being redeemed in part or (iv) any Notes between a Regular Record Date and corresponding Interest Payment Date. 

All Notes issued upon any registration of transfer or exchange of Notes in accordance with this Indenture shall be the valid obligations of
the Company, evidencing the same debt, and entitled to the same benefits under this Indenture as the Notes surrendered upon such registration of transfer or exchange. 

(b) So long as the Notes are eligible for book-entry settlement with the Depositary, unless otherwise required by law, subject to the fourth
paragraph from the end of Section 2.05(c) all Notes shall be represented by one or more Notes in global form (each, a “Global Note”) registered in the name of the Depositary or the nominee of the Depositary. The transfer and
exchange of beneficial interests in a Global Note that does not involve the issuance of a Physical Note shall be effected through the Depositary (but not the Trustee or the Custodian) in accordance with this Indenture (including the restrictions on
transfer set forth herein) and the procedures of the Depositary therefor. 
 (c) Every Note that bears or is required under this
Section 2.05(c) to bear the legend set forth in this Section 2.05(c) (together with any Common Stock issued upon conversion of the Notes that is required to bear the legend set forth in Section 2.05(d), collectively, the
“Restricted Securities”) shall be subject to the restrictions on transfer set forth in this Section 2.05(c) (including those contained in the legend set forth below), unless such restrictions on transfer shall be eliminated or
otherwise waived by written consent of the Company, and the Holder of each such Restricted Security, by such Holder’s acceptance thereof, agrees to be bound by all such restrictions on transfer. As used in this Section 2.05(c) and
Section 2.05(d), the term “transfer” encompasses any sale, pledge, transfer or other disposition whatsoever of any Restricted Security. 
  

  
 17 

 Until the date (the “Resale Restriction Termination Date”) that is the
later of (1) the date that is one year after the last date of original issuance of the Notes, or such shorter period of time as permitted by Rule 144 or any successor provision thereto, and (2) such later date, if any, as may be required
by applicable law, any certificate evidencing such Note (and all securities issued in exchange therefor or substitution thereof, other than Common Stock, if any, issued upon conversion thereof, which shall bear the legend set forth in
Section 2.05(d), if applicable) shall bear a legend in substantially the following form (unless such Notes have been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that
continues to be effective at the time of such transfer, or sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or unless otherwise agreed by the Company in writing,
with notice thereof to the Trustee): 
 THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A
BENEFICIAL INTEREST HEREIN, THE ACQUIRER: 
 (1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A
“QUALIFIED INSTITUTIONAL BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND 

(2) AGREES FOR THE BENEFIT OF COUPA SOFTWARE INCORPORATED (THE “COMPANY”) THAT IT WILL NOT OFFER, SELL, PLEDGE
OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT
OR ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: 

(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR 

(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR 

(C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR 

(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D)
ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER FOR THE 

  
 18 

 
COMPANY TO DETERMINE THAT THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 No transfer of any Note prior to the Resale Restriction Termination
Date will be registered by the Note Registrar unless the applicable box on the Form of Assignment and Transfer has been checked. 
 Any Note
(or security issued in exchange or substitution therefor) (i) as to which such restrictions on transfer shall have expired in accordance with their terms, (ii) that has been transferred pursuant to a registration statement that has become
effective or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or (iii) that has been sold pursuant to the exemption from registration provided by Rule 144 or any similar provision
then in force under the Securities Act, may, upon surrender of such Note for exchange to the Note Registrar in accordance with the provisions of this Section 2.05, be exchanged for a new Note or Notes, of like tenor and aggregate principal
amount, which shall not bear the restrictive legend required by this Section 2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall be entitled to instruct the Custodian in writing to so surrender any Global Note as to
which any of the conditions set forth in clause (i) through (iii) of the immediately preceding sentence have been satisfied, and, upon such instruction, the Custodian shall so surrender such Global Note for exchange; and any new Global Note so
exchanged therefor shall not bear the restrictive legend specified in this Section 2.05(c) and shall not be assigned a restricted CUSIP number. The Company shall promptly notify the Trustee in writing upon the occurrence of the Resale
Restriction Termination Date and promptly after a registration statement, if any, with respect to the Notes or any Common Stock issued upon conversion of the Notes has been declared effective under the Securities Act. Any exchange pursuant to the
foregoing paragraph shall be in accordance with the applicable procedures of the Depositary. 
 Notwithstanding any other provisions of this
Indenture (other than the provisions set forth in this Section 2.05(c)), a Global Note may not be transferred as a whole or in part except (i) by the Depositary to a nominee of the Depositary or by a nominee of the Depositary to the
Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such successor Depositary and (ii) for exchange of a Global Note or a portion thereof for one or more Physical
Notes in accordance with the second immediately succeeding paragraph. 
 The Depositary shall be a clearing agency registered under the
Exchange Act. The Company initially appoints The Depository Trust Company to act as Depositary with respect to each Global Note. Initially, each Global Note shall be issued to the Depositary, registered in the name of Cede & Co., as the
nominee of the Depositary, and deposited with the Trustee as custodian for Cede & Co. 
  

  
 19 

 If (i) the Depositary notifies the Company at any time that the Depositary is unwilling
or unable to continue as depositary for the Global Notes and a successor depositary is not appointed within 90 days, (ii) the Depositary ceases to be registered as a clearing agency under the Exchange Act and a successor depositary is not
appointed within 90 days or (iii) an Event of Default with respect to the Notes has occurred and is continuing and, subject to the Depositary’s applicable procedures, a beneficial owner of any Note requests that its beneficial interest
therein be issued as a Physical Note, the Company shall execute, and the Trustee, upon receipt of an Officer’s Certificate and a Company Order for the authentication and delivery of Notes, shall authenticate and deliver (x) in the case of
clause (iii), a Physical Note to such beneficial owner in a principal amount equal to the principal amount of such Note corresponding to such beneficial owner’s beneficial interest and (y) in the case of clause (i) or (ii), Physical
Notes to each beneficial owner of the related Global Notes (or a portion thereof) in an aggregate principal amount equal to the aggregate principal amount of such Global Notes in exchange for such Global Notes, and upon delivery of the Global Notes
to the Trustee such Global Notes shall be canceled. 
 Physical Notes issued in exchange for all or a part of the Global Note pursuant to
this Section 2.05(c) shall be registered in such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, or, in the case of clause (iii) of the
immediately preceding paragraph, the relevant beneficial owner, shall instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such Physical Notes to the Persons in whose names such Physical Notes are so registered. 

At such time as all interests in a Global Note have been converted, canceled, redeemed, repurchased or transferred, such Global Note shall be,
upon receipt thereof, canceled by the Trustee in accordance with standing procedures and existing instructions between the Depositary and the Custodian. At any time prior to such cancellation, if any interest in a Global Note is exchanged for
Physical Notes, converted, canceled, redeemed, repurchased or transferred to a transferee who receives Physical Notes therefor or any Physical Note is exchanged or transferred for part of such Global Note, the principal amount of such Global Note
shall, in accordance with the standing procedures and instructions existing between the Depositary and the Custodian, be appropriately reduced or increased, as the case may be, and an endorsement shall be made on such Global Note, by the Trustee or
the Custodian, at the direction of the Trustee, to reflect such reduction or increase. 
 None of the Company, the Trustee or any agent of
the Company or the Trustee shall have any responsibility or liability for the payment of amounts to owners of beneficial interest in a Global Note, for any aspect of the records relating to or payments made on account of those interests by the
Depositary, or for maintaining, supervising or reviewing any records of the Depositary relating to such beneficial ownership those interests. 

(d) Until the Resale Restriction Termination Date, any stock certificate representing Common Stock issued upon conversion of such Note shall
bear a legend in substantially the following form (unless the Note or such Common Stock has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective
at the time of such transfer, or pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, or such Common Stock has been issued upon conversion of Notes that have been
transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer, or pursuant to the exemption from registration provided by Rule 144
or any similar provision then in force under the Securities Act, or unless otherwise agreed by the Company with written notice thereof to the Trustee and any transfer agent for the Common Stock): 

  
 20 

 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER: 

(1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A “QUALIFIED INSTITUTIONAL BUYER” (WITHIN THE
MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND 

(2) AGREES FOR THE BENEFIT OF COUPA SOFTWARE INCORPORATED (THE “COMPANY”) THAT IT WILL NOT OFFER, SELL, PLEDGE
OR OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE OF THE SERIES OF NOTES UPON THE CONVERSION OF WHICH THIS SECURITY WAS ISSUED OR SUCH
SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: 

(A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, OR 

(B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT, OR 

(C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, OR 

(D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY OTHER AVAILABLE EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 PRIOR TO THE REGISTRATION OF ANY TRANSFER IN ACCORDANCE WITH CLAUSE (2)(D)
ABOVE, THE COMPANY AND THE TRANSFER AGENT FOR THE COMPANY’S COMMON STOCK RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER FOR THE COMPANY TO DETERMINE THAT
THE PROPOSED TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 

  
 21 

 Any such Common Stock (i) as to which such restrictions on transfer shall have expired
in accordance with their terms, (ii) that has been transferred pursuant to a registration statement that has become or been declared effective under the Securities Act and that continues to be effective at the time of such transfer or
(iii) that has been sold pursuant to the exemption from registration provided by Rule 144 or any similar provision then in force under the Securities Act, may, upon surrender of the certificates representing such shares of Common Stock for
exchange in accordance with the procedures of the transfer agent for the Common Stock, be exchanged for a new certificate or certificates for a like aggregate number of shares of Common Stock, which shall not bear the restrictive legend required by
this Section 2.05(d). 
 (e) Any Note or Common Stock issued upon the conversion or exchange of a Note that is repurchased or owned by
any Affiliate of the Company (or any Person who was an Affiliate of the Company at any time during the three months immediately preceding) may not be resold by such Affiliate (or such Person, as the case may be) unless registered under the
Securities Act or resold pursuant to an exemption from the registration requirements of the Securities Act in a transaction that results in such Note or Common Stock, as the case may be, no longer being a “restricted security” (as defined
under Rule 144). The Company shall cause any Note that is repurchased or owned by it to be surrendered to the Trustee for cancellation in accordance with Section 2.08. 

(f) The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any securities laws or restrictions on
transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Depositary participants or beneficial owners of interests in any Global Note) other than
to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to
form with the express requirements hereof. 
 (g) Neither the Trustee nor any agent shall have any responsibility or liability for any
actions taken or not taken by the Depositary. 
 Section 2.06. Mutilated, Destroyed, Lost or Stolen Notes. In case any Note
shall become mutilated or be destroyed, lost or stolen, the Company in its discretion may execute, and upon its written request the Trustee or an authenticating agent appointed by the Trustee shall authenticate and deliver, a new Note, bearing a
registration number not contemporaneously outstanding, in exchange and substitution for the mutilated Note, or in lieu of and in substitution for the Note so destroyed, lost or stolen. In every case the applicant for a substituted Note shall furnish
to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless from any loss, liability, cost or expense caused by or connected with such
substitution, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company, to the Trustee and, if applicable, to such authenticating agent evidence to their satisfaction of the destruction, loss or theft of such
Note and of the ownership thereof. 

  
 22 

 The Trustee or such authenticating agent may authenticate any such substituted Note and
deliver the same upon the receipt of such security or indemnity as the Trustee, the Company and, if applicable, such authenticating agent may require. No service charge shall be imposed by the Company, the Trustee, the Note Registrar, any co-Note Registrar or the Paying Agent upon the issuance of any substitute Note, but the Company may require a Holder to pay a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or other
similar governmental charge required in connection therewith as a result of the name of the Holder of the new substitute Note being different from the name of the Holder of the old Note that became mutilated or was destroyed, lost or stolen. In case
any Note that has matured or is about to mature or has been surrendered for required repurchase or is about to be converted in accordance with Article 14 shall become mutilated or be destroyed, lost or stolen, the Company may, in its sole
discretion, instead of issuing a substitute Note, pay or authorize the payment of or convert or authorize the conversion of the same (without surrender thereof except in the case of a mutilated Note), as the case may be, if the applicant for such
payment or conversion shall furnish to the Company, to the Trustee and, if applicable, to such authenticating agent such security or indemnity as may be required by them to save each of them harmless for any loss, liability, cost or expense caused
by or connected with such substitution, and, in every case of destruction, loss or theft, evidence satisfactory to the Company, the Trustee and, if applicable, any Paying Agent or Conversion Agent of the destruction, loss or theft of such Note and
of the ownership thereof. 
 Every substitute Note issued pursuant to the provisions of this Section 2.06 by virtue of the fact that
any Note is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Note shall be found at any time, and shall be entitled to all the benefits of (but shall be
subject to all the limitations set forth in) this Indenture equally and proportionately with any and all other Notes duly issued hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express condition that the
foregoing provisions are exclusive with respect to the replacement, payment, conversion, redemption or repurchase of mutilated, destroyed, lost or stolen Notes and shall preclude any and all other rights or remedies notwithstanding any law or
statute existing or hereafter enacted to the contrary with respect to the replacement, payment, conversion, redemption or repurchase of negotiable instruments or other securities without their surrender. 

Section 2.07. Temporary Notes. Pending the preparation of Physical Notes, the Company may execute and the Trustee or an
authenticating agent appointed by the Trustee shall, upon written request of the Company, authenticate and deliver temporary Notes (printed or lithographed). Temporary Notes shall be issuable in any authorized denomination, and substantially in the
form of the Physical Notes but with such omissions, insertions and variations as may be appropriate for temporary Notes, all as may be determined by the Company. Every such temporary Note shall be executed by the Company and authenticated by the
Trustee or such authenticating agent upon the same conditions and in substantially the same manner, and with the same effect, as the Physical Notes. Without unreasonable delay, the Company shall execute and deliver to the Trustee or such
authenticating agent Physical Notes (other than any Global Note) and thereupon any or all temporary Notes (other than any Global Note) may be surrendered in exchange therefor, at each office or agency maintained by the Company pursuant to
Section 4.02 and the Trustee or such authenticating agent shall authenticate and deliver in exchange for such temporary Notes an equal aggregate principal amount of Physical Notes. Such exchange shall be made by the Company at its own expense
and without any charge therefor. Until so exchanged, the temporary Notes shall in all respects be entitled to the same benefits and subject to the same limitations under this Indenture as Physical Notes authenticated and delivered hereunder. 

  
 23 

 Section 2.08. Cancellation of Notes Paid, Converted, Etc. The Company shall
cause all Notes surrendered for payment, redemption, repurchase, registration of transfer or exchange or conversion, if surrendered to any Person other than the Trustee (including any of the Company’s agents, Subsidiaries or Affiliates), to be
delivered to the Trustee for cancellation. All Notes delivered to the Trustee shall be canceled promptly by it, and, except for Notes surrendered for transfer or exchange, or as otherwise expressly permitted by any of the provisions of this
Indenture, no Notes shall be authenticated in exchange therefor. The Trustee shall dispose of canceled Notes in accordance with its customary procedures and, after such disposition, shall deliver a certificate of such disposition to the Company upon
the Company’s written request. Except for Notes surrendered for transfer or exchange, no Notes shall be authenticated in exchange for any Notes cancelled as provided in this Indenture. 

Section 2.09. CUSIP Numbers. The Company in issuing the Notes may use “CUSIP” numbers (if then generally in use), and,
if so, the Trustee shall use “CUSIP” numbers in all notices issued to Holders as a convenience to such Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as
printed on the Notes or on such notice and that reliance may be placed only on the other identification numbers printed on the Notes. The Company shall promptly notify the Trustee in writing of any change in the “CUSIP” numbers. 

Section 2.10. Additional Notes; Repurchases. The Company may, without the consent of or notice to the Holders and notwithstanding
Section 2.01, reopen this Indenture and issue additional Notes hereunder with the same terms as the Notes initially issued hereunder (other than differences in the issue date, the issue price, interest accrued prior to the issue date of such
additional Notes and, if applicable, restrictions on transfer in respect of such additional Notes (including pursuant to Section 2.05 hereunder)) in an unlimited aggregate principal amount; provided that if any such additional Notes are
not fungible with the Notes initially issued hereunder for U.S. federal income tax or securities law purposes, such additional Notes shall have one or more separate CUSIP numbers. Any additional Notes will be treated as a single series for all
purposes under this Indenture except as set forth in the first sentence of this Section 2.10. Prior to the issuance of any such additional Notes, the Company shall deliver to the Trustee a Company Order, an Officer’s Certificate and an
Opinion of Counsel, such Officer’s Certificate and Opinion of Counsel to cover such matters required by Section 17.05. In addition, the Company may, to the extent permitted by law, and directly or indirectly (regardless of whether such
Notes are surrendered to the Company), repurchase Notes in the open market or otherwise, whether by the Company or its Subsidiaries or through a private or public tender or exchange offer or through counterparties to private agreements, including by
cash-settled swaps or other derivatives, in each case, without prior written notice to Holders. The Company shall cause any Notes so repurchased (other than Notes repurchased pursuant to cash-settled swaps or other derivatives) to be surrendered to
the Trustee for cancellation in accordance with Section 2.08 and such Notes shall no longer be considered outstanding under this Indenture upon their repurchase and, upon receipt of a Company Order and an Officer’s Certificate, the Trustee
shall cancel all Notes so surrendered. 

  
 24 

 ARTICLE 3 

SATISFACTION AND DISCHARGE 

Section 3.01. Satisfaction and Discharge. This Indenture shall upon request of the Company contained in an Officer’s
Certificate cease to be of further effect, and the Trustee, at the expense of the Company, shall execute such instruments reasonably requested by the Company acknowledging satisfaction and discharge of this Indenture, when (a) (i) all Notes
theretofore authenticated and delivered (other than (x) Notes which have been destroyed, lost or stolen and which have been replaced, paid or converted as provided in Section 2.06 and (y) Notes for whose payment money has theretofore
been deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company or discharged from such trust, as provided in Section 4.04(d)) have been delivered to the Trustee for cancellation; or (ii) the
Company has deposited with the Trustee or delivered to Holders, as applicable, after the Notes have become due and payable, whether on the Maturity Date, any Redemption Date, any Fundamental Change Repurchase Date, upon conversion or otherwise, cash
or cash, shares of Common Stock or a combination thereof, as applicable, solely to satisfy the Conversion Obligation, sufficient, without consideration of reinvestment, to pay all of the outstanding Notes and all other sums due and payable under
this Indenture by the Company; and (b) the Company has delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the satisfaction and discharge
of this Indenture have been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.06 shall survive. 

ARTICLE 4 

PARTICULAR COVENANTS OF THE COMPANY 

Section 4.01. Payment of Principal and Interest. The Company covenants and agrees that it will cause to be paid the principal
(including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, each of the Notes at the places, at the respective times and in the manner provided herein and in the Notes. 

Notwithstanding anything to the contrary contained in this Indenture, the Company may, to the extent it is required to do so by law, deduct or
withhold income or other similar taxes imposed by the United States of America from principal, premium or interest (including any Additional Interest) payments hereunder 

Section 4.02. Maintenance of Office or Agency. The Company will maintain in the contiguous United States of America an office or
agency where the Notes may be presented for registration of transfer or exchange or for payment or repurchase (“Paying Agent”) or for conversion (“Conversion Agent”) and where notices and demands to or upon the
Company in respect of the Notes and this Indenture may be served. The Company will give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to maintain
any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office in the United States of America as a place
where Notes may be presented for payment or for registration of transfer. 

  
 25 

 The Company may also from time to time designate as
co-Note Registrars one or more other offices or agencies where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind such designations; provided that
no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the contiguous United States of America so designated by the Trustee as a place for such purposes. The Company will give
prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. The terms “Paying Agent” and “Conversion Agent” include any such
additional or other offices or agencies, as applicable. 
 The Company hereby initially designates the Trustee as the Paying Agent, Note
Registrar, Custodian and Conversion Agent and the Corporate Trust Office as the office or agency in the contiguous United States of America where Notes may be presented for registration of transfer or exchange or for payment or repurchase or for
conversion and where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served; provided that the Corporate Trust Office shall not be a place for service of legal process on the Company. 

Section 4.03. Appointments to Fill Vacancies in Trustee’s Office. The Company, whenever necessary to avoid or
fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 7.09, a Trustee, so that there shall at all times be a Trustee hereunder. 

Section 4.04. Provisions as to Paying Agent. (a) If the Company shall appoint a Paying Agent other than the Trustee, the
Company will cause such Paying Agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section 4.04: 

(i) that it will hold all sums held by it as such agent for the payment of the principal (including the Redemption Price, the
Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes in trust for the benefit of the Holders of the Notes; 

(ii) that it will give the Trustee prompt written notice of any failure by the Company to make any payment of the principal
(including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes when the same shall be due and payable; and 

(iii) that at any time during the continuance of an Event of Default, upon request of the Trustee, it will forthwith pay to the
Trustee all sums so held in trust. 
 The Company shall, on or before each due date of the principal (including the Redemption Price, the
Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes, deposit with the Paying Agent a sum in immediately available U.S. Dollars sufficient to pay such principal (including the Redemption Price, the
Fundamental Change Repurchase Price, if applicable) or accrued and unpaid interest, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee in writing of any failure to take such action; provided that if
such deposit is made on the due date, such deposit must be received by the Paying Agent by 11:00 a.m., New York City time, on such date. 

  
 26 

 (b) If the Company shall act as its own Paying Agent, it will, on or before each due date of
the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, and accrued and unpaid interest on, the Notes, set aside, segregate and hold in trust for the benefit of the Holders of the Notes a sum
sufficient to pay such principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) and accrued and unpaid interest so becoming due and will promptly notify the Trustee in writing of any failure to take such
action and of any failure by the Company to make any payment of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, or accrued and unpaid interest on, the Notes when the same shall become due
and payable. 
 (c) Anything in this Section 4.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of
obtaining a satisfaction and discharge of this Indenture, or for any other reason, pay, cause to be paid or deliver to the Trustee all sums or amounts held in trust by the Company or any Paying Agent hereunder as required by this Section 4.04,
such sums or amounts to be held by the Trustee upon the trusts herein contained and upon such payment or delivery by the Company or any Paying Agent to the Trustee, the Company or such Paying Agent shall be released from all further liability but
only with respect to such sums or amounts. Upon the occurrence of any event specified in Section 6.01(h) or Section 6.01(i), the Trustee shall automatically become the Paying Agent. 

(d) Subject to applicable escheatment laws, any money or property deposited with the Trustee or any Paying Agent, or then held by the Company,
in trust for the payment of the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on and the consideration due upon conversion of any Note and remaining unclaimed for
two years after such principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable), interest or consideration due upon conversion has become due and payable shall be paid to the Company on request of the Company
contained in an Officer’s Certificate, or (if then held by the Company) shall be discharged from such trust and the Trustee shall have no further liability with respect to such funds; and the Holder of such Note shall thereafter, as an
unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money and shares of Common Stock, and all liability of the Company as trustee thereof, shall
thereupon cease. 
 Section 4.05. Existence. Subject to Article 11, the Company shall do or cause to be done all things
necessary to preserve and keep in full force and effect its corporate existence. 
 Section 4.06. Rule 144A Information Requirement
and Annual Reports. (a) At any time the Company is not subject to Section 13 or 15(d) of the Exchange Act, the Company shall, so long as any of the Notes or any shares of Common Stock issuable upon conversion thereof shall, at such
time, constitute “restricted securities” within the meaning of Rule 144(a)(3) under the Securities Act, promptly provide to the Trustee and will, upon written request, provide to any Holder, beneficial owner or prospective purchaser of
such Notes or any shares of Common Stock issuable upon conversion of such Notes, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act to facilitate the resale of such Notes or shares of Common Stock pursuant
to Rule 144A. 

  
 27 

 (b) The Company shall deliver to the Trustee, within 15 days after the same are required to
be filed with the Commission (giving effect to any grace period provided by Rule 12b-25 (or any successor rule) under the Exchange Act), copies of any documents or reports that the Company is required to file
with the Commission pursuant to Section 13 or 15(d) of the Exchange Act (excluding any such information, documents or reports, or portions thereof, subject to confidential treatment and any correspondence with the Commission). Any such document
or report that the Company files with the Commission via the Commission’s EDGAR system (or any successor thereto) shall be deemed to be delivered to the Trustee for purposes of this Section 4.06(b) at the time such documents are filed via
the EDGAR system (or any successor thereto), it being understood that the Trustee shall not be responsible for determining whether such filings have been made. 

(c) Delivery of the reports and documents described in subsection (b) above to the Trustee is for informational purposes only, and the
Trustee’s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which
the Trustee is entitled to conclusively rely on an Officer’s Certificate). 
 (d) If, at any time during the six-month period beginning on, and including, the date that is six months after the last date of original issuance of the Notes, the Company fails to timely file any document or report that it is required to file
with the Commission pursuant to Section 13 or 15(d) of the Exchange Act, as applicable (after giving effect to all applicable grace periods thereunder and other than reports on Form 8-K), or the Notes are
not otherwise freely tradable pursuant to Rule 144 by Holders other than the Company’s Affiliates or Holders that were the Company’s Affiliates at any time during the three months immediately preceding (as a result of restrictions pursuant
to U.S. securities laws or the terms of this Indenture or the Notes), the Company shall pay Additional Interest on the Notes. Such Additional Interest shall accrue on the Notes at the rate of 0.50% per annum of the principal amount of the Notes
outstanding for each day during such period for which the Company’s failure to file has occurred and is continuing or the Notes are not otherwise freely tradable pursuant to Rule 144 by Holders other than the Company’s Affiliates (or
Holders that were the Company’s Affiliates at any time during the three months immediately preceding) as a result of restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes. As used in this
Section 4.06(d), documents or reports that the Company is required to “file” with the Commission pursuant to Section 13 or 15(d) of the Exchange Act does not include documents or reports that the Company furnishes to the
Commission pursuant to Section 13 or 15(d) of the Exchange Act. 
 (e) If, and for so long as, the restrictive legend on the Notes
specified in Section 2.05(c) has not been removed, the Notes are assigned a restricted CUSIP number or the Notes are not otherwise freely tradable pursuant to Rule 144 by Holders other than the Company’s Affiliates or Holders that were the
Company’s Affiliates at any time during the three months immediately preceding (without restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes) as of the 380th day after the last date of original issuance of
the Notes, 

  
 28 

 
the Company shall pay Additional Interest on the Notes at a rate equal to 0.50% per annum of the principal amount of Notes outstanding until the restrictive legend on the Notes has been removed
in accordance with Section 2.05(c), the Notes are assigned an unrestricted CUSIP number and the Notes are freely tradable pursuant to Rule 144 by Holders other than the Company’s Affiliates (or Holders that were the Company’s
Affiliates at any time during the three months immediately preceding) (as a result of restrictions pursuant to U.S. securities laws or the terms of this Indenture or the Notes). 

(f) Additional Interest will be payable in arrears on each Interest Payment Date following accrual in the same manner as regular interest on
the Notes. 
 (g) The Additional Interest that is payable in accordance with Section 4.06(d) or Section 4.06(e) shall be in
addition to any Additional Interest that may accrue on the Notes as a result of the Company’s election pursuant to Section 6.03. 

(h) If Additional Interest is payable by the Company pursuant to Section 4.06(d) or Section 4.06(e), the Company shall deliver to the
Trustee an Officer’s Certificate to that effect stating (i) the amount of such Additional Interest that is payable and (ii) the date on which such Additional Interest is payable. Unless and until a Responsible Officer of the Trustee
receives at the Corporate Trust Office such a certificate, the Trustee may assume without inquiry that no such Additional Interest is payable. If the Company has paid Additional Interest directly to the Persons entitled to it, the Company shall
deliver to the Trustee an Officer’s Certificate setting forth the particulars of such payment. 
 Section 4.07. Stay, Extension
and Usury Laws. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other
law that would prohibit or forgive the Company from paying all or any portion of the principal of or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or that may affect the covenants or the
performance of this Indenture; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution
of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law had been enacted. 

Section 4.08. Compliance Certificate; Statements as to Defaults. The Company shall deliver to the Trustee within 120 days after
the end of each fiscal year of the Company (beginning with the fiscal year ending on January 31, 2021) an Officer’s Certificate stating whether the signers thereof know of any Default or Event of Default that occurred during the previous
year. 
 In addition, the Company shall deliver to the Trustee, within 30 days after the occurrence thereof, written notice of any Event of
Default or Default, its status and what action the Company is taking or proposing to take in respect thereof; provided that the Company will not be required to deliver such notice if such Event of Default or Default is no longer continuing or
has been cured. 

  
 29 

 Section 4.09. Further Instruments and Acts. Upon written request of the Trustee,
the Company will execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out the purposes of this Indenture. 

ARTICLE 5 
 LISTS
OF HOLDERS AND REPORTS BY THE COMPANY AND THE TRUSTEE 

Section 5.01. Lists of Holders. The Company covenants and agrees that it will furnish or cause to be furnished to the Trustee,
semi-annually, not more than 5 days after each June 1 and December 1 in each year beginning with December 1, 2020, and at such other times as the Trustee may request in writing, within 5 days after receipt by the Company of any such
request (or such lesser time as the Trustee may reasonably request in order to enable it to timely provide any notice to be provided by it hereunder), a list in such form as the Trustee may reasonably require of the names and addresses of the
Holders as of a date not more than 15 days (or such other date as the Trustee may reasonably request in order to so provide any such notices) prior to the time such information is furnished, except that no such list need be furnished so long as the
Trustee is acting as Note Registrar. 
 Section 5.02. Preservation and Disclosure of Lists. The Trustee shall preserve, in as
current a form as is reasonably practicable, all information as to the names and addresses of the Holders contained in the most recent list furnished to it as provided in Section 5.01 or maintained by the Trustee in its capacity as Note
Registrar, if so acting. The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished. 

ARTICLE 6 
 DEFAULTS
AND REMEDIES 
 Section 6.01. Events of Default. Each of the following events shall be an
“Event of Default” with respect to the Notes: 
 (a) default in any payment of interest on any Note when due and payable,
and the default continues for a period of 30 days; 
 (b) default in the payment of principal of any Note when due and payable on the
Maturity Date, upon Optional Redemption, upon any required repurchase, upon declaration of acceleration or otherwise; 
 (c) failure by the
Company to comply with its obligation to convert the Notes in accordance with this Indenture upon exercise of a Holder’s conversion right, and such failure continues for a period of three (3) Business Days; 

(d) failure by the Company to issue (i) a Fundamental Change Company Notice when due in accordance with Section 15.02(c) and such
failure continues for a period of three (3) Business Days or (ii) notice of a specified corporate transaction or event in accordance with Section 14.01(b)(ii) or (iii) when due; 

  
 30 

 (e) failure by the Company to comply with its obligations under Article 11; 

(f) failure by the Company for 60 days after written notice from the Trustee or the Holders of at least 25% in aggregate principal amount of
the Notes then outstanding has been received by the Company to comply with any of its other agreements contained in the Notes or this Indenture; 

(g) default by the Company or any Significant Subsidiary of the Company with respect to any mortgage, agreement or other instrument under which
there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $75,000,000 (or its foreign currency equivalent) in the aggregate of the Company and/or any such Significant Subsidiary,
whether such indebtedness now exists or shall hereafter be created (i) resulting in such indebtedness becoming or being declared due and payable prior to its stated maturity or (ii) constituting a failure to pay the principal of any such
indebtedness when due and payable (after the expiration of all applicable grace periods) at its stated maturity, upon required repurchase, upon declaration of acceleration or otherwise; 

(h) the Company or any Significant Subsidiary shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other
relief with respect to the Company or any such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other
similar official of the Company or any such Significant Subsidiary or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other
proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due; or 

(i) an involuntary case or other proceeding shall be commenced against the Company or any Significant Subsidiary seeking liquidation,
reorganization or other relief with respect to the Company or such Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator,
custodian or other similar official of the Company or such Significant Subsidiary or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of 30 consecutive days. 

Section 6.02. Acceleration; Rescission and Annulment. If one or more Events of Default shall have occurred and be continuing
(whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or regulation of any administrative or
governmental body), then, and in each and every such case (other than an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company), unless the principal of all of the Notes shall have already become due
and payable, either the Trustee or the Holders of at least 25% in aggregate principal amount of the Notes then outstanding determined in accordance with Section 8.04, by notice in writing to the Company (and to the Trustee if given by Holders),
may declare 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, and upon any such declaration the same shall become and shall automatically be immediately due and payable, anything in this
Indenture or in the 

  
 31 

 
Notes contained to the contrary notwithstanding. If an Event of Default specified in Section 6.01(h) or Section 6.01(i) with respect to the Company occurs and is continuing, 100% of the
principal of, and accrued and unpaid interest, if any, on, all Notes shall become and shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder. 

The immediately preceding paragraph, however, is subject to the conditions that if, at any time after the principal of the Notes shall have
been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay
installments of accrued and unpaid interest upon all Notes and the principal of any and all Notes that shall have become due otherwise than by acceleration (with interest on overdue installments of accrued and unpaid interest, and on such principal
at the rate borne by the Notes at such time) and amounts due to the Trustee pursuant to Section 7.06, and if (1) rescission would not conflict with any judgment or decree of a court of competent jurisdiction and (2) any and all
existing Events of Default under this Indenture, other than the nonpayment of the principal of and accrued and unpaid interest, if any, on Notes that shall have become due solely by such acceleration, shall have been cured or waived pursuant to
Section 6.09, then and in every such case (except as provided in the immediately succeeding sentence) the Holders of a majority in aggregate principal amount of the Notes then outstanding, by written notice to the Company and to the Trustee,
may waive all Defaults or Events of Default with respect to the Notes and rescind and annul such declaration and its consequences and such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured
for every purpose of this Indenture; but no such waiver or rescission and annulment shall extend to or shall affect any subsequent Default or Event of Default, or shall impair any right consequent thereon. Notwithstanding anything to the contrary
herein, no such waiver or rescission and annulment shall extend to or shall affect any Default or Event of Default resulting from (i) the nonpayment of the principal (including the Redemption Price and the Fundamental Change Repurchase Price,
if applicable) of, or accrued and unpaid interest on, any Notes, (ii) a failure to repurchase any Notes when required or (iii) a failure to pay or deliver, as the case may be, the consideration due upon conversion of the Notes. 

Section 6.03. Additional Interest. Notwithstanding anything in this Indenture or in the Notes to the contrary, to the extent the
Company elects, the sole remedy for an Event of Default relating to the Company’s failure to comply with its obligations as set forth in Section 4.06(b) shall, for the first 360 days after the occurrence of such an Event of Default,
consist exclusively of the right to receive Additional Interest on the Notes at a rate equal to (i) 0.25% per annum of the principal amount of the Notes outstanding for each day during the first 180 calendar days after the occurrence of such an
Event of Default during which such an Event of Default is continuing (or, if earlier, the date on which such Event of Default is cured or waived as provided for in this Indenture) and (ii) 0.50% per annum of the principal amount of the Notes
outstanding for each day from, and including, the 181st calendar day to, but excluding, the 360th calendar day following the occurrence of such an Event of Default during which such Event of Default is continuing (or, if earlier, the date on which
such Event of Default is cured or waived as provided for in this Indenture). Additional Interest payable pursuant to this Section 6.03 shall be in addition to, not in lieu of, any Additional Interest payable pursuant to Section 4.06(d) or
Section 4.06(e). If the Company so elects, such Additional Interest shall be payable in the same manner 

  
 32 

 
and on the same dates as the stated interest payable on the Notes. On the 361st day after such an Event of Default (if the Event of Default relating to the Company’s failure to comply with
its obligations as set forth in Section 4.06(b) is not cured or waived prior to such 361st day), the Notes shall be subject to acceleration as provided in Section 6.02. The provisions of this paragraph will not affect the rights of Holders
in the event of the occurrence of any Event of Default other than the Company’s failure to comply with its obligations as set forth in Section 4.06(b). In the event the Company does not elect to pay Additional Interest following an Event
of Default in accordance with this Section 6.03 or the Company elected to make such payment but does not pay the Additional Interest when due, the Notes shall be immediately subject to acceleration as provided in Section 6.02. 

In order to elect to pay Additional Interest as the sole remedy during the first 360 days after the occurrence of an Event of Default relating
to the Company’s failure to comply with its obligations as set forth in Section 4.06(b) in accordance with the immediately preceding paragraph, the Company must notify all Holders, the Trustee and the Paying Agent in writing of such
election prior to the beginning of such 360-day period. Upon the Company’s failure to timely give such notice, the Notes shall be immediately subject to acceleration as provided in Section 6.02. 

Section 6.04. Payments of Notes on Default; Suit Therefor. If an Event of Default described in clause (a) or (b) of
Section 6.01 shall have occurred and be continuing, the Company shall, upon demand of the Trustee, pay to the Trustee, for the benefit of the Holders of the Notes, the whole amount then due and payable on the Notes for principal and interest,
if any, with interest on any overdue principal and interest, if any, at the rate borne by the Notes at such time, and, in addition thereto, such further amount as shall be sufficient to cover any amounts due to the Trustee under Section 7.06.
If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such
proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon the Notes and collect the moneys adjudged or decreed to be payable in the manner provided by law out of the property of the Company or any
other obligor upon the Notes, wherever situated. 
 In the event there shall be pending proceedings for the bankruptcy or for the
reorganization of the Company or any other obligor on the Notes under Title 11 of the United States Code, or any other applicable law, or in case a receiver, assignee or trustee in bankruptcy or reorganization, liquidator, sequestrator or similar
official shall have been appointed for or taken possession of the Company or such other obligor, the property of the Company or such other obligor, or in the event of any other judicial proceedings relative to the Company or such other obligor upon
the Notes, or to the creditors or property of the Company or such other obligor, the Trustee, irrespective of whether the principal of the Notes shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of
whether the Trustee shall have made any demand pursuant to the provisions of this Section 6.04, shall be entitled and empowered, by intervention in such proceedings or otherwise, to file and prove a claim or claims for the whole amount of
principal and accrued and unpaid interest, if any, in respect of the Notes, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents and to take such other actions as it may deem necessary or advisable

  
 33 

 
in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders
allowed in such judicial proceedings relative to the Company or any other obligor on the Notes, its or their creditors, or its or their property, and to collect and receive any monies or other property payable or deliverable on any such claims, and
to distribute the same after the deduction of any amounts due to the Trustee under Section 7.06; and any receiver, assignee or trustee in bankruptcy or reorganization, liquidator, custodian or similar official is hereby authorized by each of
the Holders to make such payments to the Trustee, as administrative expenses, and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for reasonable
compensation, expenses, advances and disbursements, including agents and counsel fees, and including any other amounts due to the Trustee under Section 7.06, incurred by it up to the date of such distribution. To the extent that such payment of
reasonable compensation, expenses, advances and disbursements out of the estate in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions,
dividends, monies, securities and other property that the Holders of the Notes may be entitled to receive in such proceedings, whether in liquidation or under any plan of reorganization or arrangement or otherwise. 

Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any
plan of reorganization, arrangement, adjustment or composition affecting such Holder or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding. 

All rights of action and of asserting claims under this Indenture, or under any of the Notes, may be enforced by the Trustee without the
possession of any of the Notes, or the production thereof at any trial or other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery
of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Notes. 

In any proceedings brought by the Trustee (and in any proceedings involving the interpretation of any provision of this Indenture to which the
Trustee shall be a party) the Trustee shall be held to represent all the Holders of the Notes, and it shall not be necessary to make any Holders of the Notes parties to any such proceedings. 

In case the Trustee shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or
abandoned because of any waiver pursuant to Section 6.09 or any rescission and annulment pursuant to Section 6.02 or for any other reason or shall have been determined adversely to the Trustee, then and in every such case the Company, the
Holders and the Trustee shall, subject to any determination in such proceeding, be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Holders and the Trustee shall continue
as though no such proceeding had been instituted. 

  
 34 

 Section 6.05. Application of Monies Collected by Trustee. Any monies or property
collected by the Trustee pursuant to this Article 6 with respect to the Notes shall be applied in the following order, at the date or dates fixed by the Trustee for the distribution of such monies, upon presentation of the several Notes, and
stamping thereon the payment, if only partially paid, and upon surrender thereof, if fully paid: 
 First, to the payment of all
amounts due the Trustee under Section 7.06; 
 Second, in case the principal of the outstanding Notes shall not have become due
and be unpaid, to the payment of interest on, and any cash due upon conversion of, the Notes in default in the order of the date due of the payments of such interest and cash due upon conversion, as the case may be, with interest (to the extent that
such interest has been collected by the Trustee) upon such overdue payments at the rate borne by the Notes at such time, such payments to be made ratably to the Persons entitled thereto; 

Third, in case the principal of the outstanding Notes shall have become due, by declaration or otherwise, and be unpaid to the payment
of the whole amount (including, if applicable, the payment of the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) then owing and unpaid upon the Notes for principal and interest, if any, with interest on
the overdue principal and, to the extent that such interest has been collected by the Trustee, upon overdue installments of interest at the rate borne by the Notes at such time, and in case such monies shall be insufficient to pay in full the whole
amounts so due and unpaid upon the Notes, then to the payment of such principal (including, if applicable, the Redemption Price, the Fundamental Change Repurchase Price and any cash due upon conversion) and interest without preference or priority of
principal over interest, or of interest over principal or of any installment of interest over any other installment of interest, or of any Note over any other Note, ratably to the aggregate of such principal (including, if applicable, the Redemption
Price, the Fundamental Change Repurchase Price and any cash due upon conversion) and accrued and unpaid interest; and 
 Fourth, to
the payment of the remainder, if any, to the Company. 
 Section 6.06. Proceedings by Holders. Except to enforce the right to
receive payment of principal (including, if applicable, the Redemption Price and the Fundamental Change Repurchase Price) or interest when due, or the right to receive payment or delivery of the consideration due upon conversion, no Holder of any
Note shall have any right by virtue of or by availing of any provision of this Indenture or the Notes to institute any suit, action or proceeding in equity or at law upon or under or with respect to this Indenture, or for the appointment of a
receiver, trustee, liquidator, custodian or other similar official, or for any other remedy hereunder, unless: 
 (a) such Holder previously
shall have given to the Trustee written notice of an Event of Default and of the continuance thereof, as herein provided; 
 (b) Holders of
at least 25% in aggregate principal amount of the Notes then outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; 

  
 35 

 (c) such Holders shall have offered (and, if requested, provided) to the Trustee such
security or indemnity satisfactory to the Trustee against any loss, liability or expense to be incurred therein or thereby; 
 (d) the
Trustee for 60 days after its receipt of such notice, request and offer of such security or indemnity, shall have neglected or refused to institute any such action, suit or proceeding; and 

(e) no direction that, in the opinion of the Trustee, is inconsistent with such written request shall have been given to the Trustee by the
Holders of a majority of the aggregate principal amount of the Notes then outstanding within such 60-day period pursuant to Section 6.09, 

it being understood and intended, and being expressly covenanted by the taker and Holder of every Note with every other taker and Holder and the Trustee that
no one or more Holders shall have any right in any manner whatever by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Holder (it being understood that the Trustee shall not have an
affirmative duty to ascertain whether or not any such direction is unduly prejudicial to any other Holder), or to obtain or seek to obtain priority over or preference to any other such Holder, or to enforce any right under this Indenture, except in
the manner herein provided and for the equal, ratable and common benefit of all Holders (except as otherwise provided herein). For the protection and enforcement of this Section 6.06, each and every Holder and the Trustee shall be entitled to
such relief as can be given either at law or in equity. 
 Notwithstanding any other provision of this Indenture and any provision of any
Note, the right of any Holder to receive payment or delivery, as the case may be, of (x) the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, (y) accrued and unpaid interest, if any,
on, and (z) the consideration due upon conversion of, such Note, on or after the respective due dates expressed or provided for in such Note or in this Indenture, or to institute suit for the enforcement of any such payment or delivery, as the
case may be, on or after such respective dates against the Company shall not be impaired or affected without the consent of such Holder. 

Section 6.07. Proceedings by Trustee. In case of an Event of Default, the Trustee may in its discretion proceed to protect and
enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as are necessary to protect and enforce any of such rights, either by suit in equity or by action at law or by proceeding in bankruptcy or otherwise, whether
for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal or equitable right vested in the Trustee by this Indenture or by
law. The Trustee may maintain a proceeding even if it does not possess any Notes or does not produce any Notes in the proceeding. 

Section 6.08. Remedies Cumulative and Continuing. Except as provided in the last paragraph of Section 2.06, all powers and
remedies given by this Article 6 to the Trustee or to the Holders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the Holders of the Notes,

  
 36 

 
by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any
Holder of any of the Notes to exercise any right or power accruing upon any Default or Event of Default shall impair any such right or power, or shall be construed to be a waiver of any such Default or Event of Default or any acquiescence therein;
and, subject to the provisions of Section 6.06, every power and remedy given by this Article 6 or by law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the
Holders. 
 Section 6.09. Direction of Proceedings and Waiver of Defaults by Majority of Holders. The Holders of a majority of
the aggregate principal amount of the Notes at the time outstanding determined in accordance with Section 8.04 shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee or
exercising any trust or power conferred on the Trustee with respect to the Notes; provided, however, that (a) such direction shall not be in conflict with any rule of law or with this Indenture, and (b) the Trustee may take
any other action deemed proper by the Trustee that is not inconsistent with such direction. The Trustee may refuse to follow any direction that it determines is unduly prejudicial to the rights of any other Holder or that would involve the Trustee
in personal liability (it being understood that the Trustee does not have an affirmative duty to determine whether any direction is prejudicial to any Holder). The Holders of a majority in aggregate principal amount of the Notes at the time
outstanding determined in accordance with Section 8.04 may on behalf of the Holders of all of the Notes waive any past Default or Event of Default hereunder and its consequences except (i) a default in the payment of accrued and unpaid
interest, if any, on, or the principal (including any Redemption Price, any Fundamental Change Repurchase Price) of, the Notes when due that has not been cured pursuant to the provisions of Section 6.01, (ii) a failure by the Company to pay or
deliver, as the case may be, the consideration due upon conversion of the Notes or (iii) a default in respect of a covenant or provision hereof which under Article 10 cannot be modified or amended without the consent of each Holder of an
outstanding Note affected. Upon any such waiver the Company, the Trustee and the Holders of the Notes shall be restored to their former positions and rights hereunder; but no such waiver shall extend to any subsequent or other Default or Event of
Default or impair any right consequent thereon. Whenever any Default or Event of Default hereunder shall have been waived as permitted by this Section 6.09, said Default or Event of Default shall for all purposes of the Notes and this Indenture
be deemed to have been cured and to be not continuing; but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereon. 

Section 6.10. Notice of Defaults. The Trustee shall, within 90 days after the occurrence and continuance of a Default of which a
Responsible Officer of the Trustee has been notified in writing or has actual knowledge, deliver to all Holders notice of all such Defaults, unless such Defaults shall have been cured or waived before the giving of such notice; provided that,
except in the case of a Default in the payment of the principal of (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable), or accrued and unpaid interest on, any of the Notes or a Default in the payment or delivery
of the consideration due upon conversion, the Trustee shall be protected in withholding such notice if and so long as it in good faith determines that the withholding of such notice is in the interests of the Holders. 

  
 37 

 Section 6.11. Undertaking to Pay Costs. All parties to this Indenture agree, and
each Holder of any Note by its acceptance thereof shall be deemed to have agreed, that any court may, in its discretion, require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any
action taken or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees and
expenses, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; provided that the provisions of this Section 6.11 (to the extent permitted by law)
shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the Notes at the time outstanding determined in accordance with
Section 8.04, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or accrued and unpaid interest, if any, on any Note (including, but not limited to, the Redemption Price, the Fundamental Change
Repurchase Price with respect to the Notes being repurchased as provided in this Indenture) on or after the due date expressed or provided for in such Note or to any suit for the enforcement of the right to convert any Note in accordance with the
provisions of Article 14. 
 ARTICLE 7 

CONCERNING THE TRUSTEE 

Section 7.01. Duties and Responsibilities of Trustee. The Trustee, prior to the occurrence of an Event of Default of which a
Responsible Officer of the Trustee has written notice or actual knowledge and after the curing or waiver of all Events of Default that may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this
Indenture. In the event an Event of Default has occurred and is continuing of which a Responsible Officer of the Trustee has written notice or actual knowledge, the Trustee shall exercise such of the rights and powers vested in it by this Indenture,
and use the same degree of care and skill in its exercise, as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs; provided that if an Event of Default occurs and is continuing, the
Trustee will be under no obligation to exercise any of the rights or powers under this Indenture at the request or direction of any of the Holders unless such Holders have offered (and, if requested, provided) to the Trustee indemnity or security
satisfactory to the Trustee against any loss, liability or expense that might be incurred by it in compliance with such request or direction. 

  
 38 

 No provision of this Indenture shall be construed to relieve the Trustee from liability for
its own grossly negligent action, its own grossly negligent failure to act or its own willful misconduct, except that: 
 (a) prior to the
occurrence of an Event of Default of which a Responsible Officer of the Trustee has written notice or actual knowledge and after the curing or waiving of all Events of Default that may have occurred: 

(i) the duties and obligations of the Trustee shall be determined solely by the express provisions of this Indenture, and the
Trustee shall not be liable except for the performance of such duties and obligations as are specifically set forth in this Indenture and no implied covenants or obligations shall be read into this Indenture against the Trustee; and 

(ii) in the absence of gross negligence or willful misconduct on the part of the Trustee, the Trustee may conclusively and
without liability rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture; but, in the case of any
such certificates or opinions that by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to the requirements of this
Indenture (but need not confirm or investigate the accuracy of any mathematical calculations or other facts stated therein); 
 (b) the
Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer or Officers of the Trustee, unless it shall be proved that the Trustee was grossly negligent in ascertaining the pertinent facts; 

(c) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the
direction of the Holders of not less than a majority of the aggregate principal amount of the Notes at the time outstanding determined as provided in Section 8.04 relating to the time, method and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture; 
 (d) whether or not
therein provided, every provision of this Indenture relating to the conduct or affecting the liability of, or affording protection to, the Trustee shall be subject to the provisions of this Section; 

(e) the Trustee shall not be liable in respect of any payment (as to the correctness of amount, entitlement to receive or any other matters
relating to payment) or notice effected by the Company or any Paying Agent or any records maintained by any co-Note Registrar with respect to the Notes; 

(f) if any party fails to deliver a notice relating to an event the fact of which, pursuant to this Indenture, requires notice to be sent to
the Trustee, the Trustee may conclusively and without liability rely on its failure to receive such notice as reason to act as if no such event occurred; 

(g) in the event that the Trustee is also acting as Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or
transfer agent hereunder, the rights and protections afforded to the Trustee pursuant to this Article 7 shall also be afforded to such Custodian, Note Registrar, Paying Agent, Conversion Agent, Bid Solicitation Agent or transfer agent; and 

(h) under no circumstances shall the Trustee be liable in its individual capacity for the obligations evidenced by the Notes. 

 

  
 39 

 None of the provisions contained in this Indenture shall require the Trustee to expend or
risk its own funds or otherwise incur financial liability in the performance of any of its duties or in the exercise of any of its rights or powers. 

Section 7.02. Reliance on Documents, Opinions, Etc. Except as otherwise provided in Section 7.01: 

(a) The Trustee may conclusively and without liability rely and shall be fully protected in acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, judgment, bond, note, coupon or other paper or document (whether in its original or facsimile form) believed by it in good faith to be genuine and to have been signed or presented by the
proper party or parties. 
 (b) Any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by an
Officer’s Certificate (unless other evidence in respect thereof be herein specifically prescribed); and any Board Resolution may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant Secretary of the Company.
The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on an Officer’s Certificate, Opinion of Counsel or Board Resolution. 

(c) The Trustee may consult with counsel of its selection and require an Opinion of Counsel and any written or verbal advice of such counsel or
Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel. 

(d) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, direction, consent, judgment, order, bond, debenture or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may
see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by agent or attorney at the expense of the Company and shall
incur no liability of any kind by reason of such inquiry or investigation. 
 (e) The Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents, custodians, nominees or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent, custodian, nominee or attorney
appointed by it with due care hereunder. 
 (f) The permissive rights of the Trustee enumerated herein shall not be construed as duties. 

(g) The Trustee shall not be required to give any bond or surety in respect of the performance of its powers and duties hereunder. 

(h) The Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of officers authorized
at such time to take specified actions pursuant to this Indenture. 

  
 40 

 In no event shall the Trustee be liable for any consequential, punitive, special, incidental
or indirect loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. The Trustee shall not be charged with
knowledge of any Default or Event of Default with respect to the Notes, unless either (1) a Responsible Officer shall have actual knowledge of such Default or Event of Default or (2) written notice of such Default or Event of Default shall
have been actually received by a Responsible Officer of the Trustee, from the Company or any Holder of the Notes, at the Corporate Trust Office and such notice references the Notes and/or this Indenture and states that it is a “notice of
default.” 
 Section 7.03. No Responsibility for Recitals, Etc. The recitals contained herein and in the Notes (except in
the Trustee’s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the same. The Trustee makes no representations as to the validity or sufficiency of
this Indenture or of the Notes. The Trustee shall not be accountable for the use or application by the Company of any Notes or the proceeds of any Notes authenticated and delivered by the Trustee in conformity with the provisions of this Indenture
or any money paid to the Company or upon the Company’s direction under any provision of the Indenture. 
 Section 7.04.
Trustee, Paying Agents, Conversion Agents, Bid Solicitation Agent or Note Registrar May Own Notes. The Trustee, any Paying Agent, any Conversion Agent, Bid Solicitation Agent (if other than the Company or any Affiliate thereof) or Note
Registrar, in its individual or any other capacity, may become the owner or pledgee of Notes with the same rights it would have if it were not the Trustee, Paying Agent, Conversion Agent, Bid Solicitation Agent or Note Registrar. 

Section 7.05. Monies and Shares of Common Stock to Be Held in Trust. All monies and any shares of Common Stock received by the
Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received. Money and shares of Common Stock held by the Trustee or its designee in trust hereunder need not be segregated from other funds
or property except to the extent required by law. The Trustee shall be under no liability for interest or investment income on any money or shares of Common Stock received by it hereunder except as may be agreed from time to time by the Company and
the Trustee. 
 Section 7.06. Compensation and Expenses of Trustee. The Company covenants and agrees to pay to the Trustee, in
any capacity under this Indenture, from time to time, and the Trustee shall be entitled to, compensation for all services rendered by it hereunder in any capacity (which shall not be limited by any provision of law in regard to the compensation of a
trustee of an express trust) as mutually agreed to in writing between the Trustee and the Company, and the Company will pay or reimburse the Trustee upon its request for all reasonable expenses, disbursements and advances reasonably incurred or made
by the Trustee in accordance with any of the provisions of this Indenture in any capacity thereunder (including the reasonable compensation and the expenses and disbursements of its agents and counsel and of all Persons not regularly in its employ)
except any such expense, disbursement or advance as shall have been caused by its gross negligence or willful misconduct as determined by a final, non-appealable decision of a court of competent jurisdiction.
The Company also covenants to indemnify the Trustee in any capacity under this Indenture and any other document or transaction entered into 

  
 41 

 
in connection herewith and its officers, directors, attorneys, employees and agents and any authenticating agent for, and to hold them harmless against, any loss, claim (whether asserted by the
Company, a Holder or any Person), damage, liability or expense incurred without gross negligence or willful misconduct on the part of the Trustee, its officers, directors, attorneys, agents or employees, or such agent or authenticating agent, as the
case may be, as determined by a final, non-appealable decision of a court of competent jurisdiction, and arising out of or in connection with the acceptance or administration of this Indenture or in any other
capacity hereunder, including the costs and expenses of defending themselves against any claim of liability in the premises. The obligations of the Company under this Section 7.06 to compensate or indemnify the Trustee and to pay or reimburse
the Trustee for expenses, disbursements and advances shall be secured by a senior lien to which the Notes are hereby made subordinate on all money or property held or collected by the Trustee, except, subject to the effect of Section 6.05,
funds held in trust herewith for the benefit of the Holders of particular Notes. The Trustee’s right to receive payment of any amounts due under this Section 7.06 shall not be subordinate to any other liability or indebtedness of the
Company. The obligation of the Company under this Section 7.06 shall survive the satisfaction and discharge of this Indenture, the payment or conversion of the Notes and the earlier resignation or removal of the Trustee. The Company need not
pay for any settlement made without its consent, which consent shall not be unreasonably withheld. The indemnification provided in this Section 7.06 shall extend to the officers, directors, attorneys, agents and employees of the Trustee. 

Without prejudice to any other rights available to the Trustee under applicable law, when the Trustee and its agents and any authenticating
agent incur expenses or render services after an Event of Default specified in Section 6.01(h) or Section 6.01(i) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any
bankruptcy, insolvency or similar laws. 
 Section 7.07. Officer’s Certificate as Evidence. Except as
otherwise provided in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it necessary or desirable that a matter be proved or established prior to taking or omitting any action hereunder,
such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of gross negligence and willful misconduct on the part of the Trustee, be deemed to be conclusively proved and established by an
Officer’s Certificate delivered to the Trustee, and such Officer’s Certificate, in the absence of gross negligence or willful misconduct on the part of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it
under the provisions of this Indenture upon the faith thereof. 
 Section 7.08. Eligibility of Trustee. There shall at all times
be a Trustee hereunder which shall be a Person that is eligible pursuant to the Trust Indenture Act (as if, for this purpose, the Trust Indenture Act were applicable hereto) to act as such and has a combined capital and surplus of at least
$50,000,000. If such Person publishes reports of condition at least annually, pursuant to law or to the requirements of any supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such Person
shall be deemed to be its combined capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign
immediately in the manner and with the effect hereinafter specified in this Article. 

  
 42 

 Section 7.09. Resignation or Removal of Trustee. (a) The Trustee may at any
time resign by giving written notice of such resignation to the Company. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of
Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted appointment within 60 days after the giving of such
notice of resignation to the Company, the resigning Trustee may, upon ten Business Days’ notice to the Company and the Holders and at the expense of the Company, petition any court of competent jurisdiction for the appointment of a successor
trustee, or any Holder who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, subject to the provisions of Section 6.11, on behalf of himself or herself and all others similarly
situated, petition any such court for the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. 

(b) In case at any time any of the following shall occur: 

(i) the Trustee shall cease to be eligible in accordance with the provisions of Section 7.08 and shall fail to resign
after written request therefor by the Company or by any such Holder, or 
 (ii) the Trustee shall become incapable of acting,
or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation,
conservation or liquidation, 
 then, in either case, the Company may by a Board Resolution remove the Trustee and appoint a successor trustee by written
instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of Section 6.11, any Holder
who has been a bona fide holder of a Note or Notes for at least six months (or since the date of this Indenture) may, on behalf of himself or herself and all others similarly situated, petition any court of competent jurisdiction for the removal of
the Trustee and the appointment of a successor trustee. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. 

(c) The Holders of a majority in aggregate principal amount of the Notes at the time outstanding, as determined in accordance with
Section 8.04, may at any time remove the Trustee and nominate a successor trustee that shall be deemed appointed as successor trustee unless within ten days after notice to the Company of such nomination the Company objects thereto, in which
case the Trustee so removed or any Holder, upon the terms and conditions and otherwise as in Section 7.09(a) provided, may petition any court of competent jurisdiction for an appointment of a successor trustee. 

(d) Any resignation or removal of the Trustee and appointment of a successor trustee pursuant to any of the provisions of this
Section 7.09 shall become effective upon acceptance of appointment by the successor trustee as provided in Section 7.10. 
  

  
 43 

 Section 7.10. Acceptance by Successor Trustee. Any successor trustee appointed
as provided in Section 7.09 shall execute, acknowledge and deliver to the Company and to its predecessor trustee an instrument accepting such appointment hereunder, and thereupon the resignation or removal of the predecessor trustee shall
become effective and such successor trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its predecessor hereunder, with like effect as if originally named as Trustee
herein; but, nevertheless, on the written request of the Company or of the successor trustee, the trustee ceasing to act shall, upon payment of any amounts then due it pursuant to the provisions of Section 7.06, execute and deliver an
instrument transferring to such successor trustee all the rights and powers of the trustee so ceasing to act. Upon request of any such successor trustee, the Company shall execute any and all instruments in writing for more fully and certainly
vesting in and confirming to such successor trustee all such rights and powers. Any trustee ceasing to act shall, nevertheless, retain a senior lien to which the Notes are hereby made subordinate on all money or property held or collected by such
trustee as such, except for funds held in trust for the benefit of Holders of particular Notes, to secure any amounts then due it pursuant to the provisions of Section 7.06. 

No successor trustee shall accept appointment as provided in this Section 7.10 unless at the time of such acceptance such successor
trustee shall be eligible under the provisions of Section 7.08. 
 Upon acceptance of appointment by a successor trustee as provided in
this Section 7.10, each of the Company and the successor trustee, at the written direction and at the expense of the Company shall deliver or cause to be delivered notice of the succession of such trustee hereunder to the Holders. If the
Company fails to deliver such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to be delivered at the expense of the Company. 

Section 7.11. Succession by Merger, Etc. Any corporation or other entity into which the Trustee may be merged or converted or with
which it may be consolidated, or any corporation or other entity resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation or other entity succeeding to all or substantially all of the corporate
trust business of the Trustee (including the administration of this Indenture), shall be the successor to the Trustee hereunder without the execution or filing of any paper or any further act on the part of any of the parties hereto; provided
that in the case of any corporation or other entity succeeding to all or substantially all of the corporate trust business of the Trustee such corporation or other entity shall be eligible under the provisions of Section 7.08. 

In case at the time such successor to the Trustee shall succeed to the trusts created by this Indenture, any of the Notes shall have been
authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor trustee or authenticating agent appointed by such predecessor trustee, and deliver such Notes so authenticated; and in
case at that time any of the Notes shall not have been authenticated, any successor to the Trustee or an authenticating agent appointed by such successor trustee may authenticate such Notes either in the name of any predecessor trustee hereunder or
in the name of the successor trustee; and in all such cases such certificates shall have the full force which it is anywhere in the Notes or in this Indenture provided that the certificate of the Trustee shall have; provided, however,
that the right to adopt the certificate of authentication of any predecessor trustee or to authenticate Notes in the name of any predecessor trustee shall apply only to its successor or successors by merger, conversion or consolidation. 

  
 44 

 Section 7.12. Trustee’s Application for Instructions from the
Company. Any application by the Trustee for written instructions from the Company (other than with regard to any action proposed to be taken or omitted to be taken by the Trustee that affects the rights of the Holders of the Notes under this
Indenture) may, at the option of the Trustee, set forth in writing any action proposed to be taken or omitted by the Trustee under this Indenture and the date on and/or after which such action shall be taken or such omission shall be effective. The
Trustee shall not be liable for any action taken by, or omission of, the Trustee in accordance with a proposal included in such application on or after the date specified in such application (which date shall not be less than three Business Days
after notice to the Company has been deemed to have been given pursuant to Section 17.03, unless any such officer shall have consented in writing to any earlier date), unless, prior to taking any such action (or the effective date in the case
of any omission), the Trustee shall have received written instructions in accordance with this Indenture in response to such application specifying the action to be taken or omitted. 

ARTICLE 8 

CONCERNING THE HOLDERS 

Section 8.01. Action by Holders. Whenever in this Indenture it is provided that the Holders of a specified percentage of the
aggregate principal amount of the Notes may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action, the
Holders of such specified percentage have joined therein may be evidenced (a) by any instrument or any number of instruments of similar tenor executed by Holders in person or by agent or proxy appointed in writing, or (b) by the record of
the Holders voting in favor thereof at any meeting of Holders duly called and held in accordance with the provisions of Article 9, or (c) by a combination of such instrument or instruments and any such record of such a meeting of Holders.
Whenever the Company or the Trustee solicits the taking of any action by the Holders of the Notes, the Company or the Trustee may fix, but shall not be required to, in advance of such solicitation, a date as the record date for determining Holders
entitled to take such action. The record date if one is selected shall be not more than fifteen days prior to the date of commencement of solicitation of such action. 

Section 8.02. Proof of Execution by Holders. Subject to the provisions of Section 7.01, Section 7.02 and
Section 9.05, proof of the execution of any instrument by a Holder or its agent or proxy shall be sufficient if made in accordance with such reasonable rules and regulations as may be prescribed by the Trustee or in such manner as shall be
satisfactory to the Trustee. The holding of Notes shall be proved by the Note Register or by a certificate of the Note Registrar. The record of any Holders’ meeting shall be proved in the manner provided in Section 9.06. 

 

  
 45 

 Section 8.03. Who Are Deemed Absolute Owners. The Company, the Trustee, any
authenticating agent, any Paying Agent, any Conversion Agent and any Note Registrar may deem the Person in whose name a Note shall be registered upon the Note Register to be, and may treat it as, the absolute owner of such Note (whether or not such
Note shall be overdue and notwithstanding any notation of ownership or other writing thereon made by any Person other than the Company or any Note Registrar) for the purpose of receiving payment of or on account of the principal (including any
Redemption Price and any Fundamental Change Repurchase Price) of and (subject to Section 2.03) accrued and unpaid interest on such Note, for conversion of such Note and for all other purposes under this Indenture; and neither the Company nor
the Trustee nor any Paying Agent nor any Conversion Agent nor any Note Registrar shall be affected by any notice to the contrary. The sole registered holder of a Global Note shall be the Depositary or its nominee. All such payments or deliveries so
made to any Holder for the time being, or upon its order, shall be valid, and, to the extent of the sums or shares of Common Stock so paid or delivered, effectual to satisfy and discharge the liability for monies payable or shares deliverable upon
any such Note. Notwithstanding anything to the contrary in this Indenture or the Notes following an Event of Default, any owner of a beneficial interest in a Global Note may directly enforce against the Company, without the consent, solicitation,
proxy, authorization or any other action of the Depositary or any other Person, such holder’s right to exchange such beneficial interest for a Physical Note in accordance with the provisions of this Indenture. 

Section 8.04. Company-Owned Notes Disregarded. In determining whether the Holders of the requisite aggregate principal amount of
Notes have concurred in any direction, consent, waiver or other action under this Indenture, Notes that are owned by the Company, by any Subsidiary thereof or by any Person directly or indirectly controlling or controlled by or under direct or
indirect common control with the Company or any Subsidiary thereof shall be disregarded and deemed not to be outstanding for the purpose of any such determination; provided that for the purposes of determining whether the Trustee shall be
protected in relying on any such direction, consent, waiver or other action, only Notes with respect to which a Responsible Officer has received written notice that such Notes are so owned shall be so disregarded. Notes so owned that have been
pledged in good faith may be regarded as outstanding for the purposes of this Section 8.04 if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right to so act with respect to such Notes and that the pledgee is
not the Company, a Subsidiary thereof or a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or a Subsidiary thereof. In the case of a dispute as to such right, any decision or
indecision by the Trustee taken upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officer’s Certificate listing and identifying all Notes, if
any, known by the Company to be owned or held by or for the account of any of the above described Persons; and, subject to Section 7.01, the Trustee shall be entitled to accept such Officer’s Certificate as conclusive evidence of the facts
therein set forth and of the fact that all Notes not listed therein are outstanding for the purpose of any such determination. 

Section 8.05. Revocation of Consents; Future Holders Bound. At any time prior to (but not after) the evidencing to the Trustee, as
provided in Section 8.01, of the taking of any action by the Holders of the percentage of the aggregate principal amount of the Notes specified in this Indenture in connection with such action, any Holder of a Note that is shown by the evidence
to be included in the Notes the Holders of which have consented to such action may, by filing written notice with the Trustee at its Corporate Trust Office and upon proof of holding as provided in Section 8.02, revoke such action so far as
concerns such Note. Except as aforesaid, any such action taken by the Holder of any Note shall be conclusive and binding upon such 

  
 46 

 
Holder and upon all future Holders and owners of such Note and of any Notes issued in exchange or substitution therefor or upon registration of transfer thereof, irrespective of whether any
notation in regard thereto is made upon such Note or any Note issued in exchange or substitution therefor or upon registration of transfer thereof. 

ARTICLE 9 

HOLDERS’ MEETINGS 

Section 9.01. Purpose of Meetings. A meeting of Holders may be called at any time and from time to time pursuant to the provisions
of this Article 9 for any of the following purposes: 
 (a) to give any notice to the Company or to the Trustee or to give any directions to
the Trustee permitted under this Indenture, or to consent to the waiving of any Default or Event of Default hereunder (in each case, as permitted under this Indenture) and its consequences, or to take any other action authorized to be taken by
Holders pursuant to any of the provisions of Article 6; 
 (b) to remove the Trustee and nominate a successor trustee pursuant to the
provisions of Article 7; 
 (c) to consent to the execution of an indenture or indentures supplemental hereto pursuant to the provisions of
Article 10; or 
 (d) to take any other action authorized to be taken by or on behalf of the Holders of any specified aggregate principal
amount of the Notes under any other provision of this Indenture or under applicable law. 
 Section 9.02. Call of Meetings by
Trustee. The Trustee may at any time call a meeting of Holders to take any action specified in Section 9.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Holders, setting forth the
time and the place of such meeting and in general terms the action proposed to be taken at such meeting and the establishment of any record date pursuant to Section 8.01, shall be delivered to Holders of such Notes. Such notice shall also be
delivered to the Company. Such notices shall be delivered not less than 20 nor more than 90 days prior to the date fixed for the meeting. 

Any meeting of Holders shall be valid without notice if the Holders of all Notes then outstanding are present in person or by proxy or if
notice is waived before or after the meeting by the Holders of all Notes then outstanding, and if the Company and the Trustee are either present by duly authorized representatives or have, before or after the meeting, waived notice. 

Section 9.03. Call of Meetings by Company or Holders. In case at any time the Company, pursuant to a Board Resolution, or the
Holders of at least 10% of the aggregate principal amount of the Notes then outstanding, shall have requested the Trustee to call a meeting of Holders, by written request setting forth in reasonable detail the action proposed to be taken at the
meeting, and the Trustee shall not have delivered the notice of such meeting within 20 days after receipt of such request, then the Company or such Holders may determine the time and the place for such meeting and may call such meeting to take any
action authorized in Section 9.01, by delivering notice thereof as provided in Section 9.02. 

  
 47 

 Section 9.04. Qualifications for Voting. To be entitled to vote at any meeting
of Holders a Person shall (a) be a Holder of one or more Notes on the record date pertaining to such meeting or (b) be a Person appointed by an instrument in writing as proxy by a Holder of one or more Notes on the record date pertaining
to such meeting. The only Persons who shall be entitled to be present or to speak at any meeting of Holders shall be the Persons entitled to vote at such meeting and their counsel and any representatives of the Trustee and its counsel and any
representatives of the Company and its counsel. 
 Section 9.05. Regulations. Notwithstanding any other provisions of this
Indenture, the Trustee may make such reasonable regulations as it may deem advisable for any meeting of Holders, in regard to proof of the holding of Notes and of the appointment of proxies, and in regard to the appointment and duties of inspectors
of votes, the submission and examination of proxies, certificates and other evidence of the right to vote, and such other matters concerning the conduct of the meeting as it shall think fit. 

The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting, unless the meeting shall have been called by the
Company or by Holders as provided in Section 9.03, in which case the Company or the Holders calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent chairman and a permanent secretary of the
meeting shall be elected by vote of the Holders of a majority in aggregate principal amount of the Notes represented at the meeting and entitled to vote at the meeting. 

Subject to the provisions of Section 8.04, at any meeting of Holders each Holder or proxyholder shall be entitled to one vote for each
$1,000 principal amount of Notes held or represented by him or her; provided, however, that no vote shall be cast or counted at any meeting in respect of any Note challenged as not outstanding and ruled by the chairman of the meeting
to be not outstanding. The chairman of the meeting shall have no right to vote other than by virtue of Notes held by it or instruments in writing as aforesaid duly designating it as the proxy to vote on behalf of other Holders. Any meeting of
Holders duly called pursuant to the provisions of Section 9.02 or Section 9.03 may be adjourned from time to time by the Holders of a majority of the aggregate principal amount of Notes represented at the meeting, whether or not
constituting a quorum, and the meeting may be held as so adjourned without further notice. 
 Section 9.06. Voting. The vote
upon any resolution submitted to any meeting of Holders shall be by written ballot on which shall be subscribed the signatures of the Holders or of their representatives by proxy and the outstanding aggregate principal amount of the Notes held or
represented by them. The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and who shall make and file with the secretary of the meeting their verified
written reports in duplicate of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders shall be prepared by the secretary of the meeting and there shall be attached to said record the original reports of
the inspectors of votes on any vote by ballot taken thereat and affidavits by one or more Persons having knowledge of the facts setting forth a copy of the notice of the meeting and showing that said notice was delivered as provided in
Section 9.02. The record 

  
 48 

 
shall show the aggregate principal amount of the Notes voting in favor of or against any resolution. The record shall be signed and verified by the affidavits of the permanent chairman and
secretary of the meeting and one of the duplicates shall be delivered to the Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting. 

Any record so signed and verified shall be conclusive evidence of the matters therein stated. 

Section 9.07. No Delay of Rights by Meeting. Nothing contained in this Article 9 shall be deemed or construed to authorize or
permit, by reason of any call of a meeting of Holders or any rights expressly or impliedly conferred hereunder to make such call, any hindrance or delay in the exercise of any right or rights conferred upon or reserved to the Trustee or to the
Holders under any of the provisions of this Indenture or of the Notes. Nothing contained in this Article 9 shall be deemed or construed to limit any Holder’s actions pursuant to the applicable procedures of the Depositary so long as the Notes
are Global Notes. 
 ARTICLE 10 

SUPPLEMENTAL INDENTURES 

Section 10.01. Supplemental Indentures Without Consent of Holders. Without the consent of any Holder, the Company and the Trustee,
at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for one or more of the following purposes: 

(a) to cure any ambiguity, omission, defect or inconsistency; 

(b) to provide for the assumption by a Successor Company of the obligations of the Company under this Indenture pursuant to Article 11; 

(c) to add guarantees with respect to the Notes; 

(d) to secure the Notes; 
 (e) to
add to the covenants or Events of Default of the Company for the benefit of the Holders or surrender any right or power conferred upon the Company under this Indenture or the Notes; 

(f) to make any change that does not adversely affect the rights of any Holder under this Indenture or the Notes, as determined by the Company
in good faith; 
 (g) to increase the Conversion Rate as provided in this Indenture; 

(h) to provide for the appointment of and acceptance of appointment by a successor trustee pursuant to Section 7.09 or to facilitate the
administration of the trusts under this Indenture by more than one trustee; 

  
 49 

 (i) to irrevocably elect a Settlement Method or a Specified Dollar Amount or a Minimum
Specified Amount, or eliminate the Company’s right to elect a Settlement Method; 
 (j) to conform the provisions of this Indenture or
the Notes to any provision of the “Description of Notes” section of the Offering Memorandum, as certified by the Company in an Officer’s Certificate; 

(k) to make provisions with respect to conversion rights of the Holders pursuant to Section 14.07 in accordance with the applicable
provisions of this Indenture; or 
 (l) to comply with the rules of the Depositary. 

Upon the written request of the Company, the Trustee is hereby authorized to, and shall join with the Company in the execution of any such
supplemental indenture, to make any further appropriate agreements and stipulations that may be therein contained, except that the Trustee shall not be obligated to, but may in its discretion, enter into any supplemental indenture that affects the
Trustee’s own rights, duties, liabilities or immunities under this Indenture or otherwise. 
 Any supplemental indenture authorized by
the provisions of this Section 10.01 may be executed by the Company and the Trustee without the consent of the Holders of any of the Notes at the time outstanding, notwithstanding any of the provisions of Section 10.02. 

Section 10.02. Supplemental Indentures with Consent of Holders. With the consent (evidenced as provided in Article 8) of the
Holders of at least a majority of the aggregate principal amount of the Notes then outstanding (determined in accordance with Article 8 and including, without limitation, consents obtained in connection with a repurchase of, or tender or exchange
offer for, the Notes), the Company and the Trustee, at the Company’s expense, may from time to time and at any time enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner
or eliminating any of the provisions of this Indenture, the Notes or any supplemental indenture or of modifying in any manner the rights of the Holders; provided, however, that, without the consent of each Holder of an outstanding Note
affected, no such supplemental indenture shall: 
 (a) reduce the principal amount of Notes whose Holders must consent to an amendment; 

(b) reduce the rate of or extend the stated time for payment of interest on any Note; 

(c) reduce the principal of or extend the Maturity Date of any Note; 

(d) make any change that adversely affects the conversion rights of any Notes; 

(e) reduce the Redemption Price or the Fundamental Change Repurchase Price of any Note or amend or modify in any manner adverse to the Holders
the Company’s obligation to make such payments, whether through an amendment or waiver of provisions in the covenants, definitions or otherwise; 

  
 50 

 (f) make any Note payable in money, or at a place of payment, other than that stated in the
Note; 
 (g) change the ranking of the Notes; 

(h) impair the right of any Holder to receive payment of principal and interest on such Holder’s Notes on or after the due dates therefor
or to institute suit for the enforcement of any payment on or with respect to such Holder’s Note; or 
 (i) make any change in this
Article 10 that requires each Holder’s consent or in the waiver provisions in Section 6.02 or Section 6.09. 
 Upon the
written request of the Company, and upon the delivery to the Trustee of evidence of the consent of the requisite Holders as aforesaid and subject to Section 10.05, the Trustee shall join with the Company in the execution of such supplemental
indenture unless such supplemental indenture affects the Trustee’s own rights, duties, liabilities or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such
supplemental indenture. 
 Holders do not need under this Section 10.02 to approve the particular form of any proposed supplemental
indenture. It shall be sufficient if such Holders approve the substance thereof. After any such supplemental indenture becomes effective, the Company shall deliver to the Holders (with a copy to the Trustee) a notice briefly describing such
supplemental indenture. However, the failure to give such notice to all the Holders, or any defect in the notice, will not impair or affect the validity of the supplemental indenture. 

Section 10.03. Effect of Supplemental Indentures. Upon the execution of any supplemental indenture pursuant to the provisions of
this Article 10, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the
Holders shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental indenture shall be and be deemed to be part of the terms
and conditions of this Indenture for any and all purposes. 
 Section 10.04. Notation on Notes. Notes authenticated and
delivered after the execution of any supplemental indenture pursuant to the provisions of this Article 10 may, at the Company’s request and expense, bear a notation in form approved by the Trustee as to any matter provided for in such
supplemental indenture. If the Company or the Trustee shall so determine, new Notes so modified as to conform, in the opinion of the Trustee and the Company, to any modification of this Indenture contained in any such supplemental indenture may, at
the Company’s expense, be prepared and executed by the Company, authenticated upon receipt of a Company Order by the Trustee (or an authenticating agent duly appointed by the Trustee pursuant to Section 17.10) and delivered in exchange for
the Notes then outstanding, upon surrender of such Notes then outstanding. 
  

  
 51 

 Section 10.05. Evidence of Compliance of Supplemental Indenture to Be Furnished
Trustee. In addition to the documents required by Section 17.05, the Trustee shall receive an Officer’s Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies with
the requirements of this Article 10 and is permitted or authorized by this Indenture and that the supplemental indenture constitutes the legal, valid and binding obligation of the Company enforceable in accordance with its terms. 

ARTICLE 11 

CONSOLIDATION, MERGER, SALE, CONVEYANCE AND LEASE 

Section 11.01. Company May Consolidate, Etc. on Certain Terms. Subject to the provisions of Section 11.02, the Company shall
not consolidate with or merge with or into, or sell, convey, transfer or lease in one transaction or a series of transactions all or substantially all of the consolidated properties and assets of the Company and its Subsidiaries, taken as a whole,
to another Person (other than any such sale, conveyance, transfer or lease to one or more of the Company’s Wholly Owned Subsidiaries), unless: 

(a) the resulting, surviving or transferee Person (the “Successor Company”), if not the Company, shall be a corporation
organized and existing under the laws of the United States of America, any State thereof or the District of Columbia, and the Successor Company (if not the Company) shall expressly assume, by supplemental indenture all of the obligations of the
Company under the Notes and this Indenture; and 
 (b) immediately after giving effect to such transaction, no Default or Event of Default
shall have occurred and be continuing under this Indenture. 
 For purposes of this Section 11.01, the sale, conveyance, transfer or
lease of all or substantially all of the properties and assets of one or more Subsidiaries of the Company to another Person, which properties and assets, if held by the Company instead of such Subsidiaries, would constitute all or substantially all
of the properties and assets of the Company on a consolidated basis, shall be deemed to be the sale, conveyance, transfer or lease of all or substantially all of the properties and assets of the Company to another Person. 

Section 11.02. Successor Corporation to Be Substituted. In case of any such consolidation, merger, sale, conveyance, transfer or
lease (other than any such sale, conveyance, transfer or lease to one or more of the Company’s Wholly Owned Subsidiaries) and upon the assumption by the Successor Company, by supplemental indenture, executed and delivered to the Trustee, of all
of the obligations of the Company under the Notes and this Indenture, such Successor Company (if not the Company) shall succeed to and, except in the case of a lease of all or substantially all of the Company’s properties and assets, shall be
substituted for the Company, with the same effect as if it had been named herein as the party of the first part, and may thereafter exercise every right and power of, the Company under this Indenture. Such Successor Company thereupon may cause to be
signed, and may issue either in its own name or in the name of the Company any or all of the Notes issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such Successor
Company instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall authenticate and shall deliver, or cause to be authenticated and delivered, any Notes that previously shall have
been signed and delivered 

  
 52 

 
by the Officers of the Company to the Trustee for authentication, and any Notes that such Successor Company thereafter shall cause to be signed and delivered to the Trustee for that purpose. All
the Notes so issued shall in all respects have the same legal rank and benefit under this Indenture as the Notes theretofore or thereafter issued in accordance with the terms of this Indenture as though all of such Notes had been issued at the date
of the execution hereof. In the event of any such consolidation, merger, sale, conveyance or transfer (but not in the case of a lease), upon compliance with this Article 11 the Person named as the “Company” in the first paragraph of this
Indenture (or any successor that shall thereafter have become such in the manner prescribed in this Article 11) may be dissolved, wound up and liquidated at any time thereafter and, except in the case of a lease, such Person shall be released from
its liabilities as obligor and maker of the Notes and from its obligations under this Indenture and the Notes. 
 In case of any such
consolidation, merger, sale, conveyance, transfer or lease, such changes in phraseology and form (but not in substance) may be made in the Notes thereafter to be issued as may be appropriate. 

Section 11.03. Opinion of Counsel to Be Given to Trustee. No such consolidation, merger, sale, conveyance, transfer or lease shall
be effective unless the Trustee shall receive an Officer’s Certificate and an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale, conveyance, transfer or lease and any such assumption and, if a supplemental
indenture is required in connection with such transaction, such supplemental indenture, complies with the provisions of this Article 11. 

ARTICLE 12 

IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND
DIRECTORS 
 Section 12.01. Indenture and Notes Solely Corporate Obligations. No recourse for the payment of the
principal of or accrued and unpaid interest on any Note, nor for any claim based thereon or otherwise in respect thereof, and no recourse under or upon any obligation, covenant or agreement of the Company in this Indenture or in any supplemental
indenture or in any Note, nor because of the creation of any indebtedness represented thereby, shall be had against any incorporator, stockholder, employee, agent, Officer or director or Subsidiary, as such, past, present or future, of the Company
or of any successor corporation, either directly or through the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly
understood that all such liability is hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issue of the Notes. 

  
 53 

 ARTICLE 13 

INTENTIONALLY OMITTED 

ARTICLE 14 

CONVERSION OF NOTES 

Section 14.01. Conversion Privilege. (a) Subject to and upon compliance with the provisions of this Article 14, each Holder
of a Note shall have the right, at such Holder’s option, to convert all or any portion (if the portion to be converted is $1,000 principal amount or a multiple thereof) of such Note (i) subject to satisfaction of the conditions described
in Section 14.01(b), at any time prior to the close of business on the Business Day immediately preceding March 15, 2026 under the circumstances and during the periods set forth in Section 14.01(b), and (ii) regardless of the
conditions described in Section 14.01(b), on or after March 15, 2026 and prior to the close of business on the second Scheduled Trading Day immediately preceding the Maturity Date, in each case, at an initial conversion rate of 3.3732
shares of Common Stock (subject to adjustment as provided in this Article 14, the “Conversion Rate”) per $1,000 principal amount of Notes (subject to, and in accordance with, the settlement provisions of Section 14.02, the
“Conversion Obligation”). 
 (b) (i) Prior to the close of business on the Business Day immediately preceding March 15,
2026, a Holder may surrender all or any portion of its Notes for conversion at any time during the five Business Day period immediately after any ten consecutive Trading Day period (the “Measurement Period”) in which the Trading
Price per $1,000 principal amount of Notes, as determined following a written request by a Holder of Notes in accordance with this Section 14.01(b)(i), for each Trading Day of the Measurement Period was less than 98% of the product of the Last
Reported Sale Price of the Common Stock and the Conversion Rate on each such Trading Day. The Trading Prices shall be determined by the Bid Solicitation Agent pursuant to this Section 14.01(b)(i) and the definition of Trading Price set forth in
this Indenture. The Bid Solicitation Agent (if other than the Company) shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes unless the Company has requested such determination in writing, and the Company shall
have no obligation to make such request (or, if the Company is acting as Bid Solicitation Agent, the Company shall have no obligation to determine the Trading Price per $1,000 principal amount of Notes) unless a Holder of at least $2,000,000
aggregate principal amount of Notes provides the Company with reasonable evidence that the Trading Price per $1,000 principal amount of Notes would be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the
Conversion Rate, at which time the Company shall instruct the Bid Solicitation Agent in writing (if other than the Company) to determine, or if the Company is acting as Bid Solicitation Agent, the Company shall determine the Trading Price per $1,000
principal amount of Notes beginning on the next Trading Day and on each successive Trading Day until the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common
Stock and the Conversion Rate. At such time as the Company directs the Bid Solicitation Agent in writing to solicit bid quotations, the Company shall provide the Bid Solicitation Agent with the names and contact details of the three independent
nationally recognized securities dealers selected by the Company, and the Company shall direct those security dealers to provide bids to the Bid Solicitation Agent. Any such determination will be 

  
 54 

 
conclusive absent manifest error. If (x) the Company is not acting as Bid Solicitation Agent, and the Company does not, when the Company is required to, instruct the Bid Solicitation Agent
to obtain bids, or if the Company so instructs the Bid Solicitation Agent to obtain bids and the Bid Solicitation Agent fails to make such determination, or (y) the Company is acting as Bid Solicitation Agent and the Company fails to make such
determination. then, in either case, the Trading Price per $1,000 principal amount of Notes shall be deemed to be less than 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate on each Trading Day of such
failure. If the Trading Price condition set forth above has been met, the Company shall so notify the Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing. If, at any time after the Trading Price condition set forth
above has been met, the Trading Price per $1,000 principal amount of Notes is greater than or equal to 98% of the product of the Last Reported Sale Price of the Common Stock and the Conversion Rate for such date, the Company shall so notify the
Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing, and thereafter neither the Company nor the Bid Solicitation Agent (if other than the Company) shall be required to solicit bids (or determine the Trading Price of
the Notes as set forth in this Indenture) again until a new Holder request is made pursuant to this Section 14.01(b)(i). 

(ii) If, prior to the close of business on the Business Day immediately preceding March 15, 2026, the Company elects to:

 (A) issue to all or substantially all holders of the Common Stock any rights, options or warrants (other than in
connection with a stockholder rights plan) entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of the Common Stock at a price per share that is less than
the average of the Last Reported Sale Prices of the Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance; or 

(B) distribute to all or substantially all holders of the Common Stock the Company’s assets, securities or rights to
purchase securities of the Company (other than in connection with a stockholder rights plan prior to the separation of such rights from the Common Stock), which distribution has a per share value, as reasonably determined by the Company, exceeding
10% of the Last Reported Sale Price of the Common Stock on the Trading Day preceding the date of announcement for such distribution, 
 then, in either
case, the Company shall notify the Holders of the Notes, the Trustee and the Conversion Agent (if other than the Trustee) in writing at least 30 Scheduled Trading Days prior to the Ex-Dividend Date for such
issuance or distribution; provided, however, that if the Company is then otherwise permitted to settle conversions by Physical Settlement (and, for the avoidance of doubt, the Company has not elected another Settlement Method to apply,
including pursuant to Section 14.02), then the Company may instead elect to provide such notice at least five (5) Scheduled Trading Days prior to such Ex-Dividend Date. In that event, the Company
shall be required to settle all conversions with a Conversion Date occurring on or after the date the Company provides such notice and before such Ex-Dividend Date (or, if earlier, the date the

  
 55 

 
Company announces that such issuance or distribution will not take place) by Physical Settlement, and the Company shall describe the same in such notice. Once the Company has given such notice, a
Holder may surrender all or any portion of its Notes for conversion at any time until the earlier of (1) the close of business on the Business Day immediately preceding the Ex-Dividend Date for such
issuance or distribution and (2) the Company’s announcement that such issuance or distribution will not take place, even if the Notes are not otherwise convertible at such time. 

(iii) If (A) a transaction or event that constitutes (x) a Fundamental Change or (y) a Make-Whole Fundamental
Change occurs prior to the close of business on the Business Day immediately preceding March 15, 2026, regardless of whether a Holder has the right to require the Company to repurchase the Notes pursuant to Section 15.02, or (B) if
the Company is a party to a consolidation, merger, binding share exchange, or transfer or lease of all or substantially all of its assets that occurs prior to the close of business on the Business Day immediately preceding March 15, 2026, in
each case pursuant to which the Common Stock would be converted into cash, securities or other assets (other than a merger effected solely to change the Company’s jurisdiction of incorporation that does not otherwise constitute a Make-Whole
Fundamental Change or a Fundamental Change), then, in each case, all or any portion of a Holder’s Notes may be surrendered for conversion at any time from or after the effective date of the transaction or event until 35 Trading Days after the
actual effective date of such transaction or event or, if such transaction also constitutes a Fundamental Change, until the related Fundamental Change Repurchase Date. The Company shall notify Holders, the Trustee and the Conversion Agent (if other
than the Trustee) in writing as promptly as practicable following the date the Company publicly announces such transaction or event, but in no event later than the actual effective date of such transaction or event. 

(iv) Prior to the close of business on the Business Day immediately preceding March 15, 2026, a Holder may surrender all
or any portion of its Notes for conversion at any time during any fiscal quarter commencing after the fiscal quarter ending on October 31, 2020 (and only during such fiscal quarter), if the Last Reported Sale Price of the Common Stock for at
least 20 Trading Days (whether or not consecutive) during the period of 30 consecutive Trading Days ending on, and including, the last Trading Day of the immediately preceding fiscal quarter is greater than or equal to 130% of the Conversion Price
on each applicable Trading Day. 
 (v) If the Company calls any or all of the Notes for redemption pursuant to Article 16
prior to the Maturity Date, then a Holder may surrender all or any portion of its Called Notes for conversion at any time prior to the close of business on the second Scheduled Trading Day prior to the Redemption Date, even if the Called Notes are
not otherwise convertible at such time. After that time, the right to convert such Called Notes on account of the Company’s delivery of a Redemption Notice shall expire, unless the Company defaults in the payment of the Redemption Price, in
which case a Holder of Called Notes may convert all or any portion of its Called Notes until the Redemption Price has been paid or duly provided for. If the Company elects to redeem fewer than all of the outstanding Notes pursuant to Article 16, and
the Holder of any Note (or any owner of a beneficial interest in any Global Note) is reasonably not able to determine, 

  
 56 

 
before the close of business on the 24th Scheduled Trading Day immediately before the relevant Redemption Date, whether such Note or beneficial interest, as applicable, is to be redeemed pursuant
to such redemption, then such Holder or owner, as applicable, shall be entitled to convert such Note or beneficial interest, as applicable, at any time before the close of business on the second Scheduled Trading Day prior to such Redemption Date,
unless the Company defaults in the payment of the Redemption Price, in which case such Holder or owner, as applicable, shall be entitled to convert such Note or beneficial interest, as applicable, until the Redemption Price has been paid or duly
provided for, and each such conversion shall be deemed to be of a Note called for redemption, and such Note or beneficial interest shall be deemed called for redemption solely for the purposes of such conversion (“Deemed
Redemption”). If a Holder elects to convert Called Notes pursuant to this Section 14.01(b)(v) during the related Redemption Period, the Company shall, under certain circumstances, increase the Conversion Rate for such Called Notes
pursuant to Section 14.03. Accordingly, if the Company elects to redeem fewer than all of the outstanding Notes pursuant to Article 16, Holders of the Notes that are not Called Notes shall not be entitled to convert such Notes pursuant to this
Section 14.01(b)(v) and shall not be entitled to an increased Conversion Rate on account of the Redemption Notice, even if such Notes are otherwise convertible pursuant to any other provision of this Section 14.01(b) and are converted
during the related Redemption Period. 
 Section 14.02. Conversion Procedure; Settlement Upon Conversion. 

(a) Subject to this Section 14.02, Section 14.03(b) and Section 14.07(a), upon conversion of any Note, the Company shall satisfy
its Conversion Obligation by paying or delivering, as the case may be, to the converting Holder, in respect of each $1,000 principal amount of Notes being converted, cash (“Cash Settlement”), shares of Common Stock, together with
cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (“Physical Settlement”) or a combination of cash and shares of Common Stock, together
with cash, if applicable, in lieu of delivering any fractional share of Common Stock in accordance with subsection (j) of this Section 14.02 (“Combination Settlement”), at its election, as set forth in this
Section 14.02. 
 (i) All conversions occurring (x) on or after March 15, 2026 or (y) during a Redemption
Period shall be settled using the same Settlement Method. 
 (ii) Except for any conversions for which the relevant
Conversion Date occurs during a Redemption Period and any conversions for which the relevant Conversion Date occurs on or after March 15, 2026, and except to the extent the Company elects Physical Settlement to apply pursuant to
Section 14.01(b)(ii) in a notice as described in such Section, the Company shall use the same Settlement Method for all conversions occurring on the same Conversion Date, but the Company shall not have any obligation to use the same Settlement
Method with respect to conversions that occur on different Conversion Dates. 

  
 57 

 (iii) If, in respect of any Conversion Date (or one of the periods described
in the fourth immediately succeeding set of parentheses, as the case may be), the Company elects a Settlement Method, the Company shall deliver a written notice (the “Settlement Notice”) of the Settlement Method so elected in
respect of such Conversion Date (or such period, as the case may be) to converting Holders, the Trustee and the Conversion Agent (if other than the Trustee) no later than the close of business on the Trading Day immediately following the relevant
Conversion Date (or, in the case of any conversions (A) occurring (x) during a Redemption Period, in such Redemption Notice, or (y) on or after March 15, 2026, no later than the close of business on the Business Day immediately
preceding March 15, 2026, (B) for which the Company has irrevocably elected Physical Settlement to apply pursuant to Section 14.01(b)(ii) in a notice as described in such Section or (C) for which the Company has irrevocably elected
Combination Settlement, with a certain Specified Dollar Amount or a Minimum Specified Amount per $1,000 principal amount of Notes, to apply pursuant to the provisions of this Section 14.02(a)(iii), as described in this
Section 14.02(a)(iii). If the Company does not timely elect a Settlement Method prior to the deadline set forth in the immediately preceding sentence, the Company shall no longer have the right to elect Cash Settlement or Physical Settlement
for such conversion or during such period and the Company shall be deemed to have elected Combination Settlement in respect of its Conversion Obligation, and the Specified Dollar Amount per $1,000 principal amount of Notes shall be equal to $1,000.
Such Settlement Notice shall specify the relevant Settlement Method and in the case of an election of Combination Settlement, the relevant Settlement Notice shall indicate the Specified Dollar Amount per $1,000 principal amount of Notes. If the
Company delivers a Settlement Notice electing Combination Settlement in respect of its Conversion Obligation but does not timely notify converting Holders, the Trustee and the Conversion Agent of the Specified Dollar Amount per $1,000 principal
amount of Notes in such Settlement Notice, the Specified Dollar Amount per $1,000 principal amount of Notes shall be deemed to be $1,000. By written notice to the Holders, the Trustee and the Conversion Agent, the Company may, prior to
March 15, 2026, at its option, elect to irrevocably fix the Settlement Method to any Settlement Method that the Company is then permitted to elect, including Combination Settlement with a Specified Dollar Amount per $1,000 principal amount of
Notes of $1,000 or with an ability to continue to set the Specified Dollar Amount per $1,000 principal amount of Notes at or above a specific amount (the “Minimum Specified Amount”) set forth in such election notice. If the Company
irrevocably elects Combination Settlement with an ability to continue to set the Specified Dollar Amount per $1,000 principal amount of Notes at or above a specific amount, the Company shall, after the date of such election, send written notice to
Holders converting their Notes, the Trustee and the Conversion Agent of such Specified Dollar Amount no later than the close of business on the Trading Day immediately following the related Conversion Date, or, if the Company does not timely notify
Holders, the Trustee and the Conversion Agent in writing, such Specified Dollar Amount shall be the Minimum Specified Amount set forth in the election notice, unless no Minimum Specified Amount was set forth in the election notice, in which case
such Specified Dollar Amount shall be $1,000 per $1,000 principal amount of Notes. The irrevocable election shall apply to all Note conversions on Conversion Dates occurring subsequent to delivery of such notice; provided that (x) any
such election that is made during a Redemption Period (but after the Redemption Notice Date) shall not apply to any conversions of Notes called for redemption with 

  
 58 

 
Conversion Dates that occur during such Redemption Period and (y) any such election shall not apply to any conversions for which the Company has irrevocably elected Physical Settlement to
apply pursuant to Section 14.01(b)(ii) in a notice as described in such Section. For the avoidance of doubt, such an irrevocable election, if made, shall be effective without the need to amend this Indenture or the Notes, including pursuant to
Section 10.01(i). However, the Company may nonetheless choose to execute such an amendment at its option. 
 (iv) The
cash, shares of Common Stock or combination of cash and shares of Common Stock in respect of any conversion of Notes (the “Settlement Amount”) shall be computed as follows: 

(A) if the Company elects to satisfy its Conversion Obligation in respect of such conversion by Physical Settlement, the
Company shall deliver to the converting Holder in respect of each $1,000 principal amount of Notes being converted a number of shares of Common Stock equal to the Conversion Rate in effect on the Conversion Date; 

(B) if the Company elects to satisfy its Conversion Obligation in respect of such conversion by Cash Settlement, the Company
shall pay to the converting Holder in respect of each $1,000 principal amount of Notes being converted cash in an amount equal to the sum of the Daily Conversion Values for each of the 20 consecutive Trading Days during the related Observation
Period; and 
 (C) if the Company elects (or is deemed to have elected) to satisfy its Conversion Obligation in respect of
such conversion by Combination Settlement, the Company shall pay or deliver, as the case may be, in respect of each $1,000 principal amount of Notes being converted, a Settlement Amount equal to the sum of the Daily Settlement Amounts for each of
the 20 consecutive Trading Days during the related Observation Period. 
 (v) The Daily Settlement Amounts (if applicable)
and the Daily Conversion Values (if applicable) shall be determined by the Company promptly following the last day of the Observation Period. Promptly after such determination of the Daily Settlement Amounts or the Daily Conversion Values, as the
case may be, and the amount of cash payable in lieu of delivering any fractional share of Common Stock, the Company shall notify the Trustee and the Conversion Agent (if other than the Trustee) of the Daily Settlement Amounts or the Daily Conversion
Values, as the case may be, and the amount of cash payable in lieu of delivering fractional shares of Common Stock. The Trustee and the Conversion Agent (if other than the Trustee) shall have no responsibility for any such determination. 

(b) Subject to Section 14.02(e), before any Holder of a Note shall be entitled to convert a Note as set forth above, such Holder shall
(i) in the case of a Global Note, comply with the procedures of the Depositary in effect at that time for converting a beneficial interest in a Global Note and, if required, pay funds equal to interest payable on the next Interest Payment Date
to 

  
 59 

 
which such Holder is not entitled as set forth in Section 14.02(h) (and, if required, pay all transfer or similar taxes, if any, as set forth in Section 14.02(d) and
Section 14.02(e)) and (ii) in the case of a Physical Note (1) complete, manually sign and deliver an irrevocable notice to the Conversion Agent as set forth in the Form of Notice of Conversion (or a facsimile, PDF or other electronic
transmission thereof) (a “Notice of Conversion”) at the office of the Conversion Agent and state in writing therein the principal amount of Notes to be converted and the name or names (with addresses) in which such Holder wishes the
certificate or certificates for any shares of Common Stock to be delivered upon settlement of the Conversion Obligation to be registered, (2) surrender such Notes, duly endorsed to the Company or in blank (and accompanied by appropriate
endorsement and transfer documents), at the office of the Conversion Agent, (3) if required, furnish appropriate endorsements and transfer documents and (4) if required, pay funds equal to interest payable on the next Interest Payment Date
to which such Holder is not entitled as set forth in Section 14.02(h). The Trustee (and, if different, the Conversion Agent) shall notify the Company of any conversion pursuant to this Article 14 on the Conversion Date for such conversion. No
Notes may be surrendered for conversion by a Holder thereof if such Holder has also delivered a Fundamental Change Repurchase Notice to the Company in respect of such Notes and has not validly withdrawn such Fundamental Change Repurchase Notice in
accordance with Section 15.03. 
 If more than one Note shall be surrendered for conversion at one time by the same Holder, the
Conversion Obligation with respect to such Notes shall be computed on the basis of the aggregate principal amount of the Notes (or specified portions thereof to the extent permitted thereby) so surrendered. 

(c) A Note shall be deemed to have been converted immediately prior to the close of business on the date (the “Conversion
Date”) that the Holder has complied with the requirements set forth in subsection (b) above. Except as set forth in Section 14.03(b) and Section 14.07(a), the Company shall pay or deliver, as the case may be, the
consideration due in respect of the Conversion Obligation on the second Business Day immediately following the relevant Conversion Date, if the Company elects Physical Settlement, or on the second Business Day immediately following the last Trading
Day of the relevant Observation Period, in the case of any other Settlement Method; provided that, with respect to any Conversion Date occurring during a Redemption Period or on or after March 15, 2026, (x) the Company will settle any
such conversion for which Physical Settlement is applicable on the relevant Redemption Date or the Maturity Date, as applicable and (y) the Company will settle any such conversion for which Cash Settlement or Combination Settlement is
applicable on the second Business Day immediately following the last Trading Day of the relevant Observation Period). If any shares of Common Stock are due to converting Holders, the Company shall issue or cause to be issued, and deliver to such
Holder, or such Holder’s nominee or nominees, certificates or a book-entry transfer through the Depositary for the full number of shares of Common Stock to which such Holder shall be entitled in satisfaction of the Company’s Conversion
Obligation. 
 (d) In case any Note shall be surrendered for partial conversion, the Company shall execute and the Trustee shall authenticate
and deliver to or upon the written order of the Holder of the Note so surrendered a new Note or Notes in authorized denominations in an aggregate principal amount equal to the unconverted portion of the surrendered Note, without payment of any
service charge by the converting Holder but, if required by the Company or Trustee, with 

  
 60 

 
payment of a sum sufficient to cover any documentary, stamp or similar issue or transfer tax or similar governmental charge required by law or that may be imposed in connection therewith as a
result of the name of the Holder of the new Notes issued upon such conversion being different from the name of the Holder of the old Notes surrendered for such conversion. 

(e) If a Holder submits a Note for conversion, the Company shall pay any documentary, stamp or similar issue or transfer tax or other similar
governmental charge due on any issuance of any shares of Common Stock upon conversion, unless the tax is due because the Holder requests any such shares to be issued in a name other than the Holder’s name, in which case the Holder shall pay
that tax. The Conversion Agent may refuse to deliver the certificates representing the shares of Common Stock being issued in a name other than the Holder’s name until the Trustee receives a sum sufficient to pay any tax that is due by such
Holder in accordance with the immediately preceding sentence. 
 (f) Except as provided in Section 14.04, no adjustment shall be made
for dividends on any shares of Common Stock issued upon the conversion of any Note as provided in this Article 14. 
 (g) Upon the conversion
of an interest in a Global Note, the Trustee, or the Custodian at the direction of the Trustee, shall make a notation on such Global Note as to the reduction in the principal amount represented thereby. The Company shall notify the Trustee in
writing of any conversion of Notes effected through any Conversion Agent other than the Trustee. 
 (h) Upon conversion, a Holder shall not
receive any separate cash payment for accrued and unpaid interest, if any, except as set forth below. The Company’s settlement of the full Conversion Obligation shall be deemed to satisfy in full its obligation to pay the principal amount of
the Note and accrued and unpaid interest, if any, to, but excluding, the relevant Conversion Date. As a result, accrued and unpaid interest, if any, to, but excluding, the relevant Conversion Date shall be deemed to be paid in full rather than
cancelled, extinguished or forfeited. Upon a conversion of Notes into a combination of cash and shares of Common Stock, accrued and unpaid interest will be deemed to be paid first out of the cash paid upon such conversion. Notwithstanding the
foregoing, if Notes are converted after the close of business on a Regular Record Date and prior to the open of business on the corresponding Interest Payment Date, Holders of such Notes as of the close of business on such Regular Record Date will
receive the full amount of interest payable on such Notes on the corresponding Interest Payment Date notwithstanding the conversion. Notes surrendered for conversion during the period from the close of business on any Regular Record Date to the open
of business on the immediately following Interest Payment Date must be accompanied by funds equal to the amount of interest payable on the Notes so converted; provided that no such payment shall be required (1) for conversions following
the Regular Record Date immediately preceding the Maturity Date; (2) if the Company has specified a Fundamental Change Repurchase Date that is after a Regular Record Date and on or prior to the Business Day immediately succeeding the
corresponding Interest Payment Date; (3) if the Company has specified a Redemption Date that is after a Regular Record Date and on or prior to the Business Day immediately succeeding the corresponding Interest Payment Date; or (4) to the
extent of any overdue interest, if any overdue interest exists at the time of conversion with respect to such Note. Therefore, for the avoidance of doubt, all Holders of record on the Regular Record Date immediately preceding the Maturity Date shall
receive the full interest payment due on the Maturity Date in cash regardless of whether their Notes have been converted following such Regular Record Date. 
  

  
 61 

 (i) The Person in whose name the certificate for any shares of Common Stock delivered upon
conversion is registered shall be deemed to be the holder of record of such shares of Common Stock as of the close of business on the relevant Conversion Date (if the Company elects to satisfy the related Conversion Obligation by Physical
Settlement) or the last Trading Day of the relevant Observation Period (if the Company elects to satisfy the related Conversion Obligation by Combination Settlement), as the case may be. Upon a conversion of Notes, such Person shall no longer be a
Holder of such Notes surrendered for conversion. 
 (j) The Company shall not issue any fractional share of Common Stock upon conversion of
the Notes and shall instead pay cash in lieu of delivering any fractional share of Common Stock issuable upon conversion based on the Daily VWAP on the relevant Conversion Date (in the case of Physical Settlement) or based on the Daily VWAP on the
last Trading Day of the relevant Observation Period (in the case of Combination Settlement). For each Note surrendered for conversion, if the Company has elected (or is deemed to have elected) Combination Settlement, the full number of shares that
shall be issued upon conversion thereof shall be computed on the basis of the aggregate Daily Settlement Amounts for the relevant Observation Period and any fractional shares remaining after such computation shall be paid in cash. 

(k) If a Holder converts more than one Note on a Conversion Date, then the consideration due upon such conversion will (in the case of any
Global Note, to the extent permitted by, and practicable under, the applicable procedures of the Depositary) be computed based on the total principal amount of Notes converted on such Conversion Date by that Holder. 

Section 14.03. Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Fundamental Changes or
Called Notes During a Redemption Period. (a) If (i) the Effective Date of a Make-Whole Fundamental Change occurs prior to the Maturity Date and a Holder elects to convert its Notes in connection with such Make-Whole Fundamental Change or
(ii) the Company issues a Redemption Notice pursuant to Section 16.02 and a Holder elects to convert its Called Notes pursuant to Section 14.01(b)(v) during the related Redemption Period, as the case may be, the Company shall, under
the circumstances described below, increase the Conversion Rate for the Notes so surrendered for conversion by a number of additional shares of Common Stock (the “Additional Shares”), as described below. A conversion of Notes shall
be deemed for these purposes to be “in connection with” such Make-Whole Fundamental Change if the relevant Notice of Conversion is received by the Conversion Agent from, and including, the Effective Date of the Make-Whole Fundamental
Change up to, and including, the Business Day immediately prior to the related Fundamental Change Repurchase Date (or, in the case of a Make-Whole Fundamental Change that would have been a Fundamental Change but for the proviso in clause
(b) of the definition thereof, the 35th Trading Day immediately following the Effective Date of such Make-Whole Fundamental Change) (such period, the “Make-Whole Fundamental Change Period”). For the avoidance of doubt, if the
Company issues a Redemption Notice pursuant to Section 16.02, the Company shall increase the Conversion Rate hereunder during the related Redemption Period only with respect to conversions of Called Notes, and not for Notes that are not Called
Notes. Accordingly, if the 

  
 62 

 
Company elects to redeem fewer than all of the outstanding Notes pursuant to Article 16, Holders of the Notes that are not Called Notes shall not be entitled to convert such Notes pursuant to
Section 14.01(b)(v) and shall not be entitled to an increased Conversion Rate for conversions of such Notes on account of the Redemption Notice, even if such Notes are otherwise convertible pursuant to Section 14.01(b)(i)-(iv) and are
converted during the related Redemption Period. 
 (b) Upon surrender of Notes for conversion in connection with a Make-Whole Fundamental
Change pursuant to Section 14.01(b)(iii) or upon surrender of Called Notes during a Redemption Period pursuant to Section 14.01(b)(v), the Company shall, at its option, satisfy the related Conversion Obligation by Physical Settlement, Cash
Settlement or Combination Settlement in accordance with Section 14.02 based on the Conversion Rate as increased to reflect the Additional Shares pursuant to the table below; provided, however, that if, the Reference Property in
any Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental Change is composed entirely of cash, for any conversion of Notes following the Effective Date of such Make-Whole Fundamental Change, the Conversion
Obligation shall be calculated based solely on the Stock Price for the transaction and shall be deemed to be an amount of cash per $1,000 principal amount of converted Notes equal to the Conversion Rate (including any increase to reflect the
Additional Shares), multiplied by such Stock Price. In such event, the Conversion Obligation shall be determined and paid to Holders in cash on the second Business Day following the Conversion Date. The Company shall notify the Holders, the
Trustee and the Conversion Agent (if other than the Trustee) in writing of the Effective Date of any Make-Whole Fundamental Change no later than five Business Days after such Effective Date. 

(c) The number of Additional Shares, if any, by which the Conversion Rate shall be increased for conversions during the Make-Whole Fundamental
Change Period or, with respect to conversions of Called Notes, during the Redemption Period shall be determined by reference to the table below, based on the date on which the Make-Whole Fundamental Change occurs or becomes effective (the
“Effective Date”) or the Redemption Notice Date, as applicable and the price (the “Stock Price”) paid (or deemed to be paid) per share of Common Stock in the Make-Whole Fundamental Change or on the Redemption Notice
Date, as applicable, as set forth in this Section 14.03. If the holders of the Common Stock receive in exchange for their Common Stock only cash in a Make-Whole Fundamental Change described in clause (b) of the definition of Fundamental
Change, the Stock Price shall be the cash amount paid per share. In the case of any other Make-Whole Fundamental Change or in the case of any Optional Redemption, the Stock Price shall be the average of the Last Reported Sale Prices of the Common
Stock over the five consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Effective Date of the Make-Whole Fundamental Change or the Redemption Notice Date, as the case may be. In the event that a
Conversion Date occurs during both a Redemption Period and a Make-Whole Fundamental Change Period, a Holder of any such Notes to be converted will be entitled to a single increase to the Conversion Rate with respect to the first to occur of the
applicable Redemption Notice Date or Effective Date, and the later event shall be deemed not to have occurred for purposes of this Section 14.03. 

  
 63 

 (d) The Stock Prices set forth in the column headings of the table below shall be adjusted
as of any date on which the Conversion Rate for the Notes is otherwise adjusted. The adjusted Stock Prices shall equal the Stock Prices applicable immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the
Conversion Rate immediately prior to such adjustment giving rise to the Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted. The number of Additional Shares set forth in the table below shall be adjusted in the
same manner and at the same time as the Conversion Rate as set forth in Section 14.04. 
 (e) The following table sets forth the number
of Additional Shares by which the Conversion Rate shall be increased per $1,000 principal amount of Notes pursuant to this Section 14.03 for each Stock Price and Effective Date or Redemption Notice Date, as applicable, set forth below: 

 

																																																	
	 	  	Stock Price	 
	 Effective Date/
Redemption Notice Date
	  	$223.74	 	  	$230.00	 	  	$260.00	 	  	$296.45	 	  	$330.00	 	  	$360.00	 	  	$385.39	 	  	$450.00	 	  	$525.00	 	  	$600.00	 	  	$750.00	 	  	$1,000.00	 
	 June 15, 2020
	  	 	1.0962	 	  	 	1.0412	 	  	 	0.8223	 	  	 	0.6304	 	  	 	0.5017	 	  	 	0.4136	 	  	 	0.3536	 	  	 	0.2430	 	  	 	0.1623	 	  	 	0.1110	 	  	 	0.0537	 	  	 	0.0150	 
	 June 15, 2021
	  	 	1.0962	 	  	 	1.0412	 	  	 	0.8223	 	  	 	0.6206	 	  	 	0.4859	 	  	 	0.3948	 	  	 	0.3335	 	  	 	0.2223	 	  	 	0.1435	 	  	 	0.0949	 	  	 	0.0430	 	  	 	0.0107	 
	 June 15, 2022
	  	 	1.0962	 	  	 	1.0412	 	  	 	0.8135	 	  	 	0.5979	 	  	 	0.4577	 	  	 	0.3645	 	  	 	0.3027	 	  	 	0.1934	 	  	 	0.1188	 	  	 	0.0748	 	  	 	0.0306	 	  	 	0.0060	 
	 June 15, 2023
	  	 	1.0962	 	  	 	1.0412	 	  	 	0.7881	 	  	 	0.5595	 	  	 	0.4145	 	  	 	0.3204	 	  	 	0.2594	 	  	 	0.1553	 	  	 	0.0886	 	  	 	0.0517	 	  	 	0.0178	 	  	 	0.0020	 
	 June 15, 2024
	  	 	1.0962	 	  	 	1.0396	 	  	 	0.7402	 	  	 	0.4963	 	  	 	0.3477	 	  	 	0.2553	 	  	 	0.1978	 	  	 	0.1057	 	  	 	0.0528	 	  	 	0.0268	 	  	 	0.0065	 	  	 	0.0000	 
	 June 15, 2025
	  	 	1.0962	 	  	 	0.9945	 	  	 	0.6501	 	  	 	0.3842	 	  	 	0.2364	 	  	 	0.1537	 	  	 	0.1074	 	  	 	0.0442	 	  	 	0.0164	 	  	 	0.0059	 	  	 	0.0003	 	  	 	0.0000	 
	 June 15, 2026
	  	 	1.0962	 	  	 	0.9747	 	  	 	0.4730	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 	  	 	0.0000	 

 The exact Stock Prices and Effective Dates or Redemption Notice Dates, may not be set forth in the table above, in which case:

 (i) if the Stock Price is between two Stock Prices in the table above or the Effective Date or the Redemption Notice Date,
as the case may be, is between two Effective Dates or Redemption Notice Dates, as applicable, in the table above, the number of Additional Shares by which the Conversion Rate shall be increased shall be determined by a straight-line interpolation
between the number of Additional Shares set forth for the higher and lower Stock Prices and the earlier and later Effective Dates or Redemption Notice Dates, as applicable, based on a 365-day year; 

(ii) if the Stock Price is greater than $1,000.00 per share (subject to adjustment in the same manner as the Stock Prices set
forth in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate; and 

(iii) if the Stock Price is less than $223.74 per share (subject to adjustment in the same manner as the Stock Prices set forth
in the column headings of the table above pursuant to subsection (d) above), no Additional Shares shall be added to the Conversion Rate. 

Notwithstanding the foregoing, in no event shall the Conversion Rate per $1,000 principal amount of Notes exceed 4.4694 shares of Common Stock, subject to
adjustment in the same manner as the Conversion Rate pursuant to Section 14.04. 

  
 64 

 (f) Nothing in this Section 14.03 shall prevent an adjustment to the Conversion Rate
that would otherwise be required pursuant to Section 14.04. 
 Section 14.04. Adjustment of Conversion Rate. The Conversion
Rate shall be adjusted from time to time by the Company if any of the following events occurs, except that the Company shall not make any adjustments to the Conversion Rate if Holders of the Notes participate (other than in the case of (x) a
share split or share combination or (y) a tender or exchange offer), at the same time and upon the same terms as holders of the Common Stock and solely as a result of holding the Notes, in any of the transactions described in this
Section 14.04, without having to convert their Notes, as if they held a number of shares of Common Stock equal to the Conversion Rate, multiplied by the principal amount (expressed in thousands) of Notes held by such Holder. 

(a) If the Company exclusively issues shares of Common Stock as a dividend or distribution on shares of the Common Stock, or if the Company
effects a share split or share combination, the Conversion Rate shall be adjusted based on the following formula: 
  
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date of such dividend or distribution, or immediately prior to the open of business on the Effective
Date of such share split or share combination, as applicable;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date or Effective Date;
			
	OS0	  	=	  	the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date (before giving effect to any such dividend, distribution,
share split or share combination); and
			
	OS’	  	=	  	the number of shares of Common Stock outstanding immediately after giving effect to such dividend, distribution, share split or share combination.

 Any adjustment made under this Section 14.04(a) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution, or immediately after the open of business on the Effective Date for such share split or share combination, as applicable. If any dividend or distribution of the
type described in this Section 14.04(a) is declared but not so paid or made, the Conversion Rate shall be immediately readjusted, effective as of the date the Company determines not to pay such dividend or distribution, to the Conversion Rate
that would then be in effect if such dividend or distribution had not been declared. 

  
 65 

 (b) If the Company issues to all or substantially all holders of Common Stock any rights,
options or warrants entitling them, for a period of not more than 45 calendar days after the announcement date of such issuance, to subscribe for or purchase shares of Common Stock at a price per share that is less than the average of the Last
Reported Sale Prices of Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, the Conversion Rate shall be increased based on the following
formula: 
  
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such issuance;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date;
			
	OS0	  	=	  	the number of shares of Common Stock outstanding immediately prior to the open of business on such Ex-Dividend Date;
			
	X	  	=	  	the total number of shares of Common Stock issuable pursuant to such rights, options or warrants; and
			
	Y	  	=	  	the number of shares of Common Stock equal to the aggregate price payable to exercise such rights, options or warrants, divided by the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive
Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of the issuance of such rights, options or warrants.

 Any increase made under this Section 14.04(b) shall be made successively whenever any such rights, options or warrants
are issued and shall become effective immediately after the open of business on the Ex-Dividend Date for such issuance. To the extent that shares of the Common Stock are not delivered after the expiration of
such rights, options or warrants, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect had the increase with respect to the issuance of such rights, options or warrants been made on the basis of delivery of only
the number of shares of Common Stock actually delivered. If such rights, options or warrants are not so issued, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such
Ex-Dividend Date for such issuance had not occurred. 
 For purposes of this Section 14.04(b)
and Section 14.01(b)(ii)(A), in determining whether any rights, options or warrants entitle the holders of Common Stock to subscribe for or purchase shares of the Common Stock at less than such average of the Last Reported Sale Prices of the
Common Stock for the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the date of announcement of such issuance, and in determining the aggregate offering price of such shares of Common Stock, there
shall be taken into account any consideration received by the Company for such rights, options or warrants and any amount payable on exercise or conversion thereof, the value of such consideration, if other than cash, to be determined by the
Company. 

  
 66 

 (c) If the Company distributes shares of its Capital Stock, evidences of its indebtedness,
other assets or property of the Company or rights, options or warrants to acquire its Capital Stock or other securities of the Company, to all or substantially all holders of the Common Stock, excluding (i) dividends, distributions or issuances
as to which an adjustment was effected pursuant to Section 14.04(a) or Section 14.04(b), (ii) dividends or distributions paid exclusively in cash as to which an adjustment was effected pursuant to Section 14.04(d),
(iii) distributions of Reference Property in a transaction described in Section 14.07 and (iv) Spin-Offs as to which the provisions set forth below in this Section 14.04(c) shall apply (any of such shares of Capital Stock,
evidences of indebtedness, other assets or property or rights, options or warrants to acquire Capital Stock or other securities, the “Distributed Property”), then the Conversion Rate shall be increased based on the following
formula: 
  
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such distribution;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the open of business on such Ex-Dividend Date;
			
	SP0	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day immediately preceding the Ex-Dividend Date
for such distribution; and
			
	FMV	  	=	  	the fair market value (as determined by the Company) of the Distributed Property with respect to each outstanding share of the Common Stock on the Ex-Dividend Date for such
distribution.

 Any increase made under the portion of this Section 14.04(c) above shall become effective immediately after the open of
business on the Ex-Dividend Date for such distribution. If such distribution is not paid or made, the Conversion Rate shall be decreased to the Conversion Rate that would then be in effect if such distribution
had not been declared. In the case of any distribution of rights, options or warrants, to the extent such rights, options or warrants expire unexercised, the applicable Conversion Rate shall be immediately readjusted to the applicable Conversion
Rate that would then be in effect had the increase made for the distribution of such rights, options or warrants been made on the basis of delivery of only the number of shares of Common Stock actually delivered upon the exercise of such rights,
options or warrants. Notwithstanding the foregoing, if “FMV” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each
Holder of a Note shall receive, in respect of each $1,000 principal amount thereof, at the same time and upon the same terms as holders of the Common Stock receive the Distributed Property, the amount and kind of Distributed Property such Holder
would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend Date for the distribution. 

 

  
 67 

 With respect to an adjustment pursuant to this Section 14.04(c) where there has been a
payment of a dividend or other distribution on the Common Stock of shares of Capital Stock of any class or series, or similar equity interest, of or relating to any Subsidiary or other business unit of the Company, that are, or, when issued, will
be, listed or admitted for trading on a U.S. national securities exchange (a “Spin-Off”), the Conversion Rate shall be increased based on the following formula: 

 
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the end of the Valuation Period;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the end of the Valuation Period;
			
	FMV0	  	=	  	the average of the Last Reported Sale Prices of the Capital Stock or similar equity interest distributed to holders of the Common Stock applicable to one share of the Common Stock (determined by reference to the definition of Last
Reported Sale Price as set forth in Section 1.01 as if references therein to Common Stock were to such Capital Stock or similar equity interest) over the first 10 consecutive Trading Day period after, and including, the Ex-Dividend Date of the Spin-Off (the “Valuation Period”); and
			
	MP0	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the Valuation Period.

 The adjustment to the Conversion Rate under the preceding paragraph shall occur at the close of business on the last Trading
Day of the Valuation Period; provided that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the relevant Conversion Date occurs during the Valuation Period, references to “10” in the
portion of this Section 14.04(c) related to Spin-Offs shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date of such Spin-Off to, and including, the Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement is applicable, for any
Trading Day that falls within the relevant Observation Period for such conversion and within the Valuation Period, references to “10” in the portion of this Section 14.04(c) related to Spin-Offs shall be deemed replaced with such
lesser number of Trading Days as have elapsed from, and including, the Ex-Dividend Date of such Spin-Off to, and including, such Trading Day in determining the
Conversion Rate as of such Trading Day. If any dividend or distribution that constitutes a Spin-Off is declared but not so paid or made, the Conversion Rate shall be immediately decreased, effective as of the
date the Company determines not to pay or make such dividend or distribution, to the Conversion Rate that would then be in effect if such dividend or distribution had not been declared or announced. 

  
 68 

 For purposes of this Section 14.04(c) (and subject in all respect to
Section 14.11), rights, options or warrants distributed by the Company to all holders of the Common Stock entitling them to subscribe for or purchase shares of the Company’s Capital Stock, including Common Stock (either initially or under
certain circumstances), which rights, options or warrants, until the occurrence of a specified event or events (“Trigger Event”): (i) are deemed to be transferred with such shares of the Common Stock; (ii) are not exercisable;
and (iii) are also issued in respect of future issuances of the Common Stock, shall be deemed not to have been distributed for purposes of this Section 14.04(c) (and no adjustment to the Conversion Rate under this Section 14.04(c)
will be required) until the occurrence of the earliest Trigger Event, whereupon such rights, options or warrants shall be deemed to have been distributed and an appropriate adjustment (if any is required) to the Conversion Rate shall be made under
this Section 14.04(c). If any such right, option or warrant, including any such existing rights, options or warrants distributed prior to the date of this Indenture, are subject to events, upon the occurrence of which such rights, options or
warrants become exercisable to purchase different securities, evidences of indebtedness or other assets, then the date of the occurrence of any and each such event shall be deemed to be the date of distribution and
Ex-Dividend Date with respect to new rights, options or warrants with such rights (in which case the existing rights, options or warrants shall be deemed to terminate and expire on such date without exercise
by any of the holders thereof). In addition, in the event of any distribution (or deemed distribution) of rights, options or warrants, or any Trigger Event or other event (of the type described in the immediately preceding sentence) with respect
thereto that was counted for purposes of calculating a distribution amount for which an adjustment to the Conversion Rate under this Section 14.04(c) was made, (1) in the case of any such rights, options or warrants that shall all have
been redeemed or purchased without exercise by any holders thereof, upon such final redemption or purchase (x) the Conversion Rate shall be readjusted as if such rights, options or warrants had not been issued and (y) the Conversion Rate
shall then again be readjusted to give effect to such distribution, deemed distribution or Trigger Event, as the case may be, as though it were a cash distribution, equal to the per share redemption or purchase price received by a holder or holders
of Common Stock with respect to such rights, options or warrants (assuming such holder had retained such rights, options or warrants), made to all holders of Common Stock as of the date of such redemption or purchase, and (2) in the case of
such rights, options or warrants that shall have expired or been terminated without exercise by any holders thereof, the Conversion Rate shall be readjusted as if such rights, options and warrants had not been issued. 

For purposes of Section 14.04(a), Section 14.04(b) and this Section 14.04(c), if any dividend or distribution to which this
Section 14.04(c) is applicable also includes one or both of: 
 (A) a dividend or distribution of shares of Common Stock to which
Section 14.04(a) is applicable (the “Clause A Distribution”); or 
 (B) a dividend or distribution of rights, options
or warrants to which Section 14.04(b) is applicable (the “Clause B Distribution”), 

  
 69 

 then, in either case, (1) such dividend or distribution, other than the Clause A Distribution and the
Clause B Distribution, shall be deemed to be a dividend or distribution to which this Section 14.04(c) is applicable (the “Clause C Distribution”) and any Conversion Rate adjustment required by this Section 14.04(c) with
respect to such Clause C Distribution shall then be made, and (2) the Clause A Distribution and Clause B Distribution shall be deemed to immediately follow the Clause C Distribution and any Conversion Rate adjustment required by
Section 14.04(a) and Section 14.04(b) with respect thereto shall then be made, except that, if determined by the Company (I) the “Ex-Dividend Date” of the Clause A Distribution and the
Clause B Distribution shall be deemed to be the Ex-Dividend Date of the Clause C Distribution and (II) any shares of Common Stock included in the Clause A Distribution or Clause B Distribution shall be
deemed not to be “outstanding immediately prior to the open of business on such Ex-Dividend Date or Effective Date” within the meaning of Section 14.04(a) or “outstanding immediately prior
to the open of business on such Ex-Dividend Date” within the meaning of Section 14.04(b). 

(d) If any cash dividend or distribution is made to all or substantially all holders of the Common Stock, the Conversion Rate shall be adjusted
based on the following formula: 
  
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the open of business on the Ex-Dividend Date for such dividend or distribution;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the open of business on the Ex-Dividend Date for such dividend or distribution;
			
	SP0	  	=	  	the Last Reported Sale Price of the Common Stock on the Trading Day immediately preceding the Ex-Dividend Date for such dividend or distribution; and
			
	C	  	=	  	the amount in cash per share the Company distributes to all or substantially all holders of the Common Stock.

 Any increase pursuant to this Section 14.04(d) shall become effective immediately after the open of business on the Ex-Dividend Date for such dividend or distribution. If such dividend or distribution is not so paid, the Conversion Rate shall be decreased, effective as of the date the Company determines not to make or pay such
dividend or distribution, to be the Conversion Rate that would then be in effect if such dividend or distribution had not been declared. Notwithstanding the foregoing, if “C” (as defined above) is equal to or greater than “SP0” (as defined above), in lieu of the foregoing increase, each Holder of a Note shall receive, for each $1,000 principal amount of Notes it holds, at the same time and upon the same terms as
holders of shares of the Common Stock, the amount of cash that such Holder would have received if such Holder owned a number of shares of Common Stock equal to the Conversion Rate in effect on the Ex-Dividend
Date for such cash dividend or distribution. 

  
 70 

 (e) If the Company or any of its Subsidiaries make a payment in respect of a tender or
exchange offer for the Common Stock (other than any odd-lot tender offer), to the extent that the cash and value of any other consideration included in the payment per share of the Common Stock exceeds the
average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the last date on which tenders or exchanges may be made pursuant to such tender or
exchange offer, the Conversion Rate shall be increased based on the following formula: 
  
 

 
 where, 
  

					
	CR0	  	=	  	the Conversion Rate in effect immediately prior to the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;
			
	CR’	  	=	  	the Conversion Rate in effect immediately after the close of business on the 10th Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires;
			
	AC	  	=	  	the aggregate value of all cash and any other consideration (as determined by the Company) paid or payable for shares of Common Stock purchased in such tender or exchange offer;
			
	OS0	  	=	  	the number of shares of Common Stock outstanding immediately prior to the date such tender or exchange offer expires (prior to giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such
tender or exchange offer);
			
	OS’	  	=	  	the number of shares of Common Stock outstanding immediately after the date such tender or exchange offer expires (after giving effect to the purchase of all shares of Common Stock accepted for purchase or exchange in such tender or
exchange offer); and
			
	SP’	  	=	  	the average of the Last Reported Sale Prices of the Common Stock over the 10 consecutive Trading Day period commencing on, and including, the Trading Day next succeeding the date such tender or exchange offer expires.

 The adjustment to the Conversion Rate under this Section 14.04(e) shall occur at the close of business on the 10th
Trading Day immediately following, and including, the Trading Day next succeeding the date such tender or exchange offer expires; provided that (x) in respect of any conversion of Notes for which Physical Settlement is applicable, if the
relevant Conversion Date occurs during the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or exchange offer, references to “10” or “10th” in this
Section 14.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the trading day next succeeding the expiration date of such tender 

  
 71 

 
or exchange offer to, and including, such Conversion Date in determining the Conversion Rate and (y) in respect of any conversion of Notes for which Cash Settlement or Combination Settlement
is applicable, for any Trading Day that falls within the relevant Observation Period for such conversion and within the 10 Trading Days immediately following, and including, the Trading Day next succeeding the expiration date of any tender or
exchange offer, references to “10” or “10th” in this Section 14.04(e) shall be deemed replaced with such lesser number of Trading Days as have elapsed from, and including, the trading day next succeeding the expiration date
of such tender or exchange offer to, and including, such Trading Day in determining the Conversion Rate as of such Trading Day. 
 If the Company is
obligated to purchase shares of Common Stock pursuant to any such tender or exchange offer described in this Section 14.04(e) but is permanently prevented by applicable law from effecting any such purchase or all such purchases are rescinded,
the applicable Conversion Rate will be readjusted to be the Conversion Rate that would then be in effect if such tender or exchange offer had not been made or had been made only in respect of the purchases that have been made. 

(f) Notwithstanding this Section 14.04 or any other provision of this Indenture or the Notes, if a Conversion Rate adjustment becomes
effective on any Ex-Dividend Date, and a Holder that has converted its Notes on or after such Ex-Dividend Date and on or prior to the related Record Date would be deemed
to be the record holder of the shares of Common Stock as of the related Conversion Date as described under Section 14.02(i) based on an adjusted Conversion Rate for such Ex-Dividend Date, then,
notwithstanding the Conversion Rate adjustment provisions in this Section 14.04, the Conversion Rate adjustment relating to such Ex-Dividend Date shall not be made for such converting Holder. Instead,
such Holder shall be treated as if such Holder were the record owner of the shares of Common Stock on an unadjusted basis and participate in the related dividend, distribution or other event giving rise to such adjustment. 

(g) Except as stated herein, the Company shall not adjust the Conversion Rate for the issuance of shares of the Common Stock or any securities
convertible into or exchangeable for shares of the Common Stock or the right to purchase shares of the Common Stock or such convertible or exchangeable securities. 

(h) In addition to those adjustments required by clauses (a), (b), (c), (d) and (e) of this Section 14.04, and subject to the
applicable listing standards of The Nasdaq Global Select Market, the Company from time to time may increase the Conversion Rate by any amount for a period of at least 20 Business Days if the Company determines that such increase would be in the
Company’s best interest. In addition, subject to the applicable listing standards of The Nasdaq Global Select Market, the Company may (but is not required to) increase the applicable Conversion Rate to avoid or diminish income tax to holders of
Common Stock or rights to purchase shares of Common Stock in connection with a dividend or distribution of shares of Common Stock (or rights to acquire shares of Common Stock) or similar event. 

  
 72 

 (i) Notwithstanding anything to the contrary in this Article 14, the Conversion Rate shall
not be adjusted: 
 (i) upon the issuance of any shares of Common Stock pursuant to any present or future plan providing for
the reinvestment of dividends or interest payable on the Company’s securities and the investment of additional optional amounts in shares of Common Stock under any plan; 

(ii) upon the issuance of any shares of Common Stock or options or rights to purchase those shares pursuant to any present or
future employee, director or consultant benefit or incentive plan or program of or assumed by the Company or any of the Company’s Subsidiaries; 

(iii) upon the issuance of any shares of Common Stock pursuant to any option, warrant, right or exercisable, exchangeable or
convertible security not described in clause (ii) of this subsection and outstanding as of the date the Notes were first issued 

(iv) upon the repurchase of shares of Common Stock pursuant to an open-market share repurchase program or other buy-back transaction that is not a tender offer or exchange offer of the nature described in Section 14.04(e); 

(v) solely for a change in the par value of the Common Stock; or 

(vi) for accrued and unpaid interest, if any. 

(j) The Company shall not be required to make an adjustment pursuant to clauses (a), (b), (c), (d) or (e) of this Section 14.04
unless such adjustment would result in a change of at least 1% of the then effective Conversion Rate. However, the Company shall carry forward any adjustment that the Company would otherwise have to make and take that adjustment into account in any
subsequent adjustment. Notwithstanding the foregoing, all such carried-forward adjustments shall be made with respect to the Notes (i) where the aggregate of all such carried-forward adjustments equals or exceeds 1% of the Conversion Rate and
(ii) regardless of whether the aggregate adjustment is less than 1% of the Conversion Rate, (x) on the Conversion Date for any Notes (in the case of Physical Settlement) and (y) on each Trading Day of any Observation Period with
respect to any Notes (in the case of Cash Settlement or Combination Settlement). All calculations and other determinations under this Article 14 shall be made by the Company and shall be made to the nearest
one-ten thousandth (1/10,000th) of a share. 
 (k) Whenever the Conversion Rate is adjusted as herein
provided, the Company shall promptly deliver to the Trustee (and the Conversion Agent if not the Trustee) an Officer’s Certificate setting forth (i) the adjusted Conversion Rate, (ii) the subsection of this Section 14.04 pursuant
to which such adjustment has been made, showing in reasonable detail the facts upon which such adjustment is based and (iii) the date as of which such adjustment is effective (which certificates shall be conclusive evidence of the accuracy of
such adjustment absent manifest error). Unless and until a Responsible Officer of the Trustee shall have received such Officer’s Certificate, the Trustee shall not be deemed to have knowledge of any adjustment of the Conversion Rate and may
assume without inquiry that the last Conversion Rate of which it has knowledge is still in effect. Promptly after delivery of such certificate, the Company shall prepare a notice of such adjustment of the Conversion Rate setting forth the adjusted
Conversion Rate and the date on which each adjustment becomes effective and shall deliver such notice of such adjustment of the Conversion Rate to each Holder. Failure to deliver such notice shall not affect the legality or validity of any such
adjustment. 

  
 73 

 (l) For purposes of this Section 14.04, the number of shares of Common Stock at any
time outstanding shall not include shares of Common Stock held in the treasury of the Company so long as the Company does not pay any dividend or make any distribution on shares of Common Stock held in the treasury of the Company, but shall include
shares of Common Stock issuable in respect of scrip certificates issued in lieu of fractions of shares of Common Stock. 

Section 14.05. Adjustments of Prices. Whenever any provision of this Indenture requires the Company to calculate the Last Reported
Sale Prices, the Daily VWAPs, the Daily Conversion Values or the Daily Settlement Amounts over a span of multiple days (including, without limitation, an Observation Period and the period, if any, for determining the Stock Price for purposes of a
Make-Whole Fundamental Change), the Company shall make appropriate adjustments in good faith and in a commercially reasonable manner to each to account for any adjustment to the Conversion Rate that becomes effective, or any event requiring an
adjustment to the Conversion Rate where the Ex-Dividend Date, Effective Date or expiration date of the event occurs, at any time during the period when the Last Reported Sale Prices, the Daily VWAPs, the Daily
Conversion Values or the Daily Settlement Amounts are to be calculated. 
 Section 14.06. Shares to Be Fully Paid. The Company
shall provide, free from preemptive rights, out of its authorized but unissued shares or shares held in treasury, sufficient shares of Common Stock to provide for conversion of the Notes from time to time as such Notes are presented for conversion
(assuming delivery of the maximum number of Additional Shares pursuant to Section 14.03 and that at the time of computation of such number of shares, all such Notes would be converted by a single Holder and that Physical Settlement is
applicable). 
 Section 14.07. Effect of Recapitalizations, Reclassifications and Changes of the Common Stock. 

(a) In the case of: 

(i) any recapitalization, reclassification or change of the Common Stock (other than changes resulting from a subdivision or
combination), 
 (ii) any consolidation, merger or combination involving the Company, 

(iii) any sale, lease or other transfer to a third party of the consolidated assets of the Company and the Company’s
Subsidiaries substantially as an entirety or 
 (iv) any statutory share exchange, 

in each case, as a result of which the Common Stock would be converted into, or exchanged for, stock, other securities, other property or assets (including
cash or any combination thereof) (any such event, a “Merger Event”), then, at and after the effective time of such Merger Event, the right to convert each $1,000 principal amount of Notes shall be changed into a right to convert
such principal amount of Notes into the kind and amount of shares of stock, other securities or other property or assets (including cash or any combination thereof) that a holder of a number of 

  
 74 

 
shares of Common Stock equal to the Conversion Rate immediately prior to such Merger Event would have owned or been entitled to receive (the “Reference Property”, with each
“unit of Reference Property” meaning the kind and amount of Reference Property that a holder of one share of Common Stock is entitled to receive) upon such Merger Event and, prior to or at the effective time of such Merger Event,
the Company or the successor or purchasing Person, as the case may be, shall execute with the Trustee a supplemental indenture permitted under Section 10.01(k) providing for such change in the right to convert each $1,000 principal amount of
Notes; provided, however, that at and after the effective time of the Merger Event (A) the Company shall continue to have the right to determine the form of consideration to be paid or delivered, as the case may be, upon
conversion of Notes in accordance with Section 14.02 and (B) (I) any amount payable in cash upon conversion of the Notes in accordance with Section 14.02 shall continue to be payable in cash, (II) any shares of Common Stock that
the Company would have been required to deliver upon conversion of the Notes in accordance with Section 14.02 shall instead be deliverable in the amount and type of Reference Property that a holder of that number of shares of Common Stock would
have received in such Merger Event and (III) the Daily VWAP shall be calculated based on the value of a unit of Reference Property. 

If the Merger Event causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of
consideration (determined based in part upon any form of stockholder election), then (i) the Reference Property into which the Notes will be convertible shall be deemed to be the weighted average of the types and amounts of consideration
actually received by the holders of Common Stock, and (ii) the unit of Reference Property for purposes of the immediately preceding paragraph shall refer to the consideration referred to in clause (i) attributable to one share of Common
Stock. If the holders of the Common Stock receive only cash in such Merger Event, then for all conversions for which the relevant Conversion Date occurs after the effective date of such Merger Event (A) the consideration due upon conversion of
each $1,000 principal amount of Notes shall be solely cash in an amount equal to the Conversion Rate in effect on the Conversion Date (as may be increased by any Additional Shares pursuant to Section 14.03), multiplied by the price paid
per share of Common Stock in such Merger Event and (B) the Company shall satisfy the Conversion Obligation by paying cash to converting Holders on the second Business Day immediately following the relevant Conversion Date. The Company shall
notify Holders, the Trustee and the Conversion Agent (if other than the Trustee) in writing of such weighted average as soon as practicable after such determination is made. 

Such supplemental indenture described in the second immediately preceding paragraph shall provide for anti-dilution and other adjustments that
are as nearly equivalent as possible to the adjustments provided for in this Article 14. If, in the case of any Merger Event, the Reference Property includes shares of stock, securities or other property or assets of a Person other than the Company
or the successor or purchasing corporation (excluding, for the avoidance of doubt, cash paid by such surviving company, successor or purchasing corporation), as the case may be, in such Merger Event, then such supplemental indenture shall also be
executed by such other Person and shall contain such additional provisions to protect the interests of the Holders as the Company reasonably considers necessary by reason of the foregoing, including the provisions providing for the purchase rights
set forth in Article 15. 

  
 75 

 (b) When the Company executes a supplemental indenture pursuant to subsection (a) of
this Section 14.07, the Company shall promptly deliver to the Trustee an Officer’s Certificate briefly stating the reasons therefor, the kind or amount of cash, securities or property or asset that will comprise a unit of Reference
Property after any such Merger Event, any adjustment to be made with respect thereto and that all conditions precedent have been complied with, and shall promptly deliver or cause to be delivered notice thereof to all Holders. The Company shall
cause notice of the execution of such supplemental indenture to be delivered to each Holder within 20 days after execution thereof. Failure to deliver such notice shall not affect the legality or validity of such supplemental indenture. 

(c) The Company shall not become a party to any Merger Event unless its terms are consistent with this Section 14.07. None of the
foregoing provisions shall affect the right of a holder of Notes to convert its Notes into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, as set forth in Section 14.01 and Section 14.02
prior to the effective date of such Merger Event. 
 (d) The above provisions of this Section shall similarly apply to successive Merger
Events. 
 (e) Upon the consummation of any Merger Event, references to “Common Stock” shall be deemed to refer to any Reference
Property that constitutes capital stock after giving effect to such Merger Event. 
 Section 14.08. Certain Covenants.
(a) The Company covenants that all shares of Common Stock issued upon conversion of Notes will be fully paid and non-assessable by the Company and free from all taxes, liens and charges with respect to
the issue thereof. 
 (b) The Company covenants that, if any shares of Common Stock to be provided for the purpose of conversion of Notes
hereunder require registration with or approval of any governmental authority under any federal or state law before such shares of Common Stock may be validly issued upon conversion, the Company will, to the extent then permitted by the rules and
interpretations of the Commission, secure such registration or approval, as the case may be. 
 (c) The Company further covenants that if at
any time the Common Stock shall be listed on any national securities exchange or automated quotation system the Company will list and keep listed, so long as the Common Stock shall be so listed on such exchange or automated quotation system, any
Common Stock issuable upon conversion of the Notes. 
 Section 14.09. Responsibility of Trustee. The Trustee and any other
Conversion Agent shall not at any time be under any duty or responsibility to any Holder to determine the Conversion Rate (or any adjustment thereto) or whether any facts exist that may require any adjustment (including any increase) of the
Conversion Rate, or with respect to the nature or extent or calculation of any such adjustment when made, or with respect to the method employed, or herein or in any supplemental indenture provided to be employed, in making the same. The Trustee and
any other Conversion Agent shall not be accountable with respect to the validity or value (or the kind or amount) of any shares of Common Stock, or of any securities, property or cash that may at any time be issued or delivered upon the conversion
of any Note; 

  
 76 

 
and the Trustee and any other Conversion Agent make no representations with respect thereto. Neither the Trustee nor any Conversion Agent shall be responsible for any failure of the Company to
issue, transfer or deliver any shares of Common Stock or stock certificates or other securities or property or cash upon the surrender of any Note for the purpose of conversion or to comply with any of the duties, responsibilities or covenants of
the Company contained in this Article. Without limiting the generality of the foregoing, neither the Trustee nor any Conversion Agent shall be under any responsibility to determine the correctness of any provisions contained in any supplemental
indenture entered into pursuant to Section 14.07 relating either to the kind or amount of shares of stock or securities or property (including cash) receivable by Holders upon the conversion of their Notes after any event referred to in such
Section 14.07 or to any adjustment to be made with respect thereto, but, subject to the provisions of Section 7.01, may accept (without any independent investigation) as conclusive evidence of the correctness of any such provisions, and
shall be protected in conclusively relying upon, the Officer’s Certificate (which the Company shall be obligated to deliver to the Trustee prior to the execution of any such supplemental indenture) with respect thereto. Neither the Trustee nor
the Conversion Agent shall be responsible for determining whether any event contemplated by Section 14.01(b) has occurred that makes the Notes eligible for conversion or no longer eligible therefor until the Company has delivered to the Trustee
and the Conversion Agent the notices referred to in Section 14.01(b) with respect to the commencement or termination of such conversion rights, on which notices the Trustee and the Conversion Agent may conclusively rely, and the Company agrees
to deliver such notices to the Trustee and the Conversion Agent immediately after the occurrence of any such event or at such other times as shall be provided for in Section 14.01(b). Except as otherwise expressly provided herein, neither the
Trustee nor any other agent acting under this Indenture (other than the Company, if acting in such capacity) shall have any obligation to make any calculation or to determine whether the Notes may be surrendered for conversion pursuant to this
Indenture, or to notify the Company or the Depositary or any of the Holders if the Notes have become convertible pursuant to the terms of this Indenture. 

Section 14.10. Notice to Holders Prior to Certain Actions. In case of any: 

(a) action by the Company or one of its Subsidiaries that would require an adjustment in the Conversion Rate pursuant to Section 14.04 or
Section 14.11; 
 (b) Merger Event; or 

(c) voluntary or involuntary dissolution, liquidation or winding-up of the Company or any of its
Subsidiaries; 
 then, in each case (unless notice of such event is otherwise required pursuant to another provision of this Indenture), the Company shall
cause to be delivered to the Trustee and the Conversion Agent (if other than the Trustee) and to be delivered to each Holder, as promptly as possible but in any event at least 20 days prior to the applicable date hereinafter specified, a notice
stating (i) the date on which a record is to be taken for the purpose of such action by the Company or one of its Subsidiaries or, if a record is not to be taken, the date as of which the holders of Common Stock of record are to be determined
for the purposes of such action by the Company or one of its Subsidiaries, or (ii) the date on which such Merger Event, dissolution, liquidation or winding-up is expected to become effective or occur, and
the date as of which it is 

  
 77 

 
expected that holders of Common Stock of record shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding-up. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such action by the Company or one of its Subsidiaries, Merger Event, dissolution, liquidation or winding-up. 
 Section 14.11. Stockholder Rights Plans. If the Company has a stockholder
rights plan in effect upon conversion of the Notes, each share of Common Stock, if any, issued upon such conversion shall be entitled to receive the appropriate number of rights, if any, and the certificates representing the Common Stock issued upon
such conversion shall bear such legends, if any, in each case as may be provided by the terms of any such stockholder rights plan, as the same may be amended from time to time. However, if, prior to any conversion of Notes, the rights have separated
from the shares of Common Stock in accordance with the provisions of the applicable stockholder rights plan so that the Holders would not be entitled to receive any rights in respect of Common Stock, if any, issuable upon conversion of the Notes,
the Conversion Rate shall be adjusted at the time of separation as if the Company distributed to all or substantially all holders of the Common Stock Distributed Property as provided in Section 14.04(c), subject to readjustment in the event of
the expiration, termination or redemption of such rights. 
 Section 14.12. Exchange In Lieu Of Conversion. (a) When a
Holder surrenders its Notes for conversion, the Company may, at its election, direct the Conversion Agent to surrender, on or prior to the Business Day immediately following the relevant Conversion Date, such Notes to one or more financial
institutions designated by the Company (each, a “Designated Institution”) for exchange in lieu of conversion (an “Exchange Election”). In order to accept any Notes surrendered for conversion for exchange in lieu of
conversion, the Designated Institution(s) must agree to timely pay or deliver, as the case may be, in exchange for such Notes, cash, shares of Common Stock or a combination of cash and shares of Common Stock, at the Company’s election, that
would otherwise be due upon conversion as described in Section 14.02 above or such other amount agreed to by the converting Holder and the Designated Institution(s) (the “Conversion Consideration”). If the Company makes the
election described above, the Company shall, by the close of business on the Business Day following the relevant Conversion Date, notify in writing the Holder surrendering Notes for conversion, the Trustee and the Conversion Agent (if other than the
Trustee), that it has made such election, and the Company shall notify the Designated Institution(s) of the relevant deadline for delivery of the Conversion Consideration and the type of Conversion Consideration to be paid and/or delivered (unless
the form of Conversion Consideration has been otherwise agreed by the Holder and the Designated Institution(s) as set forth in this Section 14.12. Any Notes exchanged by any Designated Institution will remain outstanding, subject to applicable
procedures of the Depositary. 
 (b) If any Designated Institution agrees to accept any Notes for exchange but does not timely pay and/or
deliver, as the case may be, the related Conversion Consideration to the Conversion Agent, or if such Designated Institution does not accept such Notes for exchange, the Company shall, within the time period specified in Section 14.02(c), pay
or deliver, as the case may be, the Conversion Consideration in accordance with the provisions of Section 14.02 as if the Company had not made the Exchange Election. 

  
 78 

 (c) For the avoidance of doubt, in no event will the Company’s designation of a
Designated Institution pursuant to this Section 14.12 require such Designated Institution to accept any Notes for exchange. 
 ARTICLE
15 
 REPURCHASE OF NOTES AT OPTION OF
HOLDERS 
 Section 15.01. Intentionally Omitted.  

Section 15.02. Repurchase at Option of Holders Upon a Fundamental Change. (a) If a Fundamental Change occurs at any
time prior to the Maturity Date, each Holder shall have the right, at such Holder’s option, to require the Company to repurchase for cash all of such Holder’s Notes, or any portion of the principal amount thereof properly surrendered and
not validly withdrawn pursuant to Section 15.03 that is equal to $1,000 or a multiple of $1,000, on the date (the “Fundamental Change Repurchase Date”) specified by the Company that is not less than 20 or more than 35 Business
Days following the date of the Fundamental Change Company Notice at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest thereon to, but excluding, the Fundamental Change Repurchase Date (the
“Fundamental Change Repurchase Price”), unless the Fundamental Change Repurchase Date falls after a Regular Record Date but on or prior to the Interest Payment Date to which such Regular Record Date relates, in which case the
Company shall instead pay the full amount of accrued and unpaid interest to the Holder of record as of such Regular Record Date, and the Fundamental Change Repurchase Price shall be equal to 100% of the principal amount of Notes to be repurchased
pursuant to this Article 15. Any Notes so repurchased by the Company shall be paid for in cash. The Fundamental Change Repurchase Date shall be subject to postponement in order to allow the Company to comply with applicable law as a result of
changes to such applicable law occurring after the date of this Indenture. 
 (b) Repurchases of Notes under this Section 15.02 shall be
made, at the option of the Holder thereof, upon: 
 (i) delivery to the Paying Agent by a Holder of a duly completed written
notice (the “Fundamental Change Repurchase Notice”) in the form set forth in Attachment 2 to the Form of Note attached hereto as Exhibit A, if the Notes are Physical Notes, or in compliance with the Depositary’s procedures for
surrendering interests in Global Notes, if the Notes are Global Notes, in each case on or before the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date; and 

(ii) delivery of the Notes, if the Notes are Physical Notes, to the Paying Agent at any time after delivery of the Fundamental
Change Repurchase Notice (together with all necessary endorsements for transfer) at the Corporate Trust Office of the Paying Agent, or book-entry transfer of the Notes, if the Notes are Global Notes, in compliance with the procedures of the
Depositary, in each case such delivery being a condition to receipt by the Holder of the Fundamental Change Repurchase Price therefor. 

  
 79 

 The Fundamental Change Repurchase Notice in respect of any Notes to be repurchased shall
state: 
 (i) in the case of Physical Notes, the certificate numbers of the Notes to be delivered for repurchase; 

(ii) the portion of the principal amount of Notes to be repurchased, which must be $1,000 or a multiple thereof; and 

(iii) that the Notes are to be repurchased by the Company pursuant to the applicable provisions of the Notes and this
Indenture; 
 provided, however, that if the Notes are Global Notes, the Fundamental Change Repurchase Notice must comply with appropriate
Depositary procedures. 
 Notwithstanding anything herein to the contrary, any Holder delivering to the Paying Agent the Fundamental Change
Repurchase Notice contemplated by this Section 15.02 shall have the right to withdraw, in whole or in part, such Fundamental Change Repurchase Notice at any time prior to the close of business on the Business Day immediately preceding the
Fundamental Change Repurchase Date by delivery of a written notice of withdrawal to the Paying Agent in accordance with Section 15.03. 

The Paying Agent shall promptly notify the Company of the receipt by it of any Fundamental Change Repurchase Notice or written notice of
withdrawal thereof. 
 (c) On or before the 20th Business Day after the occurrence of the effective date of a Fundamental Change, the Company
shall provide to all Holders, the Trustee, the Conversion Agent and the Paying Agent (in the case of a Paying Agent other than the Trustee) a written notice (the “Fundamental Change Company Notice”) of the occurrence of the
effective date of the Fundamental Change and of the resulting repurchase right at the option of the Holders arising as a result thereof. In the case of Physical Notes, such notice shall be by first class mail or, in the case of Global Notes, such
notice shall be delivered in accordance with the applicable procedures of the Depositary. Each Fundamental Change Company Notice shall specify: 

(i) the events causing the Fundamental Change; 

(ii) the effective date of the Fundamental Change; 

(iii) the last date on which a Holder may exercise the repurchase right pursuant to this Article 15; 

(iv) the Fundamental Change Repurchase Price; 

(v) the Fundamental Change Repurchase Date; 

(vi) the name and address of the Paying Agent and the Conversion Agent, if applicable; 

  
 80 

 (vii) if applicable, the Conversion Rate and any adjustments to the
Conversion Rate as a result of such Fundamental Change (or related Make-Whole Fundamental Change); 
 (viii) that the Notes
with respect to which a Fundamental Change Repurchase Notice has been delivered by a Holder may be converted only if the Holder validly withdraws the Fundamental Change Repurchase Notice in accordance with the terms of this Indenture; and 

(ix) the procedures that Holders must follow to require the Company to repurchase their Notes. 

No failure of the Company to give the foregoing notices and no defect therein shall limit the Holders’ repurchase rights or affect the
validity of the proceedings for the repurchase of the Notes pursuant to this Section 15.02. 
 At the Company’s written request,
given at least five days prior to the date the Fundamental Change Company Notice is to be sent, the Trustee shall give such notice in the Company’s name and at the Company’s expense; provided, however, that, in all cases, the
text of such Fundamental Change Company Notice shall be prepared by the Company. 
 (d) Notwithstanding the foregoing, no Notes may be
repurchased by the Company on any date at the option of the Holders upon a Fundamental Change if the principal amount of the Notes has been accelerated, and such acceleration has not been rescinded, on or prior to such date (except in the case of an
acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes). The Paying Agent will promptly return to the respective Holders thereof any Physical Notes held by it during
the acceleration of the Notes (except in the case of an acceleration resulting from a Default by the Company in the payment of the Fundamental Change Repurchase Price with respect to such Notes), or any instructions for book-entry transfer of the
Notes in compliance with the procedures of the Depositary shall be deemed to have been cancelled, and, upon such return or cancellation, as the case may be, the Fundamental Change Repurchase Notice with respect thereto shall be deemed to have been
withdrawn. 
 (e) The Company shall not be required to repurchase or make an offer to repurchase Notes upon the occurrence of a Fundamental
Change otherwise required under this Section 15.02 if a third party makes such an offer to purchase Notes in the same manner, at the same time and otherwise in compliance with the requirements for an offer made by the Company as set forth in
this Indenture and such third party purchases all Notes properly surrendered and not validly withdrawn under such offer to purchase. 

Section 15.03. Withdrawal of Fundamental Change Repurchase Notice. (a) A Fundamental Change Repurchase Notice may be
withdrawn (in whole or in part) by means of a written notice of withdrawal delivered to the Paying Agent in accordance with this Section 15.03 at any time prior to the close of business on the Business Day immediately preceding the relevant
Fundamental Change Repurchase Date, specifying: 

  
 81 

 (i) the principal amount of the Notes with respect to which such notice of
withdrawal is being submitted, which must be $1,000 or a multiple thereof, 
 (ii) if Physical Notes have been issued, the
certificate numbers of the Notes in respect of which such notice of withdrawal is being submitted, and 
 (iii) the principal
amount, if any, of such Notes that remains subject to the original Fundamental Change Repurchase Notice, which portion must be in principal amounts of $1,000 or a multiple of $1,000; 

provided, however, that if the Notes are Global Notes, the notice must comply with appropriate procedures of the Depositary. 

Section 15.04. Deposit of Fundamental Change Repurchase Price. (a) The Company will deposit with the Trustee (or other Paying
Agent appointed by the Company, or if the Company is acting as its own Paying Agent, set aside, segregate and hold in trust as provided in Section 4.04) on or prior to 11:00 a.m., New York City time, on the Fundamental Change Repurchase Date an
amount of money sufficient to repurchase all of the Notes to be repurchased at the appropriate Fundamental Change Repurchase Price. Subject to receipt of funds and/or Notes by the Trustee (or other Paying Agent appointed by the Company), payment for
Notes surrendered for repurchase (and not withdrawn prior to the close of business on the Business Day immediately preceding the Fundamental Change Repurchase Date) will be made on the later of (i) the Fundamental Change Repurchase Date
(provided the Holder has satisfied the conditions in Section 15.02) and (ii) the time of book-entry transfer or the delivery of such Note to the Trustee (or other Paying Agent appointed by the Company) by the Holder thereof in the
manner required by Section 15.02 by mailing checks for the amount payable to the Holders of such Notes entitled thereto as they shall appear in the Note Register; provided, however, that payments to the Depositary shall be made by
wire transfer of immediately available funds to the account of the Depositary or its nominee. The Trustee shall, promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Fundamental Change
Repurchase Price. 
 (b) If by 11:00 a.m. New York City time, on the Fundamental Change Repurchase Date, the Trustee (or other Paying Agent
appointed by the Company) holds money sufficient to pay the Fundamental Change Repurchase Price of the Notes to be repurchased on the Fundamental Change Repurchase Date, then, with respect to the Notes that have been properly surrendered for
repurchase to the Trustee (or other Paying Agent appointed by the Company) and have not been validly withdrawn in accordance with the provisions of this Indenture, (i) such Notes will cease to be outstanding, (ii) interest will cease to
accrue on such Notes (whether or not book-entry transfer of the Notes has been made or the Notes have been delivered to the Trustee (or other Paying Agent appointed by the Company)) and (iii) all other rights of the Holders of such Notes will
terminate (other than the right to receive the Fundamental Change Repurchase Price). 
 (c) Upon surrender of a Note that is to be
repurchased in part pursuant to Section 15.02, the Company shall execute and the Trustee shall authenticate and deliver to the Holder a new Note in an authorized denomination equal in principal amount to the unrepurchased portion of the Note
surrendered. 

  
 82 

 Section 15.05. Covenant to Comply with Applicable Laws Upon Repurchase of Notes.
In connection with any repurchase offer pursuant to this Article 15, the Company will, if required: 
 (a) comply with the provisions of any
tender offer rules under the Exchange Act that may then be applicable; 
 (b) file a Schedule TO or any other required schedule under the
Exchange Act; and 
 (c) otherwise comply with all federal and state securities laws in connection with any offer by the Company to
repurchase the Notes; 
 in each case, so as to permit the rights and obligations under this Article 15 to be exercised in the time and in the manner
specified in this Article 15. 
 ARTICLE 16 

OPTIONAL REDEMPTION 

Section 16.01. Optional Redemption. The Notes shall not be redeemable by the Company prior to June 20, 2023. On or after
June 20, 2023 and prior to the 21st Scheduled Trading Day immediately preceding the Maturity Date, the Company may, at its option, redeem (an “Optional Redemption”) for cash all or any portion of the Notes, at the Redemption
Price, if the Last Reported Sale Price of the Common Stock has been at least 130% of the Conversion Price then in effect for at least 20 Trading Days (whether or not consecutive) during any 30 consecutive Trading Day period (including the last
trading day of such period) ending on, and including, the Trading Day immediately preceding the date on which the Company provides the Redemption Notice in accordance with Section 16.02. 

Section 16.02. Notice of Optional Redemption; Selection of Notes. (a) In case the Company exercises its Optional Redemption
right to redeem all or, as the case may be, any part of the Notes pursuant to Section 16.01, it shall fix a date for redemption (each, a “Redemption Date”) and it or, at its written request received by the Trustee not less than
5 Business Days prior to the date such Redemption Notice is to be sent (or such shorter period of time as may be acceptable to the Trustee), the Trustee, in the name of and at the expense of the Company, shall deliver or cause to be delivered a
written notice of such Optional Redemption (a “Redemption Notice”) not less than 25 nor more than 35 Scheduled Trading Days prior to the Redemption Date to the Trustee, the Conversion Agent (if other than the Trustee), the Paying
Agent, and each Holder of Notes so to be redeemed as a whole or in part; provided that, if the Company shall give such notice, it shall also give written notice of the Redemption Date to the Trustee. The Redemption Date must be a Business
Day. 
 (b) The Redemption Notice, if delivered in the manner herein provided, shall be conclusively presumed to have been duly given,
whether or not the Holder receives such notice. In any case, failure to give such Redemption Notice or any defect in the Redemption Notice to the Holder of any Note designated for redemption as a whole or in part shall not affect the validity of the
proceedings for the redemption of any other Note. 

  
 83 

 (c) Each Redemption Notice shall specify: 

(i) the Redemption Date; 

(ii) the Redemption Price; 

(iii) that on the Redemption Date, the Redemption Price will become due and payable upon each Note to be redeemed, and that
interest thereon, if any, shall cease to accrue on and after the Redemption Date; 
 (iv) the place or places where such
Notes are to be surrendered for payment of the Redemption Price; 
 (v) that Holders of Called Notes may surrender their
Called Notes for conversion at any time prior to the close of business on the second Scheduled Trading Day immediately preceding the Redemption Date; 

(vi) the procedures a converting Holder must follow to convert its Called Notes and the Settlement Method; 

(vii) the Conversion Rate and, if applicable, the number of Additional Shares added to the Conversion Rate in accordance with
Section 14.03; 
 (viii) the CUSIP, ISIN or other similar numbers, if any, assigned to such Notes; and 

(ix) in case any Note is to be redeemed in part only, the portion of the principal amount thereof to be redeemed and on and
after the Redemption Date, upon surrender of such Note, a new Note in principal amount equal to the unredeemed portion thereof shall be issued, which principal amount must be $1,000 or a multiple thereof. 

A Redemption Notice shall be irrevocable. 
 (d)
If fewer than all of the outstanding Notes are to be redeemed, the Notes to be redeemed will be selected according to the Depositary’s applicable procedures, in the case of Notes represented by a Global Note, or, in the case of Notes
represented by Physical Notes, the Trustee shall select, in such manner as it shall deem appropriate and fair, Notes to be redeemed in whole or in part. If any Note selected for partial redemption is submitted for conversion in part after such
selection, the portion of the Note submitted for conversion shall be deemed (so far as may be possible) to be the portion selected for redemption, subject, in the case of Notes represented by a Global Note, to the Depositary’s applicable
procedures. 
 Section 16.03. Payment of Notes Called for Redemption. (a) If any Redemption Notice has been given in
respect of the Notes in accordance with Section 16.02, the Notes shall become due and payable on the Redemption Date at the place or places stated in the Redemption Notice and at the applicable Redemption Price. On presentation and surrender of
the Notes at the place or places stated in the Redemption Notice, the Notes shall be paid and redeemed by the Company at the applicable Redemption Price. 

  
 84 

 (b) Prior to 11:00 a.m. New York City time on the Redemption Date, the Company shall deposit
with the Paying Agent or, if the Company or a Subsidiary of the Company is acting as the Paying Agent, shall segregate and hold in trust as provided in Section 7.05 an amount of cash (in immediately available funds if deposited on the
Redemption Date), sufficient to pay the Redemption Price of all of the Notes to be redeemed on such Redemption Date. Subject to receipt of funds by the Paying Agent, payment for the Notes to be redeemed shall be made on the Redemption Date for such
Notes. The Paying Agent shall, promptly after such payment and upon written demand by the Company, return to the Company any funds in excess of the Redemption Price. 

Section 16.04. Restrictions on Redemption. The Company may not redeem any Notes on any date if the principal amount of the Notes
has been accelerated in accordance with the terms of this Indenture, and such acceleration has not been rescinded, on or prior to the Redemption Date (except in the case of an acceleration resulting from a Default by the Company in the payment of
the Redemption Price with respect to such Notes). 
 ARTICLE 17 

MISCELLANEOUS PROVISIONS 

Section 17.01. Provisions Binding on Company’s Successors. All the covenants, stipulations, promises and
agreements of the Company contained in this Indenture shall bind its successors and assigns whether so expressed or not. 

Section 17.02. Official Acts by Successor Corporation. Any act or proceeding by any provision of this Indenture authorized or
required to be done or performed by any board, committee or Officer of the Company shall and may be done and performed with like force and effect by the like board, committee or officer of any corporation or other entity that shall at the time be
the lawful sole successor of the Company. 
 Section 17.03. Addresses for Notices, Etc. Any notice or demand that by any
provision of this Indenture is required or permitted to be given or served by the Trustee or by the Holders on the Company shall be deemed to have been sufficiently given or made, for all purposes if given or served by being deposited postage
prepaid by registered or certified mail in a post office letter box addressed (until another address is delivered by the Company to the Trustee) to Coupa Software Incorporated, 1855 S. Grant Street, San Mateo, CA 94402, Attention: General Counsel.
Any notice, direction, request or demand hereunder to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or served by being deposited postage prepaid by registered or certified mail in a post
office letter box addressed to the Corporate Trust Office or sent electronically in PDF format. Notwithstanding any other provision of the Indenture, notices to the Trustee shall only be deemed received upon actual receipt thereof by a Responsible
Officer. 

  
 85 

 The Trustee, by notice to the Company, may designate additional or different addresses for
subsequent notices or communications. 
 Any notice or communication delivered or to be delivered to a Holder of Physical Notes shall be
mailed to it by first class mail, postage prepaid, at its address as it appears on the Note Register and shall be sufficiently given to it if so mailed within the time prescribed. Any notice or communication delivered or to be delivered to a Holder
of Global Notes shall be delivered in accordance with the applicable procedures of the Depositary and shall be sufficiently given to it if so delivered within the time prescribed. 

Failure to mail or deliver a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other
Holders. If a notice or communication is mailed or delivered, as the case may be, in the manner provided above, it is duly given, whether or not the addressee receives it. 

In case by reason of the suspension of regular mail service or by reason of any other cause it shall be impracticable to give such notice to
Holders by mail, then such notification as shall be made with the approval of the Trustee shall constitute a sufficient notification for every purpose hereunder. 

Section 17.04. Governing Law; Jurisdiction. THIS INDENTURE AND EACH NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR
RELATED TO THIS INDENTURE AND EACH NOTE, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 The
Company irrevocably consents and agrees, for the benefit of the Holders from time to time of the Notes and the Trustee, that any legal action, suit or proceeding against it with respect to obligations, liabilities or any other matter arising out of
or in connection with this Indenture or the Notes may be brought in the courts of the State of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and, until amounts due and to become due in
respect of the Notes have been paid, hereby irrevocably consents and submits to the non-exclusive jurisdiction of each such court in personam, generally and unconditionally with respect to any action,
suit or proceeding for itself in respect of its properties, assets and revenues. 
 The Company irrevocably and unconditionally waives, to
the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any of the aforesaid actions, suits or proceedings arising out of or in connection with this Indenture brought in the courts of the State
of New York or the courts of the United States located in the Borough of Manhattan, New York City, New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or
proceeding brought in any such court has been brought in an inconvenient forum. 
 Section 17.05. Evidence of Compliance with
Conditions Precedent; Certificates and Opinions of Counsel to Trustee. Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an
Officer’s Certificate and, if requested by the Trustee, an Opinion of Counsel stating 

  
 86 

 
that such action is permitted by the terms of this Indenture and that all conditions precedent to such action have been complied with; provided that no Opinion of Counsel shall be required
to be delivered in connection with the removal of the restricted CUSIP of the Restricted Securities to an unrestricted CUSIP pursuant to the applicable procedures of the Depositary upon the Notes becoming freely tradable by non-Affiliates of the Company under Rule 144, unless either a new Note is to be issued and authenticated (in which case the Opinion of Counsel required by Section 2.04 shall be delivered); provided
further that no Opinion of Counsel shall be required to be delivered in connection with a request by the Company that the Trustee deliver a notice to Holders under the Indenture where the Trustee receives an Officer’s Certificate with
respect to such notice. With respect to matters of fact, an Opinion of Counsel may rely on an Officer’s Certificate or certificates of public officials. 

Each Officer’s Certificate and Opinion of Counsel provided for, by or on behalf of the Company in this Indenture and delivered to the
Trustee with respect to compliance with this Indenture (other than the Officer’s Certificates provided for in Section 4.08) shall include (a) a statement that the person signing such certificate is familiar with the requested action
and this Indenture; (b) a brief statement as to the nature and scope of the examination or investigation upon which the statement contained in such certificate is based; (c) a statement that, in the judgment of such person, he or she has
made such examination or investigation as is necessary to enable him or her to express an informed judgment as to whether or not such action is permitted by this Indenture; and (d) a statement as to whether or not, in the judgment of such
person, such action is permitted by this Indenture and that all conditions precedent thereto have been complied with. 
 Notwithstanding
anything to the contrary in this Section 17.05, if any provision in this Indenture specifically provides that the Trustee shall or may receive an Opinion of Counsel in connection with any action to be taken by the Trustee or the Company
hereunder, the Trustee shall be entitled to such Opinion of Counsel. 
 Section 17.06. Legal Holidays. In any case where any
Interest Payment Date, Fundamental Change Repurchase Date or Maturity Date is not a Business Day, then any action to be taken on such date need not be taken on such date, but may be taken on the next succeeding Business Day with the same force and
effect as if taken on such date, and no interest shall accrue on such payment in respect of the delay. 
 Section 17.07. No Security
Interest Created. Nothing in this Indenture or in the Notes, expressed or implied, shall be construed to constitute a security interest under the Uniform Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any
jurisdiction. 
 Section 17.08. Benefits of Indenture. Nothing in this Indenture or in the Notes, expressed or implied, shall
give to any Person, other than the Holders, the parties hereto, any Paying Agent, any Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder, any benefit or any legal or equitable right, remedy or claim under
this Indenture. 

  
 87 

 Section 17.09. Table of Contents, Headings, Etc. The table of contents and the
titles and headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 

Section 17.10. Authenticating Agent. The Trustee may appoint an authenticating agent that shall be authorized to act on its behalf
and subject to its direction in the authentication and delivery of Notes in connection with the original issuance thereof and transfers and exchanges of Notes hereunder, including under Section 2.04, Section 2.05, Section 2.06,
Section 2.07, Section 10.04 and Section 15.04 as fully to all intents and purposes as though the authenticating agent had been expressly authorized by this Indenture and those Sections to authenticate and deliver Notes. For all
purposes of this Indenture, the authentication and delivery of Notes by the authenticating agent shall be deemed to be authentication and delivery of such Notes “by the Trustee” and a certificate of authentication executed on behalf of the
Trustee by an authenticating agent shall be deemed to satisfy any requirement hereunder or in the Notes for the Trustee’s certificate of authentication. Such authenticating agent shall at all times be a Person eligible to serve as trustee
hereunder pursuant to Section 7.08. 
 Any corporation or other entity into which any authenticating agent may be merged or converted
or with which it may be consolidated, or any corporation or other entity resulting from any merger, consolidation or conversion to which any authenticating agent shall be a party, or any corporation or other entity succeeding to the corporate trust
business of any authenticating agent, shall be the successor of the authenticating agent hereunder, if such successor corporation or other entity is otherwise eligible under this Section 17.10, without the execution or filing of any paper or
any further act on the part of the parties hereto or the authenticating agent or such successor corporation or other entity. 
 Any
authenticating agent may at any time resign by giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any authenticating agent by giving written notice of termination to such
authenticating agent and to the Company. Upon receiving such a notice of resignation or upon such a termination, or in case at any time any authenticating agent shall cease to be eligible under this Section, the Trustee may appoint a successor
authenticating agent (which may be the Trustee), shall give written notice of such appointment to the Company. 
 The Company agrees to pay
to the authenticating agent from time to time reasonable compensation for its services although the Company may terminate the authenticating agent, if it determines such agent’s fees to be unreasonable. 

The provisions of Section 7.02, Section 7.03, Section 7.04, Section 8.03 and this Section 17.10 shall be applicable
to any authenticating agent. 

  
 88 

 If an authenticating agent is appointed pursuant to this Section 17.10, the Notes may
have endorsed thereon, in addition to the Trustee’s certificate of authentication, an alternative certificate of authentication in the following form: 

__________________________, 
 as Authenticating Agent, certifies
that this is one of the Notes described 
 in the within-named Indenture. 
  

	
	By: ____________________
	Authorized Signatory

 Section 17.11. Execution in Counterparts. This Indenture may be executed in any number of
counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Indenture and of signature pages by facsimile, PDF or other electronic transmission
shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile, PDF or such other electronic
means shall be deemed to be their original signatures for all purposes. Unless otherwise provided in this Indenture or in any Note, the words “execute,” “execution,” “signed” and “signature” and words of
similar import used in or related to any document to be signed in connection with this Indenture, any Note or any of the transactions contemplated hereby (including amendments, waivers, consents and other modifications) shall be deemed to include
electronic signatures and the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature in ink or the use of a paper-based recordkeeping system, as applicable,
to the fullest extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other similar state laws based on the
Uniform Electronic Transactions Act; provided that, notwithstanding anything herein to the contrary, the Trustee is not under any obligation to agree to accept electronic signatures in any form or in any format except for facsimile or .PDF
unless expressly agreed to by the Trustee pursuant to procedures approved by the Trustee. 
 Section 17.12. Severability. In the
event any provision of this Indenture or in the Notes shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the remaining provisions shall not in any way be affected or
impaired. 
 Section 17.13. Waiver of Jury Trial. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

Section 17.14. Force Majeure. In no event shall the Trustee or any of the agents be responsible or liable for any failure or delay
in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, any act or provision of any present or future law or regulation or governmental authority,
strikes, work stoppages, accidents, acts of war or terrorism, pandemics, epidemics, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer
(software and hardware) services or the unavailability of the Federal Reserve Bank wire or telex or other wire or communication facility; it being understood that the Trustee or any of the agents, as the case may be, shall use reasonable efforts
that are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. 

  
 89 

 Section 17.15. Calculations. Except as otherwise provided herein, the Company
shall be responsible for making all calculations called for under the Notes. These calculations include, but are not limited to, determinations of the Stock Price, the Last Reported Sale Prices of the Common Stock, the Daily VWAPs, the Daily
Conversion Values, the Daily Settlement Amounts, accrued interest payable on the Notes (including, for the avoidance of doubt, any Additional Interest payable under this Indenture), the Conversion Rate and the Conversion Price of the Notes. The
Company shall make all these calculations in good faith and, absent manifest error, the Company’s calculations shall be final and binding on Holders. The Company shall provide a schedule of its calculations to each of the Trustee and the
Conversion Agent, and each of the Trustee and Conversion Agent is entitled to rely conclusively upon the accuracy of the Company’s calculations without independent verification. The Trustee will forward the Company’s calculations to any
registered Holder upon the written request of that Holder at the sole cost and expense of the Company. Neither the Trustee nor the Conversion Agent shall have any responsibility to make calculations under this Indenture nor shall either of them have
any responsibility to monitor the Company’s stock or trading price, determine whether the conditions to convertability of the Notes have been met or determine whether the circumstances requiring changes to the Conversion Rate have occurred.

 Section 17.16. U.S.A. PATRIOT Act. The parties hereto acknowledge that in accordance with Section 326 of the U.S.A.
PATRIOT Act, the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a
relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. PATRIOT Act. 

Section 17.17. No Personal Liability of Directors, Officers, Employees or Stockholders. None of the Company’s past, present
or future directors, officers, employees or stockholders, as such, shall have any liability for any of the Company’s obligations under the Notes or this Indenture or for any claim based on, or in respect or by reason of, such obligations or
their creation. By accepting a Note, each Holder waives and releases all such liability. This waiver and release is part of the consideration for the Notes. 

[Remainder of page intentionally left blank] 
  

  
 90 

 IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of
the date first written above. 
  

			
	COUPA SOFTWARE INCORPORATED
		
	By:	 	 /s/ Jon Stueve

		 	Name: Jon Stueve
		 	Title: Senior Vice President and General Counsel

  

			
	 WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee

		
	By:	 	 /s/ Nedine P. Sutton

		 	Name: Nedine P. Sutton
		 	Title: Vice President

  

 EXHIBIT A 

[FORM OF FACE OF NOTE] 
 [INCLUDE
FOLLOWING LEGEND IF A GLOBAL NOTE] 
 [UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY,
A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREUNDER IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY
PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.] 
 [INCLUDE FOLLOWING LEGEND IF A
RESTRICTED SECURITY] 
 [THIS SECURITY AND THE COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST
HEREIN, THE ACQUIRER: 
 (1) REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A “QUALIFIED INSTITUTIONAL
BUYER” (WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND 

(2) AGREES FOR THE BENEFIT OF COUPA SOFTWARE INCORPORATED (THE “COMPANY”) THAT IT WILL NOT OFFER, SELL, PLEDGE OR
OTHERWISE TRANSFER THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN PRIOR TO THE DATE THAT IS THE LATER OF (X) ONE YEAR AFTER THE LAST ORIGINAL ISSUE DATE HEREOF OR SUCH SHORTER PERIOD OF TIME AS PERMITTED BY RULE 144 UNDER THE SECURITIES ACT OR
ANY SUCCESSOR PROVISION THERETO AND (Y) SUCH LATER DATE, IF ANY, AS MAY BE REQUIRED BY APPLICABLE LAW, EXCEPT: 
 (A) TO
THE COMPANY OR ANY SUBSIDIARY THEREOF, OR 
 (B) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BECOME EFFECTIVE UNDER THE
SECURITIES ACT, OR 

  
 A-1 

 (C) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER
THE SECURITIES ACT, OR 
 (D) PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT OR ANY
OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. 
 PRIOR TO THE REGISTRATION OF ANY TRANSFER IN
ACCORDANCE WITH CLAUSE (2)(D) ABOVE, THE COMPANY AND THE TRUSTEE RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH LEGAL OPINIONS, CERTIFICATIONS OR OTHER EVIDENCE AS MAY REASONABLY BE REQUIRED IN ORDER FOR THE COMPANY TO DETERMINE THAT THE PROPOSED
TRANSFER IS BEING MADE IN COMPLIANCE WITH THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. NO REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.] 

  
 A-2 

 Coupa Software Incorporated 

0.375% Convertible Senior Note due 2026 
  

			
	 No. [__]
	  	 [Initially]1 $[_________]

 CUSIP No. 22266L AE62 

Coupa Software Incorporated, a corporation duly organized and validly existing under the laws of the State of Delaware (the
“Company,” which term includes any successor corporation or other entity under the Indenture referred to on the reverse hereof), for value received hereby promises to pay to [CEDE & CO.]3 [_______]4, or registered assigns, the principal sum [as set forth in the “Schedule of Exchanges of Notes” attached hereto]5 [of $[_______]]6, which amount, taken together with the principal amounts of all other outstanding Notes, shall not, unless permitted by the
Indenture, exceed $1,380,000,000 in aggregate at any time, in accordance with the rules and procedures of the Depositary, on June 15, 2026, and interest thereon as set forth below. 

This Note shall bear interest at the rate of 0.375% per year from and including June 15, 2020, or from and including the most recent date
to which interest has been paid or provided for to, but excluding, the next scheduled Interest Payment Date until June 15, 2026. Accrued interest on this Note shall be computed on the basis of a 360-day
year composed of twelve 30-day months and, for partial months, on the basis of the number of days actually elapsed in a 30-day month. Interest is payable semi-annually
in arrears on each June 15 and December 15, commencing on December 15, 2020, to Holders of record at the close of business on the preceding June 1 and December 1 (whether or not such day is a Business Day), respectively.
Additional Interest will be payable as set forth in Section 4.06(d), Section 4.06(e) and Section 6.03 of the within-mentioned Indenture, and any reference to interest on, or in respect of, any Note therein shall be deemed to include
Additional Interest if, in such context, Additional Interest is, was or would be payable pursuant to any of such Section 4.06(d), Section 4.06(e) or Section 6.03, and any express mention of the payment of Additional Interest in any
provision therein shall not be construed as excluding Additional Interest in those provisions thereof where such express mention is not made. 

Any Defaulted Amounts shall accrue interest per annum at the rate borne by the Notes, from, and including, the relevant payment date to, but
excluding, the date on which such Defaulted Amounts shall have been paid by the Company, at its election, in accordance with Section 2.03(c) of the Indenture. 

 

	1 	 Include if a global note. 

	2 	 This Note will be deemed to be identified by CUSIP No. 22266L AF3 from and after such time when the Company
delivers, pursuant to Section 2.05(c) of the within-mentioned Indenture, written notice to the Trustee of the occurrence of the Resale Restriction Termination Date and the removal of the restrictive legend affixed to this Note in accordance
with the applicable procedures of the Depositary. 

	3 	 Include if a global note. 

	4 	 Include if a physical note. 

	5 	 Include if a global note. 

	6 	 Include if a physical note. 

  
 A-3 

 The Company shall pay the principal of and interest on this Note, if and so long as such
Note is a Global Note, in immediately available funds in lawful money of the United States at the time to the Depositary or its nominee, as the case may be, as the registered Holder of such Note. As provided in and subject to the provisions of the
Indenture, the Company shall pay the principal of any Notes (other than Notes that are Global Notes) at the office or agency designated by the Company for that purpose. The Company has initially designated the Trustee as its Paying Agent and Note
Registrar in respect of the Notes and its Corporate Trust Office in the contiguous United States of America, as a place where Notes may be presented for payment or for registration of transfer and exchange. 

Reference is made to the further provisions of this Note set forth on the reverse hereof, including, without limitation, provisions giving the
Holder of this Note the right to convert this Note into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, on the terms and subject to the limitations set forth in the Indenture. Such further provisions
shall for all purposes have the same effect as though fully set forth at this place. 
 This Note, and any claim, controversy or dispute
arising under or related to this Note, shall be construed in accordance with and governed by the laws of the State of New York. 
 In
the case of any conflict between this Note and the Indenture, the provisions of the Indenture shall control and govern. 
 This Note shall
not be valid or become obligatory for any purpose until the certificate of authentication hereon shall have been signed manually by the Trustee or a duly authorized authenticating agent under the Indenture. 

[Remainder of page intentionally left blank] 
  

  
 A-4 

 IN WITNESS WHEREOF, the Company has caused this Note to be duly executed. 

 

			
	COUPA SOFTWARE INCORPORATED
		
	By:	 	
                     
            

		 	Name:
		 	Title:

  

			
	Dated:
	
	TRUSTEE’S CERTIFICATE OF AUTHENTICATION
	
	WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee, certifies that this is one of the Notes described in the within-named Indenture.
		
	By:	 	
                     

		 	Authorized Signatory

 [FORM OF REVERSE OF NOTE] 

Coupa Software Incorporated 

0.375% Convertible Senior Note due 2026 

This Note is one of a duly authorized issue of Notes of the Company, designated as its 0.375% Convertible Senior Notes due 2026 (the
“Notes”), initially limited to the aggregate principal amount of $1,380,000,000 all issued or to be issued under and pursuant to an Indenture dated as of June 15, 2020 (the “Indenture”), between the Company and
Wilmington Trust, National Association, as trustee (the “Trustee”), to which Indenture and all indentures supplemental thereto reference is hereby made for a description of the rights, limitations of rights, obligations, duties and
immunities thereunder of the Trustee, the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate principal amount, subject to certain conditions specified in the Indenture. Capitalized terms used in this Note
and not defined in this Note shall have the respective meanings set forth in the Indenture. 
 In case certain Events of Default, as defined
in the Indenture, shall have occurred and be continuing, the principal of, and interest on, all Notes may be declared, by either the Trustee or Holders of at least 25% in aggregate principal amount of Notes then outstanding, and upon said
declaration shall become, due and payable, in the manner, with the effect and subject to the conditions and certain exceptions set forth in the Indenture. 

Subject to the terms and conditions of the Indenture, the Company will make all payments and deliveries in respect of the Fundamental Change
Repurchase Price on the Fundamental Change Repurchase Date and the principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a Paying Agent to collect such payments in respect of the Note. The Company will pay
cash amounts in money of the United States that at the time of payment is legal tender for payment of public and private debts. 
 The
Indenture contains provisions permitting the Company and the Trustee in certain circumstances, without the consent of the Holders of the Notes, and in certain other circumstances, with the consent of the Holders of not less than a majority in
aggregate principal amount of the Notes at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures modifying the terms of the Indenture and the Notes as described therein. It is also provided in the Indenture
that, subject to certain exceptions, the Holders of a majority in aggregate principal amount of the Notes at the time outstanding may on behalf of the Holders of all of the Notes waive any past Default or Event of Default under the Indenture and its
consequences. 
 No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay or deliver, as the case may be, the principal (including the Redemption Price, the Fundamental Change Repurchase Price, if applicable) of, accrued and unpaid interest on, and the
consideration due upon conversion of, this Note at the place, at the respective times, at the rate and in the lawful money herein prescribed. 

  
 R-1 

 The Notes are issuable in registered form without coupons in minimum denominations of $1,000
principal amount and integral multiples in excess thereof. At the office or agency of the Company referred to on the face hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be exchanged for a like aggregate
principal amount of Notes of other authorized denominations, without payment of any service charge but, if required by the Company or Trustee, with payment of a sum sufficient to cover any transfer or similar tax that may be imposed in connection
therewith as a result of the name of the Holder of the new Notes issued upon such exchange of Notes being different from the name of the Holder of the old Notes surrendered for such exchange. 

The Notes shall be redeemable at the Company’s option on or after June 20, 2023 and prior to the 21st Scheduled Trading Day
immediately preceding the Maturity Date, in accordance with the terms and subject to the conditions specified in the Indenture. No sinking fund is provided for the Notes. 

Upon the occurrence of a Fundamental Change, the Holder has the right, at such Holder’s option, to require the Company to repurchase for
cash all of such Holder’s Notes or any portion thereof (in principal amounts of $1,000 or multiples thereof) on the Fundamental Change Repurchase Date at a price equal to the Fundamental Change Repurchase Price. 

Subject to the provisions of the Indenture, the Holder hereof has the right, at its option, during certain periods and upon the occurrence of
certain conditions specified in the Indenture, prior to the close of business on the second Scheduled Trading Day immediately preceding the Maturity Date, to convert any Notes or portion thereof that is $1,000 or a multiple thereof, into cash,
shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, at the Conversion Rate specified in the Indenture, as adjusted from time to time as provided in the Indenture. 

Terms used in this Note and defined in the Indenture are used herein as therein defined. 

  
 R-2 

 ABBREVIATIONS 

The following abbreviations, when used in the inscription of the face of this Note, shall be construed as though they were written out in full
according to applicable laws or regulations: 
 TEN COM = as tenants in common 

UNIF GIFT MIN ACT = Uniform Gifts to Minors Act 
 CUST =
Custodian 
 TEN ENT = as tenants by the entireties 
 JT TEN =
joint tenants with right of survivorship and not as tenants in common 
 Additional abbreviations may also be used though not in the above
list. 

  
 R-3 

 SCHEDULE A7 

SCHEDULE OF EXCHANGES OF NOTES 

Coupa Software Incorporated 

0.375% Convertible Senior Notes due 2026 

The initial principal amount of this Global Note is _______ DOLLARS ($[_________]). The following increases or decreases in this Global Note
have been made: 
  

																	
	 Date of exchange
	  	Amount of
decrease in
principal amount
of this Global Note	 	  	Amount of
increase in
principal amount
of this Global Note	 	  	Principal amount
of this Global Note
following such
decrease or
increase	 	  	Signature of
authorized
signatory of
Trustee or
Custodian	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		  				  				  				  			
	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
  

	7	 Include if a global note. 

  
 R-4 

 ATTACHMENT 1 

[FORM OF NOTICE OF CONVERSION] 
 To: Coupa
Software Incorporated 
 To: Wilmington Trust, National Association 

246 Goose Lane, Suite 105 
 Guilford, CT 06437 

Attn: Coupa Software Incorporated Administrator 

The undersigned registered owner of this Note hereby exercises the option to convert this Note, or the portion hereof (that is $1,000
principal amount or a multiple thereof) below designated, into cash, shares of Common Stock or a combination of cash and shares of Common Stock, as applicable, in accordance with the terms of the Indenture referred to in this Note, and directs that
any cash payable and any shares of Common Stock issuable and deliverable upon such conversion, together with any cash for any fractional share, and any Notes representing any unconverted principal amount hereof, be issued and delivered to the
registered Holder hereof unless a different name has been indicated below. If any shares of Common Stock or any portion of this Note not converted are to be issued in the name of a Person other than the undersigned, the undersigned will pay all
documentary, stamp or similar issue or transfer taxes, if any in accordance with Section 14.02(d) and Section 14.02(e) of the Indenture. Any amount required to be paid to the undersigned on account of interest accompanies this Note.
Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture. 
  

					
	Dated:
                                         
       	  	                                      
                                      	  	
			
		  	                                      
                                      	  	
		  	Signature(s)	  	

  

	
	                                      
                      
	Signature Guarantee
	
	 Signature(s) must be guaranteed
 by an eligible
Guarantor Institution

	 (banks, stock brokers, savings and
 loan
associations and credit unions)
 with membership in an approved

signature guarantee medallion program
 pursuant to Securities and
Exchange

	 Commission Rule 17Ad-15 if shares

of Common Stock are to be issued, or

  
 1 

	
	Notes are to be delivered, other than to and in the name of the registered holder.
	
	Fill in for registration of shares if to be issued, and Notes if to be delivered, other than to and in the name of the registered holder:
	
	  

	(Name)
	
	  

	(Street Address)
	
	  

	(City, State and Zip Code)
	Please print name and address

  

			
		 	Principal amount to be converted (if less than all): $______,000
		
		 	NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.
		 	  

		 	Social Security or Other Taxpayer
		 	Identification Number

  
 2 

 ATTACHMENT 2 

[FORM OF FUNDAMENTAL CHANGE REPURCHASE NOTICE] 

To: Coupa Software Incorporated 
 To: Wilmington Trust, National
Association 
 246 Goose Lane, Suite 105 
 Guilford, CT 06437

 Attn: Coupa Software Incorporated Administrator 

The undersigned registered owner of this Note hereby acknowledges receipt of a notice from Coupa Software Incorporated (the
“Company”) as to the occurrence of a Fundamental Change with respect to the Company and specifying the Fundamental Change Repurchase Date and requests and instructs the Company to pay to the registered holder hereof in accordance
with Section 15.02 of the Indenture referred to in this Note (1) the entire principal amount of this Note, or the portion thereof (that is $1,000 principal amount or a multiple thereof) below designated, and (2) if such Fundamental
Change Repurchase Date does not fall during the period after a Regular Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest, if any, thereon to, but excluding, such Fundamental Change Repurchase Date.
Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Indenture. 
 In the case of Physical
Notes, the certificate numbers of the Notes to be repurchased are as set forth below: 
 Dated:    _____________________ 

 

			
		 	                                      
                                         
     
		 	Signature(s)
		
		 	                                      
                                         
     
		 	Social Security or Other Taxpayer
		 	Identification Number
		
		 	Principal amount to be repurchased (if less than all): $______,000
		
		 	NOTICE: The above signature(s) of the Holder(s) hereof must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.

  
 1 

 ATTACHMENT 3 

[FORM OF ASSIGNMENT AND TRANSFER] 
 Wilmington
Trust, National Association 
 246 Goose Lane, Suite 105 

Guilford, CT 06437 
 Attn: Coupa Software Incorporated
Administrator 
 For value received ____________________________ hereby sell(s), assign(s) and transfer(s) unto _________________ (Please insert social
security or Taxpayer Identification Number of assignee) the within Note, and hereby irrevocably constitutes and appoints _____________________ attorney to transfer the said Note on the books of the Company, with full power of substitution in the
premises. 
 In connection with any transfer of the within Note occurring prior to the Resale Restriction Termination Date, as defined in the Indenture
governing such Note, the undersigned confirms that such Note is being transferred: 
 ☐ To Coupa Software Incorporated or a subsidiary thereof; or 

☐ Pursuant to a registration statement that has become or been declared effective under the Securities Act of 1933, as amended; or 

☐ Pursuant to and in compliance with Rule 144A under the Securities Act of 1933, as amended; or 

☐ Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended, or any other available exemption from the registration
requirements of the Securities Act of 1933, as amended. 

  
 1 

	
	Dated: ________________________
	
	  

	
	  

	Signature(s)
	
	  

	Signature Guarantee
	
	Signature(s) must be guaranteed by an eligible Guarantor Institution (banks, stock brokers, savings and loan associations and credit unions) with membership in an approved signature guarantee medallion program pursuant to Securities
and Exchange Commission Rule 17Ad-15 if Notes are to be delivered, other than to and in the name of the registered holder.

 NOTICE: The signature on the assignment must correspond with the name as written upon the face of the Note in every particular
without alteration or enlargement or any change whatever. 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]